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Gastrointestinal toxicity and myelosuppression hinder the clinical use of CPT-11-
based dose-intensified regimens. Clinical studies indicated that combination with 
thalidomide or St. John’s wort (SJW) alleviated CPT-11 induced toxicity. 
However, the underlying mechanisms involved are not fully understood. In this 
thesis, a rat model with dose-limiting toxicity profiles that are similar to those 
observed in patients was developed and used to study the modulations of 
thalidomide and SJW on CPT-11 induced toxicities. Furthermore, the underlying 
pharmacodynamic and pharmacokinetic components involved were explored. The 
study demonstrated that coadministered thalidomide or SJW significantly 
ameliorated the gastrointestinal and hematological toxicities of CPT-11 in rats, as 
indicated by alleviation of late-onset diarrhea and up-regulation of decreased 
leukocyte counts as well as alleviated macroscopic and microscopic intestinal 
damages. Combination of thalidomide or SJW brought down increased 
interleukins (IL-1β and IL-6), interferon-γ (IFN-γ), and tumor necrosis factor-α 
(TNF-α) protein levels as well as TNF-α mRNA levels in the intestines. In 
addition, both thalidomide and SJW reduced intestinal epithelial apoptosis 
compared to rats treated with CPT-11 alone. Furthermore, coadministered 
thalidomide increased the area under plasma concentration-time curve (AUC) of 
CPT-11 but decreased that of SN-38, while combination of SJW decreased 
maximum plasma concentration (Cmax) of SN-38. The hydrolytic products of 
thalidomide significantly reduced the formation of SN-38 from CPT-11 in rat liver 
microsomes and H4-II-E cells (a rat hepatoma cell line). The ethanolic extracts of 
SJW significantly reduced SN-38 glucuronidation in rat liver microsomes but the 
ethanolic and aqueous extracts of SJW, hyperforin, and quercetin increased SN-38 
 viii
glucuronidation in H4-II-E cells. Additionally, hydrolytic products of thalidomide 
increased the cellular accumulation of SN-38 and CPT-11 in H4-II-E cells, 
whereas hypericin and hyperforin inhibited the intracelluar accumulation of CPT-
11 and the extracts of SJW and its major components increased the intracellular 
accumulation of SN-38. These results indicated that both pharmacodynamic and 
pharmacokinetic components play important roles in the protective effects of 
thalidomide and SJW against the gastrointestinal and hematological toxicities of 
CPT-11. Combination of CPT-11 with thalidomide will be a promising strategy to 
alleviate CPT-11 induced toxicities and possibly enhance its anti-tumor activity in 
view of the anti-neoplastic and anti-angiogenic activities of thalidomide. 
However, combination of SJW may compromise overall anti-tumor activity of 
CPT-11 by reducing the SN-38 plasma levels. Therefore, patients receiving CPT-
11 treatment should refrain from SJW coadministration and specific dosing 
guidelines should be taken when patients have to receive such a combination. The 
increased understanding for CPT-11 induced toxicity and the protective effects of 
thalidomide and SJW may provide effective strategies to circumvent CPT-11 
induced toxicities using anti-TNF-α agents through the inhibition of pro-
inflammatory cytokine expression and intestinal epithelial cellular apoptosis. In 
addition, pharmacokinetic studies on the combination of SJW with CPT-11 
indicated that caution is needed when combining chemotherapeutic agents which 
are substrates of cytochrome P450 and MDR1 P-glycoprotein with herbal 
medicines that are modulators of such enzymes and transporters, considering the 
pharmacokinetic profiles of the anti-cancer agents might be changed, leading to a 
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CHAPTER 1 GENERAL INTRODUCTION 
1.1 CANCER CHEMOTHERAPY 
In this section, basic concepts, mechanisms of action, drug resistance, and toxicity 
associated with chemotherapeutic agents as well as approaches to improve anti-
tumor activity for cancer chemotherapy will be discussed. 
Cancer is a disease that occurs when cells in the body develop abnormally and 
grow in an uncontrolled way. It is now a leading killer worldwide [1]. Cumulative 
evidence has shown that cancer is a disease with accumulation of genetic 
alterations in cells [2]. To date, the major modalities for treating cancer include 
surgery, radiation, chemotherapy, and immunotherapy [3]. However, these 
therapies are only successful for certain types of cancer (e.g. leukemia) or when 
the cancer is detected at an early stage. Conventional chemotherapy aims to kill or 
disable tumor cells by inhibiting DNA synthesis in one way or another through 
direct or indirect mechanisms, while preserving the normal cells in the body by 
the use of natural or synthetic compounds [4]. Chemotherapeutic agents generally 
have narrow margins of safety, and are usually given at maximum tolerated doses 
to achieve maximal cancer cell killing effects [5].  They kill tumor cells by direct 
cytotoxicity, or activating host immune response, inhibiting the proliferative 
processes of tumor cells and/or inducing the apoptosis of tumor cells [3].  
Apoptosis, also called programmed cell death, is an active energy-dependent 
mode of cell death, which is regulated by tightly controlled intracellular signalling 
events [6]. The term apoptosis was originally defined to describe certain 
morphological characteristics, including nuclear and cytoplasmic shrinkage and 
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chromatin condensation. Apoptosis was observed in many different tissues, both 
healthy and neoplastic, adult and embryonic [7]. Recently, it has been clearly 
proven that there are two apoptotic signalling pathways: intrinsic and extrinsic [8, 
9]. Following severe cellular stress such as DNA damage and cell cycle defects, 
the intrinsic pathway is activated, which involves activation of the pro-apoptotic 
members of the B-cell leukemia/lymphoma 2 (Bcl-2) family and subsequent 
release of apoptosis-inducing factors such as cytochrome C from the 
mitochondria. The extrinsic pathway involves members of the tumor necrosis 
factor (TNF)-superfamily, such as Fas and TNF-related-apoptosis-inducing-ligand 
(TRAIL), and plays a role in apoptosis induced by chemotherapy and cellular 
immunity. Apoptosis plays important roles in the development and maintenance 
of homeostasis and in the maturation of nervous and immune systems. It is also a 
major defence mechanism of the body, removing unwanted and potentially 
dangerous cells such as self-reactive lymphocytes, virus-infected cells and tumor 
cells. In contrast to its beneficial effects, the inappropriate activation of apoptosis 
may contribute to a variety of pathogenic processes such as the extensive T cell 
death in AIDS as well as the loss of neuronal cells in Alzheimer’s disease [10-12]. 
Although chemotherapy plays an important role in cancer treatment, it may fail 
due to drug resistance and dose-limiting toxicities. Tumor cells can develop 
acquired drug resistance due to a number of tumor-, host- and drug-associated 
factors. Tumor cells may have intrinsic resistance to current chemotherapeutic 
agents or develop resistance after exposure to the drugs. Tumor-related cellular 
factors include defective drug transport (e.g. reduced drug influx or increased 
drug efflux), altered drug activation or inactivation, enhanced repair after DNA 
damage, and/or deficient apoptotic response to DNA damage [13-16]. Host factors 
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include sanctuary sites for tumors, lack of bioactivation, increased inactivation, 
and/or dose-limiting normal organ/tissue toxicity, leading to inadequate tumor cell 
exposure [17-20]. Most anti-cancer drugs exhibit a greater toxicity in tissues with 
high growth fractions such as the bone marrow, gastrointestinal epithelium, hair 
follicles, and gonadal tissue. Most cytotoxic drugs [e.g. alkylating agents, 
topoisomerase I (Topo I) inhibitors] produce substantial hematological and 
gastrointestinal toxicities in many cancer patients. Such dose-limiting toxicities 
hinder the effective use of dose-intensified regimens in chemotherapy. Although 
supportive (e.g. growth factors and stem cells) and protective approaches have 
been widely used in combination with chemotherapeutic agents, toxicity is still a 
major hindrance for the success of chemotherapy. Therefore, there is a need for 
new approaches that decrease the toxicities of cytotoxic agents without 
compromising the anti-tumor activity. In addition, pharmacokinetic parameters of 
many anti-cancer drugs are associated with clinical treatment outcomes (e.g. 
response and/or toxicity). Most anti-cancer agents have wide interindividual 
pharmacokinetic variabilities, which affect the absorption, distribution, 
metabolism and excretion of anti-cancer drugs, thus resulting in unpredictable 
toxicity, drug resistance and various clinical responses in cancer patients.  
In order to obtain better therapeutic efficacy for cancer chemotherapy, many 
approaches have been developed. Among which, co-administration of multiple 
anti-cancer agents has become a standard regimen for the treatment of nearly all 
carcinomas. Combination chemotherapy has several important advantages. Firstly, 
combination therapy usually results in a decreased incidence of resistance. 
Secondly, there is often a greater than additive or synergistic effect of the drugs 
due to complementary mechanisms of action. Finally, by using drugs with 
 3
different types of toxic effects, the overall toxicity or at least the toxicity to any 
one-organ system could be reduced. There are three generally accepted guidelines 
to choose drugs for combination chemotherapy:  a) drugs that are active against 
the tumor when used alone should be selected for combination use; b) drugs with 
different mechanisms of action should be combined to obtain maximal tumor 
killing effect and to avoid combined resistance; and c) drugs with minimally 
overlapping toxicities are preferentially combined. 
Aside from drug combination strategy, the development of new anti-cancer agents 
with improved anti-cancer activity and/or reduced toxicity represents another 
effective way to kill cancer cells more effectively and/or selectively. Newer and 
more recent chemotherapeutic agents as well as novel drug delivery systems, drug 
transporter inhibitors and signal transduction inhibitors have been developed 
based on the knowledge of cancer biology involving signal transduction, cell-
cycle regulation, apoptosis, and angiogenesis [21-24]. In addition, biological 
response modifiers have also become an important complementary approach to 
cancer treatment. These are agents or approaches that modify the relationship 
between the host and tumor by modifying the host’s biological response to tumor 
cells with resultant therapeutic effects. Most biological response modifiers appear 
to act by inhibiting angiogenesis, activating the reactivity of immunological 
effectors, or modulating cellular growth and/or apoptotic process [25-28]. 
Moreover, to decrease inter-individual pharmacokinetic differences, doses should 
ideally be tailored to the individual patient, which has been done by normalizing 
dose to body surface area, which is calculated from patient’s height and weight. In 
addition, genotype-directed dosing and phenotype-based dosing have been applied 
to identify suitable doses to patients and to reduce inter-patient pharmacokinetic 
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variability [29-31]. In addition, population pharmacokinetic modelling has been 
developed to study the variability in plasma drug concentration between 
individuals who receive standard dosage regimens and those who represent the 
target patient population [32-34]. 
1.2 IRINOTECAN (CPT-11) 
Following the general introduction of cancer chemotherapy, an introduction for 
CPT-11 including its anti-tumor activity, pharmacokinetic profiles, and related 
toxicities that limit its clinical application will be discussed.  
1.2.1 Anti-tumor activity and mechanism of action of CPT-11 
The camptothecins (CPTs), a relatively new group of anti-cancer compounds, are 
potent DNA topoisomerase I (Topo I) inhibitors [35-38]. DNA topoisomerases are 
a group of enzymes that alter the topology of DNA and are present in all 
organisms including bacteria, viruses, yeast, and mammalian including humans 
[39, 40]. There are two general types of topoisomerases, Type I and Type II. Type 
I cleaves and separates a single strand of DNA and alters the linkage quantity of 
DNA, whereas Type II cleaves both strands of DNA and changes the linking 
number of DNA by two [36, 37]. Mammalian Topo I is particularly important in 
supporting replication fork movement during DNA replication and relaxing 
supercoils formed during transcription [41], which were found to be targets for 
many anti-cancer drugs [42-44]. 
The camptothecins can induce tumor cell death due to the stabilization of Topo I-
DNA complex and the generation of permanent DNA strand breaks [45]. The 
parental compound, CPT, is an anti-cancer alkaloid isolated from the Chinese tree, 
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Camptotheca acuminata, during a screen of plant extracts for finding anti-cancer 
agents [46]. The poor aqueous solubility (approximately 3.85µM in pure water  
[47, 48]) and unacceptable toxicity are major obstacles for the clinical use of CPT. 
In the past twenty years, more effort has been made to synthesize new derivatives 
of CPT with improved water solubility and potent anti-tumor activity. This has led 
to the discovery of a series of CPT analogs including CPT-11 (irinotecan, 7-ethyl-
10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin), topotecan, 
lurtotecan, 9-amino-CPT, rubitecan (9-nitro-CPT, RFS2000), 10-hydroxy-CPT, 
silatecan (DB-67,7-tert-butyldimethylsilyl-10-hydroxy-CPT), and exatecan (DX-
8951f, a hexacyclic analog of CPT) [35].  
CPT-11, a water-soluble semi-synthetic derivative of CPT inhibiting DNA Topo I 
[49], has exhibited significant clinical anti-tumor activity with 9-43% response 
rate in non-small cell lung cancer, small cell lung caner, gastric cancer, malignant 
lymphoma, acute leukemia, cervical cancer, and pancreatic cancer [50-60]. The 
major indication for CPT-11 is advanced colorectal cancer when used as a first-
line treatment in combination with 5-fluorouracil. CPT-11 has been approved by 
Food and Drug Administration of the USA for clinical use based on its 15-30% 
response rates in advanced colorectal cancer [61].  
The cytotoxic mechanism of CPT-11 is multifaceted but is most commonly 
explained by the replication collision model [62]. In this model, CPT-11 interacts 
with cellular Topo I-DNA complexes and has an S-phase-specific cytotoxicity 
[63]. The collisions of the reversible Topo I-CPT-11-DNA cleavable complex 
with the advancing replication forks result in the formation of a double-strand 
DNA breaks, thus leading to irreversible arrest of the replication fork [64]. One or 
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more of these events eventually trigger other cellular responses, leading to the cell 
cycle arrest in the G2 phase and to cell death.  
1.2.2 Pharmacokinetics of CPT-11 
In this section, the pharmacokinetics of CPT-11 were described starting with its 
plasma pharmacokinetic profiles followed by its metabolism, distribution, and 
excretion properties.  
Plasma pharmacokinetics of CPT-11 
The plasma pharmacokinetics of CPT-11 in humans have been addressed in many 
studies [65-68]. After intravenous (i.v.) infusion at 100-350 mg/m2, maximum 
plasma concentrations (Cmax) of CPT-11 are within the 1-10 mg/L range [66]. The 
area under the plasma concentration-time curve (AUC) of both CPT-11 and SN-
38 increased proportionally to the administered dose, although marked inter-
patient variability has been observed. Enterohepatic recirculation may be related 
to the rebound peak in the plasma concentration-time curve. Plasma concentration 
profiles of CPT-11 can be described using a two- or three-compartment model 
with a mean terminal half-life (t1/2β) of 5-27 hr. Its volume of distribution at 
steady-state (Vdss) ranges from 136 to 255 L/m2, and the total body clearance (CL) 
is 8-21 L/hr/m2. Maximum concentrations of SN-38 are reached about 1 hr after 
the beginning of a short intravenous infusion. SN-38 plasma decay follows closely 
that of the parental compound with an apparent t1/2β ranging from 6 to 30 hr [32, 
66, 69, 70]. 
 
Though i.v. infusion is the major way for CPT-11 treatment in clinical use, oral 
administration is a likely route for CPT-11 dosing to achieve a better therapeutic 
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outcome. Two clinical studies using oral delivery of CPT-11 have shown 
encouraging efficacy and toxicity profiles [71, 72]. A linear relationship was 
found between dose, Cmax, and AUC for both CPT-11 and SN-38 lactone, 
implying no saturation in the conversion of CPT-11 to SN-38. The mean 
metabolic ratio ([AUCSN-38 + AUCSN-38G]/AUCCPT-11) was 0.7-0.8, which suggests 
that oral dosing results in presystemic conversion of CPT-11 to SN-38. An 
average of 72% of SN-38 was maintained in the lactone form during the first 24 
hr after administration. The maximum-tolerated dose and recommended phase II 
dosage for oral CPT-11 is 66 mg/m2/day in patients younger than 65 years of age 
and 50 mg/m2/day in patients 65 or older, administered daily for 5 days every 3 
weeks. The dose-limiting diarrhea was similar to that observed with i.v. 
administration of CPT-11. The biologic activity and favorable pharmacokinetic 
characteristics make oral administration of CPT-11 an attractive option for further 
clinical development. However, a low bioavailability (< 20%) and high variability 
(50%) in AUC were encountered, which may limit the oral use of CPT-11 [72].  
Metabolism  
The metabolism of CPT-11 is complicated and involves several drug metabolizing 
enzymes (Figure 1-1). CPT-11 is hydrolyzed by human carboxylesterases 1 and 2 
(hCE1 and 2) [73-77] to the active metabolite SN-38 (7-ethyl-10-
hydroxycamptothecin), which is 100 to 1000-fold more cytotoxic than the 
parental molecule [78, 79]. SN-38 is subsequently conjugated to SN-38 
glucuronide (SN-38G) by uridine diphosphate glucuronosyltransferase 
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Figure 1-1. Metabolism of CPT-11 in humans. APC, 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-
piperidino]-carbonyloxycamptothecin; NPC, 7-ethyl-10-[4-amino-1-piperidino]-
carbonyloxycamptothecin; CYP3A4, cytochrome P450 3A4; UGT1A1, UDP-
glucuronosyltransferase 1A1. 
 
SN-38G has only weak anti-tumor activity, which can be converted to SN-38 by 
intestinal β-glucuronidase (β-glu) and reabsorbed into the plasma. Such 
enterohepatic recirculation of SN-38 may contribute to the increased exposure of 
the intestinal epithelium to SN-38 and the late SN-38 double peaks in the plasma 
[20, 81]. SN-38G and CPT-11 can also be reabsorbed into the enterohepatic 
circulation to a certain extent by intestinal cells [82, 83].  
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A second major metabolism pathway of CPT-11 is cytochrome P-450 (CYP3A4 
and CYP3A5)-mediated bipiperidine side chain oxidation to form 7-ethyl-10-[4- 
N-(5-aminopentanoic acid)-1-piperidino)]carbonyloxycamptothecin (APC) and 7-
ethyl-10-[4-amino-1-piperidino]carbonyloxycamptothecin (NPC) [84-86]. NPC, 
but not APC, can undergo hydrolysis to form SN-38 by human hepatic and plasma 
carboxylesterases in vitro [87, 88]. Both APC and NPC lack cytotoxicity [89]. The 
peak plasma concentrations and AUC values of NPC are very low after CPT-11 
administration [90], suggesting that there is a rapid and virtually complete 
conversion of this compound to SN-38 in the systemic circulation. In addition, 
SN-38 is possibly oxidized by CYP3A4 [91]. 
Conversion of CPT-11 lactone and carboxylate forms 
CPT-11, SN-38 and SN-38G are in equilibrium with their active lactone and 
inactive carboxylate forms. The lactone form has a closed α-hydroxy-δ-lactone 
ring, which can be reversibly hydrolyzed to form the open-ring hydroxyl acid 
(carboxylate form). The rate of hydrolysis is dependent on pH [92-94], ionic 
strength [93], and protein concentration [94, 95]. The lactone form has been found 
to be essential for the stabilization of the DNA-Topo I complex and the tumor 
inhibitory activity of the lactone form is significantly greater than the carboxylate 
form [96]. Recent studies showed that in isolated intestinal cells, CPT-11 and SN-
38 lactones were both passively transported, whereas their respective carboxylate 
forms were actively transported [97]. There is no significant difference between 
the intestinal uptake rate of CPT-11 and SN-38 lactone and carboxylate. However, 
the respective intestinal uptake of CPT-11 and SN-38 lactone is about 10 times 
greater than those of the carboxylate form [98]. 
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Plasma protein binding 
CPT-11 over 0.1-4.0 mg/ml is 60-66% bound to human plasma and SN-38 is 94-
96% bound over 0.05-0.2 mg/ml [99]. Albumin is the major binding protein of 
CPT-11 and SN-38 in human plasma. In human blood, CPT-11 is mainly bound to 
plasma proteins (47%) and localized in erythrocytes (33%). The binding of SN-38 
to blood is high (99%) and most of SN-38 in blood is located in blood cells 
(approximately 66%) [99]. The lactone forms of CPT-11 and SN-38 are more 
stable in the presence of albumin, while the lifetimes of their carboxylate forms 
are insensitive to the addition of albumin [100, 101]. Binding isotherms 
constructed by the method of fluorescence lifetime titration showed that human 
albumin bound preferentially the carboxylate forms of CPT-11 and SN-38 over 
their lactone forms with a 150-fold higher affinity, providing an explanation for 
the shift to the carboxylate forms upon addition of human albumin [100]. 
Transport of CPT-11 across cellular membrane 
Several drug transporters have been implicated in the active efflux of CPT-11 
when multidrug resistance was studied. P-glycoprotein (Pgp) and the canalicular 
multispecific organic anion transporter [cMOAT, namely, multidrug resistance 
protein 2 (MRP2)] conferred resistance to CPT-11 by effluxing the drug out of the 
tumor cells [17] (Figure 1-2). In drug-resistant tumor cells overexpressing Pgp, the 
cellular accumulation of CPT-11 and SN-38 are decreased [102].  
 
CPT-11 and SN-38 in unconjugated and conjugated forms are also actively 
effluxed out of cells by MRP1 [103]. Moreover, the breast cancer resistance 
protein can transport CPT-11 and SN-38, conferring resistance to the two 
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compounds [104, 105]. The high-level expression of these transporters in tumor 






















































Figure 1-2. Primary active transport systems for CPT-11 and its metabolites in the bile canalicular 
membrane of humans. APC, 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino]-
carbonyloxycamptothecin; NPC, 7-ethyl-10-[4-amino-1-piperidino]-carbonyloxycamptothecin; 
SN-38G, SN-38 glucuronide; CYP3A4, cytochrome P450 3A4; UGT1A1, UDP 
glucuronosyltransferase 1A1; β-glu, β-glucuronidase; hCE, human carboxylesterase; Pgp, P-
glycoprotein; cMOAT, canalicular multispecific organic anion transporter. 
The mechanisms for the intestinal and biliary transport of CPT-11 and its 
metabolites have not been fully defined, although Pgp and cMOAT have been 
suggested to play an important role [106, 107]. In rat and human bile canalicular 
membrane vesicles, Pgp and cMOAT have been demonstrated to mediate the 
efflux of CPT-11 and SN-38 [108]. The involvement of Pgp and cMOAT in the 
efflux of CPT-11 and SN-38 has been further demonstrated in wild-type rats  and 
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rats defective in cMOAT in vivo [109, 110]. Intestinal efflux of CPT-11 by Pgp 
and/or cMOAT may be responsible for the low oral absorption of CPT-11. 
Excretion 
CPT-11 is predominantly eliminated in faeces with unchanged parental drug as 
the major excretion product (about 64% of the total dose) followed by smaller 
amounts of SN-38 and APC [111, 112] (Figure 1-3). On the average, 0.25 and 3% 
of the dose is excreted in the urine as SN-38 and SN-38G, respectively [20]. 
Similar results have been observed in rats where 34-55%, 7-9%, and 2-22% of 
CPT-11, SN-38 and SN-38G, respectively, were excreted into the bile over 24 hr 


















Figure 1-3. Clearance profile of CPT-11 after i.v. administration. 
 
 
Both CPT-11 and SN-38 can be reabsorbed into the enterohepatic circulation from 
the intestine following biliary excretion. Plasma concentrations of SN-38 
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gradually increased to reach peak levels within 1.5-3 hr after start of the i.v. 
administration and slowly began to decline thereafter, and a secondary peak 
appeared at 7-9 hr in some patients which contributed to 10-20% increase of the 
AUC of SN-38 [20, 111]. SN-38 is released from SN-38G due to intestinal β-glu 
mediated hydrolysis and followed by intestinal uptake [111]. This deconjugation 
and reabsorption may contribute to the observed considerable variabilities of 
pharmacokinetic parameters of CPT-11 and SN-38, as well as severe late-onset 
diarrhea caused by the increased exposure of the intestinal epithelium to SN-38, 
and the late SN-38 double peaks in the plasma caused by enterohepatic 
recirculation [20, 81, 116]. High faecal SN-38 concentrations and its 
enterohepatic circulation can be of clinical significance, as a potential recycling of 
SN-38 reduces the effective clearance and may add a distributional compartment 
by way of the enteric circuit. 
1.2.3 Toxicities of CPT-11 
Following the introduction of anti-tumor activity and pharmacokinetic profiles of 
CPT-11, the toxicities caused by CPT-11 will be discussed here. 
Although CPT-11 has been widely used for cancer treatment, its clinical 
application was circumvented by its dose-limiting toxicities, which are 
myelosuppression and gastrointestinal toxicity, in particular unpredictable severe 
diarrhea [17, 20], including early- or late-onset (< 24 hr or ≥ 24 hr after 
administration respectively). Early-onset diarrhea is observed immediately after 
CPT-11 infusion and probably due to the inhibition of acetylcholinesterase 
activity as it can be eliminated by atropine [117]. However, severe late-onset 
diarrhea of 3 (severe) or 4 (life threatening) grade, based on National Cancer 
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Institute Common Toxicity Criteria, occurring in up to 40% patients treated with 
CPT-11 after an average period of 6 days [118],  complicates the clinical use of 
CPT-11 [119, 120].  
Pharmacokinetic-toxicity relationship 
The relationship between pharmacokinetic parameters and pharmacodynamic 
effects of CPT-11 may help to elucidate the cause of inter-patient variation in side 
effects and can be used to predict the incidence of late-onset diarrhea to some 
extent [77, 78]. Most investigations found that the AUC values for both CPT-11 
and SN-38 significantly correlated with the severity of diarrhea, which were also 
related to the anti-cancer activity [121-123]. However, some studies showed that 
the correlation existed only for AUC and Cmax of CPT-11 [124-126] or only for 
those of SN-38 in mice and human [121, 127]. In addition, some researchers 
reported a positive correlation between the AUC of SN-38G and diarrhea [29, 68]. 
β-glu activity, but not intestinal tissue carboxylesterase activity, had been directly 
correlated with the severity of CPT-11-induced diarrhea [20, 83]. This gave a 
mechanistic support for treatment of diarrhea by limiting intestinal glucuronidase 
activity. At the same time, some studies suggested that there is a correlation 
between diarrhea and the biliary index of SN-38, a surrogate measure of biliary 
excretion, which is the product of the relative area ratio of SN-38 to SN-38G and 
the total CPT-11 AUC, calculated as AUCCPT-11 × (AUCSN-38/AUCSN-38G) [20, 68, 
128], suggesting that diarrhea is a function of the intraluminal exposure to SN-38 
[68, 129]. On the other hand, some trials found that this relationship only exists 
for AUC of CPT-11 and SN-38G, but not for SN-38 or biliary excretion [65] and 
some studies failed to find any relationship between diarrhea and any 
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pharmacokinetic parameters [130-132]. All these findings reflect the complexity 
of pharmacokinetic-pharmacodynamic relationship for anti-cancer agents such as 
CPT-11. 
Biochemical mechanisms for CPT-11 induced diarrhea 
Many studies have been carried out to explore the underlying biochemical 
mechanisms for CPT-11 induced toxicities. It is found that the early-onset toxicity 
is related to the adverse cholinergic effects of CPT-11, which acts as a specific 
acetylcholinesterase blocker or an acetylcholine receptor (including muscarinic 
and nicotinic receptors) agonist [133]. The piperidino side chain of CPT-11 is 
similar to dimethylphenylpiperazinium [134], which is a highly selective and 
potent stimulator of nicotinic receptors in the autonomic ganglion. Such 
cholinergic activity of CPT-11 intensifies intestinal contractility and leads to the 
disturbance in internal mucosal absorptive and secretory functions [133, 135].   
However, the biochemical mechanism for CPT-11-induced late-onset diarrhea is 
not fully identified, but several potential mechanisms have been suggested. One 
potential mechanism of late-onset diarrhea caused by CPT-11 is direct histological 
damage of SN-38 on the intestinal mucosa [136]. Intestinal bacterial microflora 
and human intestinal CE in the small intestine are involved in the etiopathogenesis 
of this effect [137-139]. Accumulation of SN-38 can cause direct damage to the 
intestinal mucosa by interfering with DNA Topo I. CPT-11  also increased 
cyclooxygenase-2 (COX-2) expression associated with an increase in 
prostaglandin E2 (PGE2) [140], which is secreted by the mucosa and smooth 
muscle of the small intestine. PGE2 is able to stimulate colonic secretion and 
hyperperistalsis of the gut, inhibit Na+,K+-ATPase which affects the absorption of 
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electrolytes [141], trigger Cl- secretion  and water loss [142]. Additionally, 
administration of CPT-11 stimulated the production of thromboxane A2, which 
has been shown to be a potent physiological stimulant of  water and Cl- secretion 
in the colon [143, 144]. Thus, it appears that the late-onset diarrhea is in part a 
consequence of thromboxane A2 and PGE2 induction secondary to colonic 
mucosal damage after CPT-11 treatment [145]. In addition, CPT-11 may induce 
secretion of cytokines such as tumor necrosis factor-α (TNF-α) in mouse and 
human mononuclear cells. TNF-α exerts cytotoxic effects on a wide range of 
tumor cells and is also a key pro-inflammatory cytokine and a primary mediator 
of immune regulation [146]. Induction of TNF-α has been associated with 
diarrhea induced by chemotherapy  [147, 148].  
Agents capable of inhibiting CPT-11 induced diarrhea 
Based on the knowledge of pharmacokinetic-toxicity relationship for CPT-11 and 
the possible underlying biochemical mechanisms related to CPT-11 induced 
toxicity, many approaches have been explored to overcome the CPT-11 induced 
diarrhea. Early treatment of severe late-onset diarrhea with high-dose loperamide 
has decreased patient morbidity [136]. Extensive studies have been conducted to 
identify other possible preventive approaches to ameliorate diarrhea. These 
included intestinal alkalization [149], oral antibiotics (e.g. neomycin) [150], 
enzyme inducers (e.g. phenobarbital), Pgp inhibitors (e.g. cyclosporine) [109], 
COX-2 inhibitors (e.g. celecoxib) [145], and blockade of biliary SN-38 secretion 
(e.g. probenecid and valproic acid) [151] (Table 1-1).   
Table 1-1. Experimental therapies and possible modes of action for CPT-11 induced diarrhea. 





• Aminoglycoside antibiotics (e.g. streptomycin) 
• Anti-cholinergic and anti-muscarinic effects  [152-154] 
• Morphine analogue (loperamide) 
• Loperamide + acetorphan 
• Opiate agonism 
• Block of calcium channels  
• Block of the calmodulin system in the colonic epithelium 
• Acetorphan is a potent enkephalinase inhibitor and antisecretory 
agent without significant effect on intestinal transit time  
• Inhibition of biliary excretion of CPT-11 
[155, 156] 
• CYPs inducers: Phenytoin, carbamazepine, & phenobarbital 
• UGT1A1 inducers: Phenobarbital & dexamethasone 
• β-Glucuronidase inhibitors: D-saccharic acid 1.4-lactone, Kampo medication Hange-
shashin-to (TJ-14) & baicalin 
• Inhibitors of the human intestinal CE:  Sulfonamide derivatives 
• Inhibitors of β-glucuronidase production: Penicillin, streptomycin, neomycin & 
bacitracin 
• All agents of this type are capable of interfering with the metabolism 
of CPT-11 and SN-38, to reduce the intestinal level of toxic SN-38 
and increased formation of APC and inactive SN-38G 
[151, 157-162] 
• Transport inhibitors: Cyclosporine A & probenecid 
• Agents that reduce intestinal drug uptake: Sodium bicarbonate, magnesium oxide, base 
water & ursodeoxycolic acid 
• Inhibition of biliary excretion of CPT-11 and SN-38 
• Inhibition of intestinal uptake of CPT-11 and SN-38  
 
• Anti-inflammatory cytokines: IL-2 & IL-15 
• Cytokine inducers: JBT-3002 
• TNF-α inhibitor: Thalidomide  
• Corticosteroid: Budesonide 
• Reduction of inflammatory cytokines 
• Increase of anti-inflammatory cytokines 
[118, 163-170]  
• COX2 inhibitor: Celecoxib • Inhibition of COX2 activity  
• Inhibition of PGs 
 
• Cytoprotectant: Amifostine 
• Proliferative agents: Glutamine 
• Protection of intestinal epithelium 
• Restoring intestinal epithelium 
 
• Octreotide • A long-acting somatostatin analogue 
• Reduces the secretion of some pancreatic and intestinal hormones 
• Prolongs intestinal transit time 
• Increases intestinal absorption of fluids and electrolytes  
[171, 172] 
• Adsorbents: activated charcoal  & oral carbonaceous adsorbent (Kremezin) • Adsorbtion of SN-38 & CPT-11 in intestine [173, 174] 
Late-onset 
• Miscellaneous agents 
- Intestinal growth factors: transforming growth factor-β and keratinocyte growth 
factor, stem-cell factor & glucagons-like peptide 2 
- Fish oil supplements 
- Valproic acid & ceftriaxone 
- Sucralfate & nifuroxazide 
- Activated charcoal 
• Promoting epithelial growth 
• Protection  of intestinal epithelium 
• Anti-diarrhea effect 
[175, 176] 
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Interestingly, a pilot clinical study in colorectal cancer patients indicated that co-
administered thalidomide almost eliminated CPT-11 induced gastrointestinal 
toxicities including nausea and diarrhea. In addition, a pilot study in 5 cancer 
patients found that oral treatment of St. John’s wort (SJW) at 900 mg/day for 18 
days alleviated irinotecan-induced toxicity [177]. However, the mechanisms for 
these protective effects are not very clear yet. In the present study, the protective 
effects of its combination with thalidomide or SJW on CPT-11 induced toxicities 
using a rat model would be investigated and the underlying pharmacodynamic and 
pharmacokinetic components involved using this rat model and in vitro models 
would be explored, which may provide a new treatment approach for 
chemotherapy-associated histological damages based on these mechanistic 
findings.  
1.3 THALIDOMIDE 
A brief introduction on the clinical activity, pharmacokinetic profile, and toxicity 
of thalidomide will be given in this section. 
Thalidomide (α-phthalimidoglutarimide) was first developed and introduced as a 
sedative to relieve nausea during pregnancy in the 1950s, but withdrawn from the 
market in 1961 due to its infamous teratogenicity [178]. It is a derivative of 
glutamic acid, containing two amide rings and a single chiral center. The 
interconversion between the enantiomers of thalidomide is very rapid at 
physiological pH in aqueous medium and biological matrices such as plasma, 
undergoing rapid spontaneous hydrolysis [179]. 
1.3.1 Clinical activity and mechanism of action of thalidomide 
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Clinical activity of thalidomide 
Potential activity has been observed in clinical trials for various hematological 
and solid tumor cancers including relapsed and/or refractory multiple myeloma 
[180],  myelodysplastic syndrome [181], mantle cell lymphoma [182], glioma 
[183], renal cell carcinoma [184, 185], metastatic melanoma [185], pancreatic 
cancer and androgen-independent prostate cancer [186, 187]. Thalidomide was 
administered to patients with myeloma based upon the observations that bone 
marrow angiogenesis was prominent in active myeloma [187, 188]. More than 
50,000 patients with multiple myeloma have been treated with thalidomide to date 
[188-190]. Research with thalidomide provides clear and convincing evidence that 
thalidomide monotherapy is efficacious in relapsed and refractory multiple 
myeloma. Results typically show a consistent ∼30% response rate [191]. 
Thalidomide has an apparent synergistic activity when used in combination with 
dexamethasone in newly diagnosed and relapsed and/or refractory multiple 
myeloma, and could even reduce the median response time when compared with 
thalidomide alone [191]. In addition, thalidomide has been used to treat complex 
regional pain syndrome related to multiple myeloma [192].  
In recent years, there is an increased use of oral thalidomide for the management 
of a variety of autoimmune diseases including erythema nodusum leprosum, graft-
versus-host disease [193, 194], microsporidiosis [195], and Crohn’s disease [196]. 
Thalidomide has also shown activity in various dermatological conditions such as 
erythema nodosum leprosum, prurigo nodularis, aphthous ulcers, and actinic 
prurigo [197]. In addition, as an anti-angiogenic agent, thalidomide has been 
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clinically used for combination therapy with cancer chemotherapeutical agents to 
obtain additive or synergistic anti-tumor effects [198-201]. 
Mechanisms of actions 
The mechanisms of the actions of thalidomide have been studied. It is possible 
that angiogenesis inhibition, direct cytotoxic effects on tumor cells, increasing 
tumor cell susceptibility to apoptotic triggers, immunomodulation, cytokine 
modulation and attenuation of metastatic potential of tumor cells by reducing 
TNF-α-induced upregulation of adhesion molecules on endothelial cells 
individually or in combination, are all implicated [202].  Its very wide range of 
activities may be explained to a great extent by its effects on nuclear factor-κB 
(NF-κB) activity through suppression of IkappaB kinase activity. NF-κB is 
involved in the transcriptional regulation of many genes including cytokines [e.g. 
TNF-α, interleukins (IL-6 and IL-12)], proteins involved in apoptosis [e.g. cellular 
inhibitor of apoptosis protein 2, Fas-associated death domain protein, Bcl-2 family 
members], and angiogenic factors [e.g. vascular endothelial growth factor 
(VEGF), TNF-α, and IL-8]. Therefore, NF-κB plays a central role in the 
regulation of pivotal processes including proliferation, tumor growth, apoptosis, 
and immune responses. Since thalidomide is able to suppress NF-κB activity 
[203], this drug has an impact on all of these processes. 
In preclinical models, growth inhibition of tumor cells by thalidomide has been 
reported against several tumor types. These effects of thalidomide are probably 
mainly due to an enhanced susceptibility to apoptosis. Thalidomide affects both 
pathways of apoptosis: the intrinsic pathway by reducing levels of the anti-
apoptotic members of the Bcl-2 family [204] and the extrinsic pathway by down-
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regulating proteins conferring resistance against Fas- or TRAIL-mediated 
apoptosis [200]. Another mechanism leading to growth inhibition is reduction of 
growth stimulating factors.  
Thalidomide also inhibits the production of TNF-α by monocytes, as well as T 
cells [205]. In addition, thalidomide enhances the production of IL-2, which itself 
may possess anti-tumor activities or may modulate the immune system [206]. Its 
effects on interferon-γ (IFN-γ) production are stimulatory or inhibitory but more 
reports have shown it to increase IFN-γ production than to inhibit it [207]. 
Thalidomide also inhibits IL-6, IL-10 and IL-12 production [208], and enhances 
IL-4 and IL-5 production [200]. IL-6 is a potent growth factor for malignant 
plasma cells, and its inhibition may be partly responsible for the action of 
thalidomide in myeloma [209]. In addition to increasing total lymphocyte counts 
as well as CD4+ and CD8+ T cells, thalidomide is a potent co-stimulator of T 
lymphocytes. Thalidomide also augments natural killer cell cytotoxicity in 
myeloma.  
Additionally, thalidomide has been shown to inhibit angiogenesis [210] by which 
thalidomide exerts its anti-tumor activity. Thalidomide inhibits the angiogenesis-
stimulating property of angiogenic factors [211, 212]. In addition, it reduces the 
levels of angiogenesis promoting factors, such as TNF-α, VEGF, and IL-6 [212]. 
Furthermore, thalidomide inhibits lipopolysaccharide-mediated induction of COX-
2 biosynthesis in murine macrophages [213], providing insights into the anti-
neoplastic properties of thalidomide. Angiogenesis, the formation of new blood 
vessels, is fundamental to wound repair, reproduction, and development. It is also 
a critical process for the growth, development, and metastasis of solid tumors 
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[214]. The growth of tumor beyond a size of 1 to 2 mm3 requires the assembly of 
a vascular network, so that tumor that is unable to elicit angiogenesis will exist in 
a dormant state. The pioneering work by Folkman et al. [215] has defined 
angiogenesis as an appealing target for the development of anti-neoplastic drugs. 
Anti-angiogenic therapy is recently becoming a research focus of cancer 
pharmacology and dozens of angiogenic inhibitors including antibody against 
VEGF (Avastin), small molecule VEGF receptor, and tyrosine kinase inhibitor are 
undergoing clinical evaluations [216-219]. Therefore, anti-angiogenic therapy is 
becoming the fifth therapeutic modality in addition to surgery, chemotherapy, 
radiotherapy, and immunotherapy. A strategy combining continuous low-dose 
chemotherapy with anti-angiogenic inhibitors has been developed recently [220]. 
These studies have pointed out that this combination suppressed the growth of 
experimental tumors more effectively than conventional therapy alone and also 
circumvent drug resistance to a certain extent. The attractiveness of anti-
angiogenic therapy in cancer treatment is its generally low toxicity, broad 
efficacy, and that the target, the neovasculature endothelial cell, is genetically 
stable and unlikely to develop acquired resistance.  
1.3.2 Pharmacokinetics of thalidomide 
Following the introduction for thalidomide clinical activity and mechanisms, 
pharmacokinetic profiles and toxicities for thalidomide will be described here.  
Oral absorption of thalidomide (typically 200 mg, as the US FDA-approved 
capsule formulation) is slow and extensive, with time to Cmax of 4-10 μM at 2-4 
hr, apparent t1/2β of 6 hr, apparent CL of 10 L/hr and an estimated bioavailability 
of 80-100% [221-225]. With larger doses (≥ 200 mg), its absorption rate decreases 
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considerably, and thus a variable and lower bioavailability is expected. This has 
been partly ascribed to the poor solubility of thalidomide in intestinal fluids that 
resulted in thalidomide’s rate-limited pharmacokinetics (the ‘flip-flop’ 
phenomenon), with its elimination rate being faster than its absorption rate. 
Thalidomide is spontaneously hydrolysed into numerous products, whereas 
CYP2C-catalyzed metabolism plays a minor role in its elimination in vivo [226]. 
Protein bindings for the (R)- and (S)-enantiomers in plasma are 55% and 65%, 
respectively. More than 90% of the absorbed drug is excreted in urine and faeces 
within 48 hr. Pharmacokinetic parameters for oral dose of racemic thalidomide 
and its separate enantiomers have been determined in healthy volunteers and 
patients [227]. 
A one-compartment model with first-order absorption and elimination best 
describes thalidomide pharmacokinetics. Multiple doses of thalidomide at 200 
mg/day over 21 days caused no change in the pharmacokinetics, with a steady-
state Cmax of 1.2 mg/L. Multiple-dose thalidomide treatment studies in cancer 
patients show pharmacokinetics comparable with those in healthy populations at 
similar dosages. Thalidomide exhibits a dose-proportional increase in AUC at 
doses from 50 to 400 mg [228]. Furthermore, some stereo-selective 
pharmacokinetic and pharmacodynamic profiles exist for thalidomide. The (S)-
isomer has been associated with the teratogenicity of thalidomide [224].  Due to 
the variable absorption caused by oral dose or disease states where patients 
experience nausea, oral pain or other swallowing problems, an i.v. formulation of 
thalidomide would be of clinical interest, but this is hindered by its poor solubility 
and rapid degradation in aqueous media [224]. 
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1.3.3 Toxicities of thalidomide 
The most common adverse events were somnolence, asthenia, rash, peripheral 
oedema, paresthesia, dizziness, constipation, dyspnoea, and leucopenia [229]. The 
most frequently observed adverse effects are related to the sedative action which 
appear to be dose-related [230]. Drowsiness, dizziness, and mood changes were 
observed in 33-100% patients. Loss of libido, nausea, pruritus, hypothyroidism, 
serious dermatological reactions including Steven-Johnson syndrome and 
menstruation abnormalities have been occasionally observed [231]. In addition, 
thalidomide can cause toxic peripheral neuropathy, which can sometimes be 
irreversible [231]. Changes in nerve conductivity are frequent and unpredictable 
adverse effects of thalidomide. Known or possible teratogenicity is of course an 
absolute contraindication to the use of thalidomide. A single dose of thalidomide 
may be sufficient for inducing malformation [232]. 
1.4 ST. JOHN’S WORT  
Following the general introduction on thalidomide, the pharmacodynamic, 
pharmacokinetic and toxicological properties of St. John’s wort will be described. 
St. John’s wort (Hypericum perforatum, SJW) is one of the most commonly used 
herbal medicines for the treatment of mild to moderate depression [233]. SJW 
contains over two dozen constituents, among which hyperforin and hypericin are 
the major active components (Figure 1-4). 
1.4.1 Pharmacodynamics of SJW 
Alcoholic extracts of SJW are mainly used for the treatment of mild to moderate 
depression as an alternative to classic anti-depressant, with a favorable side-effect 
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profile [233]. However, current evidence regarding the anti-depressive effects of 
hypericum extracts is inconsistent and confusing. In patients who met criteria for 
major depression, several recent placebo-controlled trials suggest that the tested 
hypericum extracts have minimal beneficial effects while other trials suggest that 
hypericum and standard anti-depressants have similar beneficial effects [234]. The 
anti-depressant effect of SJW extract is unlikely due to an interaction of hypericin 
with central neurotransmitter receptors. The main in vitro effects of hyperforin (at 
concentrations of 0.1-1 µM) are non-specific presynaptic effects, resulting in the 
nonselective inhibition of the uptake of many neurotransmitters, and the 
interaction with dopamine D1 and opioid receptors. 
However, it is still unclear whether these mechanisms can be applied in vivo, 
since after administration of SJW extract, brain concentrations of hyperforin are 
well below those active in vitro. In the rat, SJW extract might indirectly activate 
sigma receptors in vivo (through the formation of an unknown metabolite or 
production of an endogenous ligand), suggesting a new target for its anti-
depressant effects [235, 236]. In addition, SJW has been reported to have anti-
inflammatory effects. There are some reports attributing the anti-inflammatory 
effects of SJW or its ingredients to the inhibition of nuclear factor-κB (NF-κB) 
activation [237, 238], inhibition of protein kinase C [239], and reduction of the 
lipopolysaccharide-, cytokine- or substance P-induced expression of COX-2, 
inducible nitric-oxide synthase  or IL-6 [240, 241].  
SJW and its components (in particular hyperforin and hypericin) have 
demonstrated in vitro cytotoxicity and apoptosis-inducing effect by triggering 
activation of caspases in several tumor cell lines (e.g. HT-1080, C-26, K562, and 
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SK-N-BE) [242]. Hyperforin is also shown to inhibit matrix metalloproteinases, 
extracellular signal-regulated kinase 1/2, and leukocyte elastase [242]. The 
cytotoxicity of SJW has been shown to be partially related to the inhibition of 
protein kinase C [243] and formation of oxygen radicals [244]. SJW inhibited the 
growth and metastasis of human prostatic carcinoma orthotopically implanted in 
nude mice [245]. In a metastatic mouse model using C-26 or B16-LU8 tumor 
cells, daily intraperitoneal (i.p.) administration of hyperforin remarkably 
decreased the size of metastases with C-26 (38%) and the number of lung 
metastases with B16-LU8 (22%), with preservation of apparently healthy and 
active behaviour. Moreover, several studies showed that hypericin is a potent 
photosensitizer with powerful in vivo and in vitro anti-neoplastic and apoptosis-
inducing activity upon photoactivation with either visible or UV light [246]. 
These findings indicate that both hyperforin and hypericin are potent inducers of 
tumor cell apoptosis by targeting multiple signalling molecules. This may provide 
a rationale for the combined use of SJW or its components with other 
chemotherapeutic agents for increasing efficacy.   
1.4.2 Pharmacokinetic interactions of drugs with SJW 
However, possible pharmacokinetic interactions should be taken into account 
when SJW was combined with other chemotherapeutic agents. Extensive 
preclinical and clinical studies have been reported on the inducing effects of SJW 
(mainly via hyperforin) on CYP2B6/CYP3A4 and Pgp [247]. Hyperforin, but not 
hypericum extracts, resulted in a significant induction of CYP3A4 expression 
after treatment of primary human hepatocytes. SJW extracts and its major 
components have been reported to inhibit the activities of recombinant CYP1A2, 
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2C9, 2C19, 2D6, and 3A4 [248]. Direct evidence for induction of Pgp by SJW in 
vivo is provided by the finding that long-term pretreatment increased Pgp 







































Figure 1-4. Chemical structures of the major constituents of St. John’s wort. 
 
More importantly, a number of pharmacokinetic and/or pharmacodynamic 
interactions of SJW with other clinically important drugs (e.g. cyclosporine, 
amitriptyline, digoxin, and methadone) have been reported [251]. The induction 
of hepatic and intestinal CYP3A4 and/or Pgp may partly explain most of these 
interactions, because CYP3A4 is involved in the metabolism of more than 50% of 
current therapeutic drugs and Pgp mediates the intestinal and hepatic transport of 
many drugs. However, the clinical importance of drug interaction with SJW 
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depends on a number of factors that are associated with coadministered drugs, 
herbs and patients. In most cases, the extent of drug interactions with SJW varies 
markedly among individuals, depending on inter-individual differences in drug 
metabolizing enzymes and transporters, existing medical conditions, age and other 
factors.  
1.4.3 Side effects of SJW 
otease inhibitors used in anti-HIV treatment, are absolutely 
contraindicated [251]. 
1.5 OBJECTIVES OF THE THESIS 
In addition, observational studies with preparations of SJW have recorded adverse 
events among those treated of between 1 and 3% [252]. The most common 
adverse events are reactions of the skin exposed to light. Investigations in 
volunteers have shown that the threshold dose for an increased risk of 
photosensitization is about 2-4 g/day of a usual commercial extract (equivalent to 
approximately 5-10 mg of the hypericin). Recently, it has been reported that 
hypericum preparations must not be taken at the same time as other anti-
depressants. If co-medication with coumarin-type anti-coagulants is unavoidable, 
it must only be undertaken provided the physician closely monitors clotting 
parameters. Concomitant administrations with cyclosporine and indinavir, and for 
the time being, other pr
As mentioned above, histological damage is a common dose-limiting toxicity 
associated with cancer chemotherapy, especially in the treatment of colorectal 
cancer by use of irinotecan (CPT-11), 5-fluouracil and oxaliplatin [253, 254]. The 
occurrence of severe, uncontrollable diarrhea has limited the further evaluation of 
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more aggressive anti-tumor regimens using CPT-11. Despite great interest in 
diarrhea induced by CPT-11 and a large amount of effort put into its investigation, 
effective strategies are still needed to circumvent such toxicity, thus allowing 
safer delivery of this potential agent in the clinical setting.  
n both 
pharmacokinetics and toxicity of CPT-11 have not been fully examined.  
A good response rate and acceptable tolerability regarding gastrointestinal effects 
were demonstrated in a pilot study of the irinotecan/thalidomide combination in 
patients with metastatic colorectal cancer [165, 255, 256]. Although the 
modulation of CPT-11 plasma pharmacokinetic profiles and the beneficial 
biological response modifying effects of thalidomide have been implicated, the 
underlying mechanisms involved are not fully understood. In addition, a clinical 
pilot study in 5 patients indicated that combination of SJW with CPT-11 
significantly alleviated CPT-11 induced neutropenia, accompanied with decreased 
plasma levels of SN-38, which might be attributed to the induction effect of SJW 
on CYP3A4 expression [177]. Based on this finding, the authors advised that 
patients administered with CPT-11 should refrain from taking SJW as the 
combination may have a deleterious impact on treatment outcome. However, the 
underlying mechanisms for the modifying effects of SJW o
In the present study, a rat model with dose-limiting toxicity profiles that are 
similar to those observed in patients treated with CPT-11 was developed and used 
to study the modulations of CPT-11 induced gastrointestinal and hematological 
toxicities by the combinations of thalidomide and SJW. The rat was chosen to be 
used in this study as: a) the metabolic pathways of CPT-11 in rats and humans are 




SJW as well as the underlying mechanisms involved were evaluated.  
ave modulation effects on cytochrome P450 
and/or drug transporting proteins.  
contribution of enzymes for individual pathways including variation in the 
kinetics of hydrolysis of CPT-11 between humans and rats; b) the transport and 
elimination routes of CPT-11 in rats and humans are also similar; c) the rat is 
sensitive to CPT-11 and it has been previously used in CPT-11 toxicity studies; 
and d) rats facilitate pharmacokinetic studies by allowing repeated blood sampling 
and have been widely used for CPT-11 pharmacokinetic studies [257]. Therefore, 
the underlying pharmacodynamic and pharmacokinetic components involved in 
the protective actions of thalidomide and SJW were explored using this rat model 
and various in vitro models. Furthermore, the similarities and differences in terms 
of the protective abilities against CPT-11 induced toxicity by thali
Based on these findings, these two combination therapies can be further 
evaluated. Moreover, these mechanistic examinations for CPT-11 induced 
histological damages and the protective effects of thalidomide and SJW may 
provide some insights for identifying new effective strategies to circumvent CPT-
11 induced toxicities. The achievements in abolition of CPT-11-induced 
complication may reduce mortality caused by severe diarrhea and inflammation, 
as well as avoid overall reduction in effectiveness of therapy caused by 
interruptions or dose reductions during treatment [224, 258-262]. In addition, the 
kinetic study of the combination of SJW with CPT-11 using in vitro models may 
provide some insights into the pharmacokinetic interactions of chemotherapeutic 
agents with herbal medicines that h
CHAPTER 2 THALIDOMIDE REDUCED THE DOSE-LIMITING 
TOXICITIES OF CPT-11 IN THE RAT 
2.1 INTRODUCTION 
Irinotecan (CPT-11), a potent DNA topoisomerase I inhibitor, has been widely 
used for the treatment of advanced colorectal cancer as a first-line therapy in 
combination with 5-fluororacil [263]. However, its gastrointestinal and 
hematological toxicities have become unpredictably severe in certain patients, 
thus compromising the success of CPT-11-based chemotherapy.  
Thalidomide has been used alone and more often in combination with other anti-
cancer agents for treatment of a variety of tumors and substantial responses have 
been observed in patients with multiple myeloma [258]. Murine studies have 
demonstrated that thalidomide is able to potentiate the activity of a number of 
anti-cancer agents including melphalan, celecoxib, angiostatin, fludarabine, 
dacarbazine, paclitaxel, sulindac, cyclophosphamide [264-267]. More 
importantly, a variety of clinical studies found that combined use of thalidomide 
with carboplatin [218], cyclophosphamide [268], paclitaxel [185, 269], epirubicin 
[270], temozolomide [271], carmustine [183], dexamethasone [272], IL-2 [273], 
or IFN-α2b [274] resulted in improved clinical response and reduced resistance 
coupled with reduced or unchanged toxicity in cancer patients.  
A good response rate and acceptable tolerability regarding gastrointestinal effects 
were demonstrated in a pilot study of the irinotecan/thalidomide combination in 
patients with metastatic colorectal cancer [146, 165, 255, 256, 275]. However, the 
mechanisms underlying this striking protective effect are not very clearly elucidated 
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yet, although the beneficial biological response modifying effects of thalidomide 
have been implicated.  
In addition, studies have shown that CPT-11 induced secretion of TNF-α in 
murine and human mononuclear cells [276]. TNF-α is a key pro-inflammatory 
cytokine and a primary mediator of immune regulation [277]. There exists a close 
interaction between epithelial cellular apoptosis and pro-inflammatory cytokines 
expression in intestines. TNF-α has been shown to play an essential role in 
regulating intestinal epithelial cell apoptosis and/or survival during chronic 
inflammation [278]. TNF-α also plays a critical role in initiation of chemotherapy-
induced primary mucosal damage responses including early damage to connective 
tissue and endothelium, reduction of epithelial oxygenation, and ultimately, 
epithelial basal-cell death and injury. Therefore, TNF-α may also play an 
important role in the intestinal inflammation and damage induced by CPT-11. 
Thus, down-regulatory effect on TNF-α expression by thalidomide may provide 
another rationale for the combination with thalidomide to reduce toxicity of CPT-
11 in our study. Furthermore, as a potential anti-angiogenic agent, thalidomide 
may exert its anti-tumor activity when combined with CPT-11.  
In the present study, based on the pilot clinical report and the hypothesis that 
using anti-TNF-α agents may alleviate CPT-11-induced complication, a rat model 
was developed to investigate whether combination of thalidomide could attenuate 
gastrointestinal and hematological toxicities caused by CPT-11. In addition, the 
potential pharmacodynamic mechanisms involved for this interaction were 
explored by examining the cytokine expressions and epithelial cellular apoptosis 
using this model. The increasing understanding of the molecular events that lead to 
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chemotherapy-induced intestinal mucosal injury and the protective effect of 
thalidomide may allow us to identify new approaches to arrest chemotherapy-induced 
intestinal damages, which may then reduce mortality caused by severe diarrhea and 
inflammation and avoid overall reduction in effectiveness of therapy caused by 
interruptions or dose reductions during treatment. 
2.2 MATERIALS AND METHODS  
2.2.1 Chemicals 
CPT-11 lactone form (diethyl-4,11 hydroxy-4 (piperidino-4 piperidino-
carbonyloxy)-9 1H-pyrano (3’, 4’, 6, 7) indolizino (1, 2-b) quinolein-(4H, 12H) 
dione-3, 14 hydrochloride trihydrate, Irinotecan, > 99% purity as determined by 
high performance liquid chromatography (HPLC), molecular weight = 677.20) 
was purchased from SinoChem Ningbo Import and Export Co. (Ningbo, China). 
CPT-11 was protected from light exposure to avoid degradation. An injectable 
formulation of CPT-11 was prepared by dissolving CPT-11 (20 mg/ml), D-
sorbitol (45 mg/ml) and D-lactic acid (0.9 mg/ml) in Milli-Q water heated to 70-
90ºC for 5-10 min. The pH of this clear solution was adjusted to 3.5 by 1 M 
NaOH. The resulting solution was sterile-filtered (0.22 μm, Millipore, MA, USA) 
and stored at 4ºC under dark condition until use [135]. Thalidomide was provided 
by Celgene Co. (MA, USA). D-sorbitol, D-lactic acid, protease inhibitor cocktail, 
diethyl pyrocarbonate (DEPC), formaldehyde and Bradford reagent were all 
purchased from Sigma Chemical Co. (St. Louis, Mo, USA). Trizol and RNase 
away reagent were purchased from Invitrogen (Carlsbad, CA, USA). The water 
used was of Milli-Q grade purified by a Milli-Q UV Purification System 
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(Millipore, Bedford, MA, USA). All other chemicals were of analytical grade or 
HPLC grade obtained from commercial sources.  
2.2.2 Animals 
Healthy male Sprague Dawley rats (200-220 g, purchased from the Laboratory 
Animals Centre, National University of Singapore, Singapore) were used in the 
study after 2-4 days’ acclimatization with free access to water and regular diet. All 
animal procedures were approved by the Institutional Animal Care and Use 
Committee (IACUC) of the National University of Singapore. Rats were kept in a 
room under controlled temperature (23-24ºC) with a 12-hr light-dark cycle and 
housed in wire-bottom cages with paper lining beneath. 
2.2.3 Drug administration schedules 
To set up a CPT-11 induced toxicity model (including myelosuppression and 
gastrointestinal damages) in male Sprague Dawley rats, we adopted the dosing 
schedule [60 mg/kg i.v. once daily for four consecutive days (days 1-4)] reported 
previously by the Kurita and the Takasuna groups [125] . Using this CPT-11’s 
regimen, the diarrhea throughout days 5-8 was similar to human diarrhea in terms 
of being resistant to conventional anti-diarrhea agent, which was considered to be 
late-onset diarrhea, which prevented the adoption of CPT-11 in aggressive 
chemotherapy [125, 145]. Rats were randomly divided into three groups. One 
group was treated with CPT-11 at a dose of 60 mg/kg/day by i.v. injection (3 
ml/kg/day) for four consecutive days (days 1-4). DMSO (1%, v/v) without 
thalidomide was also given at 1 ml/kg/day by i.p. injection to this group of rats for 
eight consecutive days (starting one day before the first CPT-11 injection) as 
control vehicle. Treatment group of rats was administered with CPT-11 at 60 
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mg/kg/day by i.v. for four consecutive days in combination with thalidomide in 
1% DMSO (v/v) (100 mg/kg/day by i.p. for eight consecutive days, starting one 
day before the first CPT-11 injection). A dose of 100 mg/kg for thalidomide was 
used as this level of dose is reported to elicit significant biological response in 
extensive previous studies [267, 279-281]. In addition, another group of rats 
without any drug treatment was also included as blank. Each group consisted of 4 
-7 rats.  
2.2.4 Monitoring of CPT-11 induced diarrhea 
The severity of diarrhea and changes in body weight were monitored twice a day 
throughout the study (for a total of 12 days from the first administration of 
thalidomide). In Sprague Dawley male rats, diarrhea observed after the final 
administration (beginning from day 5) was considered to be late-onset diarrhea. 
The severity of diarrhea was scored according to the  following standard as 
described previously [282, 283]:  
• 0: normal, normal stool or absent; 
• 1: slight, slightly wet and soft stool; 
• 2: moderate, wet and unformed stool with moderate perianal staining of 
the coat; 
• 3: severe, watery stool with severe perianal staining of the coat. 
2.2.5 Counting of blood cells 
Rat blood (about 300 μl) was collected using a K2-ethylenediaminetetraacetic acid 
(EDTA) treated tube (Microtainer®, Becton Dickison and Company, Franklin 
Lakes, NJ, USA) before drug administration (day 0) and on days 5, 7, 9, and 11. 
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Leucocytes including lymphocyte and neutrophil were counted with a XE-2100 
Hematology Analyzer (Sysmex, Illinois, USA). 
2.2.6 Evaluation of intestinal damages  
Total 12 groups of rats (n = 4-6 per group) were included to examine intestinal 
damages on days 5, 7, 9, 11 after treatment of CPT-11 alone or combination with 
thalidomide.  
Among which, four groups of rats were treated with i.v. CPT-11 injection at 60 
mg/kg/day for four consecutive days and 1% DMSO (v/v) (control vehicle) by i.p. 
injection at 1 ml/kg/day for eight consecutive days starting one day before the first 
CPT-11 injection. The rats in the four groups were sacrificed on days 5, 7, 9, and 
11, respectively, and the macroscopic and microscopic gastrointestinal toxicities 
were monitored.  
For microscopic evaluation, intestinal tissues (ileum, caecum, and colon) were 
extirpated after exsanguination and fixed in 10% neutral buffered formaldehyde. 
After routine processing (Leica TP 1050 automated vacuum tissue processor, 
Leica Microsystems AG, Wetzlar, Germany), segments were embedded in 
paraffin wax (Leica EG1160 paraffin embedding station, Leica Microsystems AG, 
Wetzlar, Germany). Slices of 4-5 µm were taken by a Leica RM 2135-Rotary 
Microtome (Leica Microsystems AG, Wetzlar, Germany), stained with 
hematoxylin-eosin (H&E) and subjected to light microscopic examination (Leica 
DMRXA Microscope, Leica Microsystems AG, Wetzlar, Germany) in a blinded 
manner by covering the ID of each sample. Semi-quantitative scoring systems for 
macroscopic and microscopic evaluations of intestinal damages were used based 
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on the methods previously described [284]. Briefly, the macroscopic evaluation of 
intestinal tissues was based on the severity of gut wall thickening, hyperemia, 
hemorrhage, formation of pseudomembrane-like substance, ulceration, adhesion, 
diarrhea and stomach swelling. The microscopic evaluation was based on the 
severity of ulceration, destruction of normal mucosal architecture, crypt abscesses, 
degeneration of crypts, globlet cell mucus depletion, infiltration of leucocytes, 
muscle thickening, and edema (i.e. swelling) (Table 2-1 and Table 2-2).  
Table 2-1. The scoring criteria for the macroscopic evaluation of intestinal damages in rats. 
 
S/N Observation Score Details of damage 
    
0 Absence 
1 Slight 
2 Mild 1 Wall thickening 
3 Severe 
    
0 Absence 
1 Slight 
2 Mild 2 Hyperemia 
3 Severe 
    
0 Absence 
1 Slight 
2 Mild 3 Hemorrhage 
3 Severe 
    
0 Absence 4 Formation of pseudo membrane-like substance 2 Presence 
    
0 Absence 
2 Ulceration with inflammation at 1 site 
4 More sites of ulceration and inflammation 5 
Ulceration 
(ulcerative damages) 
6 Ulceration extending > 1 cm along the intestine 
    
0 Absence 
1 Slight: can be easily separated from other tissue 
2 Mild: difficult to be separated from other tissue 6 Adhesions 
3 Severe: can not be separated from other tissue 
    
0 Normal: normal stools or absent 
1 Slight: wet and soft stools 
2 Moderate: wet and unformed stools with moderate perianal staining of the coat 7 Diarrhea 
3 Severe: watery stools with severe perianal staining of the coat 
    
0 Absence 
1 Slight 
2 Mild 8 Stomach swell 
3 Severe 
 
Four groups of rats received i.v. CPT-11 injections at 60 mg/kg/day with 
thalidomide at 100 mg/kg/day by i.p. injections and the rats were sacrificed on 
days 5, 7, 9, and 11, respectively, with close monitoring of their toxicity. Four 
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additional groups of rats used as blank controls without any drug treatment were 
also included and sacrificed on days 5, 7, 9, and 11, respectively.  
 
Table 2-2. The scoring criteria for the microscopic evaluation of intestinal damages in rats. 
 
S/N Observation Score Details of damage 
    
0 Absence (normal appearance) 
1 Damage of surface epithelium 
2 Focal mucosal or transmucosal damage 1 Ulceration 
3 Extensive mucosal or transmucosal damage 
    
0 Normal 
1 Slight 
2 Mild 2 
Extent of destruction of normal 
mucosal architecture 
3 Severe 
    
0 Absence 
1 Slight 
2 Mild 3 Crypt abscesses 
3 Severe 
    
0 Absence 
1 Slight 
2 Mild 4 Degeneration of crypts 
3 Extensive 
    
0 Absence 
1 Slight 
2 Mild 5 Goblet cell mucus depletion 
3 Severe 
    
0 Absence 
1 Slight 
2 Mild 6 Degree of infiltration 
3 Severe (maximal infiltration) 
    
0 Absence 
1 Slight 
2 Mild 7 Muscle thickening 
3 Severe (maximal thickness) 
    
0 Absence 
1 Slight 




2.2.7 Terminal deoxynucleotidyl transferase-mediated dUTP nick-end 
labeling (TUNEL) assay 
The assay of nuclear DNA fragmentation for apoptotic cell death in paraffin-
embedded tissue sections was performed by TUNEL staining assay. TUNEL 
staining was done with standard methods according to the manufacturer’s 
recommendations (DeadEnd™ Fluorometric TUNEL System, Promega, Madison, 
WI, USA). This system measures the fragmented DNA of apoptotic cells by 
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catalytically incorporating fluorescein-12-dUTP at 3’-OH DNA ends using the 
recombinant terminal deoxynucleotidyl transferase (rTdT). rTdT forms a 
polymeric tail using the principle of the TUNEL assay. The fluorescein-12-dUTP-
labeled DNA can be visualized directly using fluorescence microscopy. 
Tissue sections embedded in paraffin as described before were first prepared by 
deparaffinization using xylene. After being rehydrated in graded ethanol and fixed 
by immersing the slides in 4% methanol-free formaldehyde solution, the tissues 
were exposed to proteinase K solution to help permeabilize tissues to the staining 
reagents. To label double-stranded DNA breaks, 50 μl of rTdT incubation buffer 
was added and incubated at 37°C for 60 min in a humidified chamber. The 
reaction was terminated by immersing the slides in 2 × standard saline citrate. 
After removing unincorporated fluorescein-12-dUTP, the samples were stained by 
immersing in propidium iodide solution which was freshly diluted to 1 μg/ml in 
phosphate buffered saline (PBS) for 15 min at room temperature in the dark. 
Then, samples were immediately analyzed under a fluorescence microscope 
(Olympus micro image analysis system with retiga exi mono 12 bit cooled 
camera) using a standard fluorescence filter set to view the green fluorescence at 
520 ± 20 nm; red fluorescence of propidium iodide at > 620 nm. In the meantime, 
negative control (using incubation buffer without rTdT) and positive control 
(using DNase I treatment to result in fragmentation of the chromosomal DNA and 
exposure of multiple 3’-OH DNA ends for labelling) were also included.  
2.2.8 Quantitation of cytokines by enzyme-linked immunosorbent assay 
(ELISA) 
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Blood samples were also collected and allowed to clot at room temperature before 
centrifuging at 2,000 × g and 4ºC for 15 min. The serum was then immediately 
collected and aliquoted, and stored at -80ºC until analysis. Tissues (including 
liver, spleen, ileum, caecum, and colon) were harvested from rats killed on days 0, 
5, 7, 9, and 11 after the first CPT-11 injection and snap-frozen in liquid nitrogen 
and then stored at -80ºC. Prior to assay, specimens were thawed and homogenized 
in a 50 mM Tris-HCl buffer containing 100 mM NaCl (pH 7.4) and 1% (v/v) 
protease inhibitor cocktail (Sigma, St. Louis, Mo. USA) on ice using a Heidolph 
homogenizer (Heidolph Instruments GmbH & Co. KG, Germany). The resultant 
homogenates were then centrifuged at 4,000 × g for 5 min at 4°C. The supernatant 
was then aliquoted and stored at -80°C for further analysis.  
Cytokine levels of IL-1β, IL-2, IL-6, IFN-γ, and TNF-α in rat sera and various 
tissues were measured using a sandwich ELISA method. The Quantikine® 
immunoassay kits for IL-1β and IL-2 determination were purchased from R&D 
Systems (Minneapolis, MN, USA); while the analyses of IL-6, IFN-γ and TNF-α 
determination were processed using BD OptEIA™ ELISA Sets (BD Biosciences, 
San Jose, CA, USA). The sensitivities for the assays of IL-1β, IL-2, IL-6, IFN-γ 
and TNF-α were 5, 15, 4, 15, and 15 pg/ml, respectively. Standards and samples 
to be assayed were added to pre-coated 96-well plates. In some cases, the liver 
samples were diluted 10 times to bring the concentrations of IL-1β and IL-6 to the 
assay linear range. Samples and standards were incubated with biotinylated 
detection antibody for 2 hr. After the addition of avidin-horseradish peroxidase 
conjugate, the colour product was developed using tetramethylbenzidine substrate 
solution. The reaction was terminated by the addition of the stop solution (1M 
phosphoric solution) and the resultant optical density determined at a wavelength 
 41
of 450 nm within 30 min using a microplate reader (TECAN Group Ltd, 
Switzerland). 
Cytokine levels in each sample were calculated by reference to a standard curve 
constructed for each assay by plotting the net absorbance versus the concentration 
of standards on a logarithmic scale. Protein content of the samples was 
determined by the Bradford assay [35] according to the manufacturer’s 
recommendations (Sigma Chemical Co. St. Louis, Mo, USA). The cytokine levels 
in each tissue sample (in pg/ml) were then normalized by the protein content of 
each tissue sample, to give a final cytokine result expressed as pg/mg protein. The 
cytokine levels in sera were expressed as pg/ml. 
2.2.9 Determination of protein concentration 
The total protein concentration in tissue homogenates was determined by the 
Bradford method [17, 20] (Sigma, St. Louis, MO. USA) with bovine serum 
albumin as the standard. Protein samples were thawed, and then diluted 
appropriately with fresh NaOH (1 M) to make all protein soluble and to ensure 
that the concentrations are within measurable ranges of the calibration curve (100-
fold dilution for liver and 50-fold dilution for other tissues). Bovine serum 
albumin was dissolved in Milli-Q water and further diluted with 1 M NaOH to 
prepare the standards with the concentration of 0.1-1.4 mg/ml. The standards and 
digested protein samples as well as 5 µl 1 M NaOH (used as blank control) were 
added in duplicate to a 96-well ELISA plate (NUNC, Rochester, NY). The 
Bradford reagent (250 µl) was then added to each well and mixed on a shaker for 
30 sec. The absorbance was read at 595 nm using a microplate reader (TECAN, 
Switzerland). Standard curves were obtained by plotting the net absorbance versus 
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the protein concentration of standards. The protein concentration of the unknown 
samples was calculated using the standard curves. 
2.2.10 Reverse transcription and polymerase chain reaction (RT-PCR) assay 
mRNA Extraction 
RNA was extracted from intestinal samples by using Trizol reagent (Invitrogen, 
Carlsbad, CA, USA) according to the manufacturer’s protocol. Briefly, tissues of 
ileum, caecum, and colon were collected from rats killed on days 0, 5, 7, 9, and 11 
and mixed with Trizol, then immediately transferred into liquid nitrogen and 
stored at -80°C prior to use.  
Before extraction, the tissues were thawed on ice and homogenized in Trizol. 
Chloroform was then added to precipitate DNA and protein. After incubating for 
2-3 min at room temperature and centrifuging at 12,000 × g for 15 min at 4°C, the 
aqueous phase of RNA was collected carefully and 0.5 ml of isopropanol was 
added to the aqueous phase to precipitate RNA. The mixture was vortexed, 
incubated for 10 min at room temperature and centrifuged at 12,000 × g for 10 
min at 4°C. The RNA precipitate formed a gel-like pellet on the side and the 
bottom of the tube. After discarding the supernatant (isopropanol), 1 ml of 75% 
ethanol (made up with 0.1% DEPC-treated water) was added to wash the RNA. 
After centrifugation at 7,500 × g for 5 min at 4°C, the ethanol was removed and 
the RNA was dried under vacuum. Finally, the RNA pellet was mixed with 100 µl 
0.1% DEPC-treated water by pipetting up and down and then the solution was 
stored at -80°C until analysis. The purity of RNA was determined using a UV 
spectrophotometer (Shimadzu, Japan) by comparing its absorbance at 260 nm 
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(peak for RNA) and 280 nm (peak for proteins).  The concentration of total RNA 
in µg/ml was calculated by the following formula:  
RNA concentration = Absorbance × 40 
RT-PCR procedure 
RT-PCR amplification of TNF-α mRNA was processed using the Access RT-PCR 
System (Promega, Madison, WI, USA). The RT-PCR reaction was performed in a 
200 µl thin-wall test tube containing 10 µl AMV/Tfl 5 × reaction buffer, 1 µl 
dNTP Mix (0.2 mM each), 0.5 µM downstream primer and 0.5 µM upstream 
primer, 1.5 mM MgSO4, 1 µl AMV reverse transcriptase (5 u/μl) and 1 µl Tfl 
DNA polymerase (5 u/μl), and 1 µg TNF-α mRNA sample. In addition to the 
TNF-α primer, the housekeeping gene β-actin was also used in the same reaction 
as a reference for standardization of the PCR procedure used. The specific 
oligonucleotide primers of TNF-α (Rattus) and β-actin (Rattus) were designed 
according to sequences published earlier. The specificity of these primers was 
confirmed using standard nucleotide-nucleotide BLAST. The sequences were as 
follows: TNF-α primer sense, 5’-TAC TGA ACT TCG GGG TGA TCG GTC G-
3’; TNF-α primer antisense, 3’-CAG CCT TGT CCC TTG AAG AGA ACC-5’, 
Genebank accession No. NM_012675 (about 300bp); β-actin sense, 5’-GCC ACT 
GCC GCA TCC TCT T-3’; β-actin antisense, 3’-ATC GTA CTC CTG CTT GCT 
GA-5’, Genebank accession No. NM_031144 (about 408bp). RT-PCR was carried 
out using Flexigene Thermal Cycler (Techne, Burlington, NJ, USA) at 45ºC for 
45 min and 94ºC for 2 min. Amplifications were then carried out using 25 cycles 
of 94ºC for 30 sec, 60ºC for 1 min, and 68ºC for 2 min, followed by 68ºC for 7 
min and soaked at 4ºC. Initial experiments were carried out to optimize the RT-
PCR conditions using a variety of annealing temperatures, primer and magnesium 
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concentrations. For both of the oligonucleotide pairs, preliminary analyses 
applying various PCR cycles were conducted to define the appropriate range of 
cycles consistent with an exponential increase of the amount of the DNA product. 
In addition, the absence of contaminants was routinely checked by RT-PCR of 
negative control samples, in which RNA samples were replaced with sterile water. 
PCR products and molecular weight markers were subjected to 1% agarose gel 
(Seakem LE Agarose, Cambres Bio Science Rockland Inc., Rockland, ME, USA) 
electrophoresis (Bio-Rad Mini-Sub Cell GT system, Hercules, CA, USA) and 
visualized by means of ethidium bromide (Promega, Madison, WI, USA) staining. 
The gel images were digitally captured using Gel-Doc (Bio-Rad, Hercules, CA, 
USA) and densitometric analysis was performed with Quantity One 1-D Analysis 
software (Bio-Rad, Hercules, CA, USA). The levels of TNF-α mRNA were 
normalized to that of β-actin present in the same sample, expressed as TNF-α-to-
β-actin ratio (band intensity). Final results were expressed as fold increase in band 
intensity compared to that at day 0 (i.e. rats killed on day 0 that received no drug 
treatment). 
2.2.11 Statistical analysis 
Data were expressed as mean ± SD (standard deviation), except otherwise 
indicated. Diarrhea scores were analyzed using Wilcoxon rank sum test. Statistical 
comparisons for multiple groups were performed using a one-way analysis of 
variance (ANOVA) followed by Student’s Newman-Keuls test. Differences 
between two groups were analysed using unpaired Student’s t-test. Statistical 
significance was set as P < 0.05.  
 45
2.3 RESULTS 
2.3.1 Effects of thalidomide on CPT-11 induced toxicities  


























Figure 2-1. Body weight changes (% compared to that on day 1) in two groups of rats treated with 
CPT-11 and the control vehicle (1% DMSO, v/v) or CPT-11 in combination with thalidomide. 
Symbols: ○, Blank (without drug treatment); ▲, CPT-11+ Thalidomide; □, CPT-11+ Control 
vehicle (1% DMSO, v/v) (N = 4-6). 
 
The present study investigated body weight changes, leukocyte counts, and 
histological damages, cytokine expressions as well as apoptosis throughout the 
gastrointestinal tract including ileum, caecum, and colon tissues for the 
combination of thalidomide with CPT-11 throughout the whole study. Rats treated 
with CPT-11 and control vehicle (1% DMSO, v/v) experienced rapid decrease in 
body weight, reached a nadir by day 8 with a decrease of 11% compared to the 
baseline (day 1), and recovered to 104% of the baseline by day 11 (Figure 2-1). 
Co-administration of thalidomide with CPT-11 resulted in lesser body weight loss 
compared to rats receiving CPT-11 and control vehicle (1% DMSO, v/v), with a 
decrease of 2% by day 8 and recovery to 114% of the baseline by day 11 (P < 







Table 2-3. Incidence of early- and late-onset diarrhea in rats treated with CPT-11 and control vehicle (1% DMSO, v/v) or CPT-11 in combination with thalidomide. 
The values are the number of animals (n) with scores of severity of diarrhea. 
 
Early-onset diarrhea score a 
Day 1  Day 2  Day 3  Day 4 Treatment Group n 
0 1 2 3 Mean  0 1 2 3 Mean  0 1 2 3 Mean  0 1 2 3 Mean 
Blank 5 10    0  10    0  10    0  10    0 
CPT-11+ Thalidomide 6 12    0  10 2   0.17  10  1 1 0.42  5  3 4 1.5 
CPT-11+ 1% DMSO (v/v) 6 8 2 2  0.50  8 3 1  0.42  5 2 4 1 1.08  3 2 1 6 1.83 
 
Late-onset diarrhea score a 
Day 5  Day 6  Day 7  Day 8 Treatment Group n 
0 1 2 3 Mean  0 1 2 3 Mean  0 1 2 3 Mean  0 1 2 3 Mean 
Blank 5 10    0  10    0  10    0  10    0 
CPT-11+ Thalidomide 6 7   5 1.25  6 1 2 3 1.17*  5 4 3 0 0.83*  10 2   0.17 
CPT-11+ 1% DMSO (v/v) 6 4   8 2.00  2 1  9 2.33  1 3 3 5 2.00  7 3 2  0.58 
*P < 0.05 vs. CPT-11+ control vehicle (1% DMSO, v/v) group. Mean = Sum of scores (1-3)/rat number; 
a Two observations each animal/day. 
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Treatment of rats with CPT-11 at 60 mg/kg/day by i.v. for four consecutive days 
and control vehicle (1% DMSO, v/v) by i.p. for eight consecutive days induced 
severe early- (days 1-4) and late-onset (days 5-8) diarrhea, with mean severity 
scores of 0.5, 0.42, 1.08, 1.83, 2.0, 2.33, 2.0, and 0.58 by days 1-8, respectively 
(Table 2-3). The severity scores for late-onset diarrhea were significantly (P < 
0.05, by Wilcoxon rank sum test) brought down in rats treated with CPT-11 in 
combination of thalidomide (100 mg/kg/day, i.p.) on days 6 and 7. Rats without 
any drug treatment did not experience any diarrhea. 
The counts of leucocytes were also monitored in the toxicity study on days 0, 5, 7, 
9, and 11, respectively. The numbers of neutrophils and lymphocytes were 
decreased and reached a minimum by day 7 in rats treated with CPT-11 and 
control vehicle (1% DMSO, v/v) (Figure 2-2). However, combination of CPT-11 
with thalidomide increased the numbers of lymphocyte (P < 0.05) and neutrophil 
on day 7 (P < 0.01). Rats receiving either CPT-11 with control vehicle or CPT-11 
plus thalidomide had increased neutrophil numbers after day 7. This may be due 
to systemic response to severe inflammation of intestines. Rats without any drug 
treatment did not induce any detectable blood toxicities. 
Marked macroscopic and microscopic gastrointestinal damages were induced in 
rats treated with CPT-11 and control vehicle (1% DMSO, v/v). Typical 
macroscopic intestinal damages included wide wall thickening and swelling, 
hyperemia, haemorrhage, ulceration, as well as adhesion. Combination of 
thalidomide significantly reduced these damages on day 5 (10.5 vs.17.5, P < 
0.01), on day 7 (6.8 vs. 12.0, P < 0.05), on day 9 (4.6 vs. 9.2, P < 0.001), and on 
day 11 (3.2 vs. 6.7, P < 0.05), respectively (Figure 2-3).  
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Figure 2-2. Comparison of lymphocyte and neutrophil counts on days 0, 5, 7, 9, and 11 in rats 
treated with CPT-11 and control vehicle (1% DMSO, v/v) or in combination with thalidomide. *P 
< 0.05; **P < 0.01 (N = 4-6). 
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Figure 2-3. Scores of macroscopic intestinal (including ileum, caecum, and colon) damages by 
days 5, 7, 9, and 11 induced by CPT-11 in rats pretreated with thalidomide or the control vehicle 
(1% DMSO, v/v). *P < 0.05; **P < 0.01; ***P < 0.001 (N = 4-6). 
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Figure 2-4. Micrographs (magnification × 100) of ileum showing histological damages on days 0, 
5, 7, 9, and 11 in rats. The rats were treated with CPT-11 and the control vehicle (1% DMSO, v/v), 
or CPT-11 in combination with thalidomide. 
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Figure 2-5. Micrographs (magnification × 100) of caecum showing histological damages on days 0, 
5, 7, 9, and 11 in rats. The rats were treated with CPT-11 and the control vehicle (1% DMSO, v/v), 
or CPT-11 in combination with thalidomide. 
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Figure 2-6. Micrographs (magnification × 100) of colon showing histological damages on days 0, 
5, 7, 9, and 11 in rats. The rats were treated with CPT-11 and the control vehicle (1% DMSO, v/v), 
or CPT-11 in combination with thalidomide. 
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Figure 2-7. Scores of microscopic intestinal (including ileum, caecum, and colon) damages on 
days 5, 7, 9, and 11 induced by CPT-11 in rats pretreated with thalidomide or the control vehicle 




Typical microscopic injuries included severe damages of the mucosal surface of 
the intestines characterized by stubby villi, goblet cell mucus depletion, epithelial 
vacuolation, crypt abscesses and inflammatory cellular infiltration noted by HE 
staining (Figure 2-4, Figure 2-5, and Figure 2-6). In particular, these histological 
damages were extremely severe in the caecum on day 5 and day 7 compared to 
the small intestine and colon. These impairments, however, were significantly 
decreased in rats treated with CPT-11 in combination with thalidomide in the 
caecum and colon (Figure 2-7). 
2.3.2 TUNEL assay 
In normal rats without any drug treatment, the number of epithelial apoptotic cells 
per crypt in ileum, caecum, and colon were 2.0 ± 0.7, 5.0 ± 1.6 and 3.2 ± 1.3, 
respectively. CPT-11 caused a maximal epithelial apoptosis (62.6 ± 11.5 per 
crypt) on day 5 in the ileum, and then decreased thereafter (12.2-40.2 per crypt 
over 7-11 days). Combination of thalidomide significantly reduced ileal epithelial 
apoptosis on day 5 by 47.9% (P < 0.01), on day 7 by 39.3% (P < 0.01), and on 
day 11 by 52.5 % (P < 0.05) compared to rats received CPT-11 and the control 
vehicle [1% DMSO (v/v)] (Figure 2-8 and Figure 2-11).  
Similarly, maximal epithelial apoptosis was detected in the caecum and colon on 
day 5. Thalidomide pretreatment caused less epithelial apoptosis by 52.4% on day 
5 (P < 0.01), by 45.7% on day 7 (P < 0.001), and by 35.8% on day 11 (P < 0.01) 
in the caecum (Figure 2-9 and Figure 2-11). In addition, coadministered 
thalidomide reduced the apoptosis by 47.0% on day 5 (P < 0.01), by 34.1% on 
day 7 (P < 0.05), and by 28.4% on day 9 (P < 0.05) in the colon (Figure 2-10 and 
Figure 2-11). 
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Figure 2-8. Detection of apoptotic cells in ileum (4-μm slices) using TUNEL assay. The 
fragmented DNA of TUNEL-positive apoptotic cells (green spots) were incorporated with 
fluorescein-dUTP at free 3’-hydroxyl ends and visualized by fluorescence microscopy 
(magnification × 100).  
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Figure 2-9. Detection of apoptotic cells in caecum (4-μm slices) using TUNEL assay. The 
fragmented DNA of TUNEL-positive apoptotic cells (green spots) were incorporated with 
fluorescein-dUTP at free 3’-hydroxyl ends and visualized by fluorescence microscopy 
(magnification × 100). 
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Figure 2-10. Detection of apoptotic cells in colon (4-μm slices) using TUNEL assay. The 
fragmented DNA of TUNEL-positive apoptotic cells (green spots) were incorporated with 
fluorescein-dUTP at free 3’-hydroxyl ends and visualized by fluorescence microscopy 
(magnification × 100). 
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Figure 2-11. Number of intestinal epithelial apoptotic cells per crypt in rats treated with CPT-11 
and 1% DMSO (v/v) or in combination with thalidomide. *P < 0.05; **P < 0.01; ***P < 0.001 (N 
= 4-6). 
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2.3.3 Quantitation of cytokines by ELISA 
The levels of TNF-α, IFN-γ, IL-1β, IL-2, and IL-6 in intestinal tissues and liver, 
spleen as well as serum are shown in Figures 2-12, 2-13, 2-14, 2-15, and 2-16, 
respectively. Treatment of CPT-11 generally increased the levels of TNF-α, IFN-
γ, IL-1β, and IL-6 compared to day 0, which achieved peak levels by day 5 or day 
9 and declined thereafter, while the level of IL-2 generally decreased compared to 
day 0, reaching minimum level by day 5 or day 7 in the above tissues.  
Significant inhibition of TNF-α was seen in ileum from rats treated with 
combination therapy on day 5 by 64.9% (P < 0.05) and on day 7 by 59.0% (P < 
0.01); and in caecum on day 5 by 44.9% and on day 7 by 46.6% (P < 0.05), 
respectively, compared to the control group. Coadministered thalidomide caused 
no significant effects on IFN-γ expression in all tissues examined except that the 
splenic IFN-γ level in the combination group was increased more that 3-fold 
compared to that in the control group that received CPT-11 and 1% DMSO (v/v) 
on day 5 (P < 0.05). Combination of thalidomide caused significant inhibitory 
effects on IL-1β expression in spleen by 39.7% on day 9 and by 38.0% on day 11 
(P < 0.05). Similar inhibitory effect was observed in the combination group for 
IL-2 level in serum by 60.5% (P < 0.001) on day 11. In addition, IL-6 levels were 
significantly brought down by the combination with thalidomide in ileum on day 
5 by 67.3% (P < 0.05); in colon on day 5 by 41.3% (P < 0.05); in spleen on days 5 
and 7 by 62.1% and 48.5% (P < 0.05), respectively.  
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Figure 2-12. Protein levels of TNF-α in ileum (A), colon (B), caecum (C), liver (D), spleen (E), 
and serum (F) on days 0, 5, 7, 9, and 11 after CPT-11 administration in the control group treated 
with CPT-11 and 1% DMSO (v/v) and the combination group treated with CPT-11 and 














































































































Figure 2-13. Protein levels of IFN-γ in ileum (A), colon (B), caecum (C), liver (D), spleen (E), and 
serum (F) on days 0, 5, 7, 9, and 11 after CPT-11 administration in the control group treated with 
CPT-11 and 1% DMSO (v/v) and the combination group treated with CPT-11 and thalidomide.  
*P  < 0.05 (N = 4-6). 
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Figure 2-14. Protein levels of IL-1β in ileum (A), colon (B), caecum (C), liver (D), spleen (E), and 
serum (F) on days 0, 5, 7, 9, and 11 after CPT-11 administration in the control group treated with 
CPT-11 and 1% DMSO (v/v) and the combination group treated with CPT-11 and thalidomide. *P 
< 0.05 (N = 4-6). 
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Figure 2-15. Protein levels of IL-2 in ileum (A), colon (B), caecum (C), liver (D), spleen (E), and 
serum (F) on days 0, 5, 7, 9, and 11 after CPT-11 administration in the control group treated with 
CPT-11 and 1% DMSO (v/v) and the combination group treated with CPT-11 and thalidomide. 
***P < 0.001 (N = 4-6). 
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Figure 2-16. Protein levels of IL-6 in ileum (A), colon (B), caecum (C), liver (D), spleen (E), and 
serum (F) on days 0, 5, 7, 9, and 11 after CPT-11 administration in the control group treated with 
CPT-11 and 1% DMSO (v/v) and the combination group treated with CPT-11 and thalidomide. *P 
< 0.05 (N = 4-6). 
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2.3.4 TNF-α mRNA expression  
We examined the expression pattern and kinetics of the transcripts for TNF-α 
genes over 11 days after administration of CPT-11 in intestinal tissues including 
ileum, caecum, and colon (Figure 2-17). The transcripts for TNF-α in ileum were 
detectable in healthy rats without any drug therapy.  The band intensity increased 
after CPT-11 injection and reached a peak level on day 9 (2.8-fold increase 
compared to that of day 0) and then started to drop on day 11. However, 
combination with thalidomide brought down the increased expression levels of 
TNF-α mRNA, as indicated by decreasing fold-increase in band intensity 
compared to that of day 0 on days 7 and 9 by 29.2% and 29.1%, respectively (P < 
0.05).   
Although the transcripts for TNF-α in caecum were almost undetectable from 
healthy rats, they were readily detectable on days 5 to 11, with gradual decrease in 
the expression level after CPT-11 administration. Decreased TNF-α transcript was 
observed in the group treated with combined thalidomide over 11 days. The fold- 
increase of band intensity was brought down by 61.4% on day 7 (P < 0.05), 
95.7% on day 9 (P < 0.01), and 95.6% on day 11 (P < 0.01). The transcripts for 
TNF-α were almost undetectable on days 9 and 11 in the rats receiving 
combination therapy.  
The transcripts for TNF-α were detectable from healthy colon. They were 
increased after CPT-11 injection and achieved the maximum level on day 7 in the 
control group treated with CPT-11 and 1% DMSO (v/v) and then decreased. 
Similar trends could be seen in the combination group with decreased expression 
levels of TNF-α over 11 days. However no significant influence was observed. 
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Figure 2-17. Representative illustrations of the development pattern of TNF-α expression in ileum 
(A & B), caecum (C & D), and colon (E & F) after CPT-11 injection on days 0, 5, 7, 9, and 11 
from rats treated with CPT-11 with 1% DMSO (v/v) or CPT-11 with thalidomide. B, D, and F, 
RT-PCR analysis of TNF-α; A, C, and E, fold-increase in band intensity compared to that at day 0, 
obtained from three independent experiments. Significant differences compared with values 
obtained in rats treated with CPT-11 and 1% DMSO (v/v): *P < 0.05; **P < 0.01 (N = 4-6).   
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2.4 CONCLUSION & DISCUSSION 
CPT-11 has been widely used for the treatment of a variety of cancers due to its 
substantial antitumor activity when dose-intensified regimens are applied. 
However, diarrhea, especially late-onset diarrhea has been observed at higher 
incidence than with other chemotherapies, which limited the further evaluation of 
more aggressive regimens using CPT-11 [285, 286]. Although loperamide is used 
as a standard therapy for management of CPT-11-induced diarrhea, some patients 
do not respond to it. Therefore, alternative approaches are needed to alleviate the 
dose-limiting toxicities of CPT-11.  
The present study investigated histological changes, cytokine expressions and 
apoptosis throughout the gastrointestinal tract including ileum, caecum, and colon 
tissues for the combination of thalidomide with CPT-11. The results demonstrated 
that coadministered thalidomide ameliorated the gastrointestinal and 
hematological toxicities of CPT-11 in the rat, as indicated by alleviation of late-
onset diarrhea and body weight loss, up-regulation of decreased leukocyte counts, 
and alleviation of macroscopic and microscopic intestinal damages. These results 
are consistent with those reported in cancer patients when thalidomide was 
combined with CPT-11 [277]. In addition, the data showed that combination of 
thalidomide suppressed the increased intestinal TNF-α and IL-6 as well as splenic 
IL-6 and IL-1β levels. Furthermore, thalidomide exhibited marked in vivo anti-
apoptotic effects in intestinal epithelial cells in our study.  
Increasing evidence show that chemotherapy-induced intestinal mucositis appears 
to be associated with intestinal exposure to these drugs which induce epithelial 
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apoptosis characterized by the generation of DNA fragments through the action of 
endogenous endonucleases, decreased crypt cell renewal, and destruction of the 
mucosal architecture, thus leading to the increased Cl- and Na+ secretion and 
severe diarrhea [277]. The findings in our study further support the apoptosis-
associated mechanism for CPT-11 induced toxicity. In addition, over-expressions 
of TNF-α and other pro-inflammatory cytokines such as IL-1 and IL-6 in 
intestinal mucosa have been reported to be associated with intestinal toxicities 
induced by cancer chemotherapy agents [287-289]. TNF-α plays a critical role in 
initiation of chemotherapy-induced primary mucosal damage responses including 
early damage to connective tissue and endothelium, reduction of epithelial 
oxygenation, and ultimately, epithelial basal-cell death and injury [278]. In our 
study, administration of CPT-11 for four consecutive days in rats showed 
significant increase in TNF-α production in rat intestinal tissues both at protein 
and mRNA levels, associated with severe diarrhea and histological damages. 
These findings may support the hypothesis that the intestinal damage induced by 
CPT-11 results from increased production of pro-inflammatory cytokines like 
TNF-α. 
The combination of thalidomide resulted in decreases in TNF-α production at both 
protein and mRNA levels compared to the control group treated with CPT-11 
alone, accompanied with decreased intestinal IL-6 expression. Studies have 
shown that blockade of TNF-α also abrogated the production of IL-6 [289]. In 
addition, co-administered thalidomide showed a marked inhibitory effect on 
intestinal epithelial cellular apoptosis. A close interaction between intestinal 
epithelial cellular apoptosis and intestinal pro-inflammatory cytokines expression 
has been observed. TNF-α has been proven to play an essential role in regulating 
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intestinal epithelial cellular apoptosis and/or survival during chronic 
inflammation. The inhibition of intestinal apoptosis by thalidomide might be 
partially ascribed to the inhibition of TNF-α expression. Thus, the protective 
effect of thalidomide on CPT-11 induced toxicity might be ascribed to its down-
regulatory effect on TNF-α expression. Furthermore, the effects of thalidomide on 
the inhibition of TNF-α protein expression might be due to its effect on mRNA 
level of TNF-α. As shown in our data, the combination of thalidomide reduced the 
transcription product levels of TNF-α mRNA compared to the group treated with 
CPT-11 alone, which might be attributed to the increased degradation of TNF-α 
mRNA by thalidomide.  
In summary, the increasing understanding for the involvement of TNF-α in CPT-
11 induced toxicity and the modulation effects of thalidomide against CPT-11 
associated histological damages via regulation of TNF-α expression may provide 
a new treatment for chemotherapy-associated histological damages by anti-TNF-α 
agent through the inhibition of inflammatory cytokines expression and intestinal 
epithelial cellular apoptosis.  
 
CHAPTER 3 EFFECTS OF THALIDOMIDE ON THE 
PHARMACOKINETICS OF CPT-11 AND THE UNDERLYING 
MECHANISMS   
3.1 INTRODUCTION  
Pharmacokinetic study is important for combination cancer therapy given that 
cytotoxic agents have narrow therapeutic indices. Such information of 
pharmacokinetic profiles is useful for developing a combination therapy strategy, 
since the chance for treatment success can be compromised by the failure to 
anticipate the likely changes in plasma concentration over time when the 
pharmacokinetics of a drug is significantly altered by concurrent drug 
administration, or the toxicity of either agent is significantly enhanced.   
Clinical study and our study in rats have shown that the combination of 
thalidomide ameliorated the toxicity induced by CPT-11 [255]. The modulation of 
cytokine levels (in particular TNF-α inhibition) and intestinal epithelial cellular 
apoptosis might partially explain this effect; however, pharmacokinetic 
mechanisms could also be involved. Though spontaneous hydrolysis is the major 
elimination pathway of thalidomide and  CYP2C-mediated metabolism plays only 
a minor role in its elimination [290], thalidomide can be hydrolyzed to more than 
a dozen of metabolites in vivo [291], which may have modulating effects on the 
metabolism and transport of other drugs. Preclinical studies have found that co-
administration of thalidomide increased the t1/2β of the investigational anti-cancer 
agent DMXAA [292] and decreased the CL of cyclophosphamide and its 
metabolites from plasma and tissue, with corresponding increases in the AUC. A 
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recent clinical study in 14 cancer patients revealed that oral administration of 
thalidomide at 400 mg/day increased the plasma level of CPT-11 by 33.4% (P < 
0.05), which may suggest a possible reduced metabolism of CPT-11 to SN-38 and 
a modest increase in SN-38 glucuronidation by thalidomide [164, 255]. In 
addition, another study also found a decreased metabolism of irinotecan into SN-
38 and SN-38G when it was administered with thalidomide. However, the in vitro 
pharmacokinetic interactions have yet to be investigated to explain the in vivo 
kinetic changes.   
In the present study, we sought to explore the potential kinetic interactions 
between the two compounds using in vivo and in vitro models. The rats were 
chosen in this study as: a) the metabolic pathways of CPT-11 in rats and humans 
are similar, despite the presence of species differences in the contribution of 
enzymes for individual pathways; b) the transport and elimination routes of CPT-
11 in rats and humans are also similar; and c) rats facilitate pharmacokinetic 
studies by allowing repeated blood sampling. Thus, the data on CPT-11 arising 
from rats might be readily extrapolated to humans. Furthermore, the effect of 
thalidomide and its hydrolytic products on the rat plasma protein binding of CPT-
11 and SN-38 was examined. Moreover, rat liver microsomes and a rat hepatoma 
cell line, H4-II-E cells, were used to study the possible metabolic interactions 
between these two drugs. In addition, H4-II-E cells were also used to investigate 
the effect of thalidomide and its hydrolytic products on the transport of CPT-11 
and SN-38. This cell line has been widely used to investigate drug metabolism 
and transport in vitro since it expresses substantial Phase I and Phase II drug 
metabolizing enzymes and drug transporters such as Pgp [293]. 
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3.2 MATERIALS AND METHODS 
3.2.1 Chemicals 
CPT analogues including irinotecan (CPT-11), CPT and SN-38, verapamil 
hydrochloride (all compounds with a purity > 99.0%) were purchased from 
SinoChem Ningbo Import and Export Co. (Ningbo, China). The ion-pairing 
reagent sodium 1-heptane-sulfonate, lyophilized type IX-A β-glucuronidase (from 
Escherichia coli, with activity of 1,724,400 units per gram solid form), 
probenecid, nifedipine, bilirubin, bis (p-nitrophenyl) phosphate sodium salt 
(BNPP), uridine diphosphate glucuronic acid (UDPGA), D-saccharic acid 1,4-
lactone, N-[2-hydroxyethyl]piperazine-N’-4-butanesulfonic acid (HEPES), 
Hank’s balanced salt solution (HBSS), Dulbecco’s modified Eagle’s medium 
(DMEM), trypan blue were all purchased from Sigma Chemical Co. (St. Louis, 
Mo. USA). The leukotriene antagonist MK-571 was a gift from Dr. Ford 
Hutchinson (Merck Frosst Canada, Inc.) [294].  Fetal bovine serum was obtained 
from Hyclone Lab Inc. (Logan, UT, USA). Phthaloyl glutamic acid (PGA, a 
hydrolytic product of thalidomide, with a purity > 99.0% as determined by HPLC) 
was a gift provided by Dr. Tom Pui-Kai Li, School of Pharmacy, Ohio State 
University, Cincinnati, USA. All other reagents were of analytical or HPLC grade 
as appropriate. The hydrolytic products of thalidomide were prepared by 
incubation of thalidomide with 0.1 M phosphate buffer at pH 7.4 overnight at 
room temperature (22oC). 
3.2.2 Animals 
Refer to Section 2.2.2. 
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3.2.3 Drug administration and sampling  
Single-dose thalidomide treatment and multiple-dose thalidomide treatment 
pharmacokinetic studies for the combination of CPT-11 and thalidomide were 
carried out. For the single-dose thalidomide treatment study, rats were randomized 
to two groups with one group receiving CPT-11 at 60 mg/kg by i.v. and control 
vehicle (1% DMSO, v/v) by i.p. at 1 ml/kg given 30 min before CPT-11 injection, 
and another group of rats treated with CPT-11 at 60 mg/kg by i.v. in combination 
with thalidomide (100 mg/kg by i.p. given 30 min prior to CPT-11 injection). 
Blood samples (200 μl) were collected in heparinised tubes at 0.25, 0.5, 1, 2, 4, 6, 
8, and 10 hr following CPT-11 administration. Plasma was obtained by immediate 
centrifugation at 1,500 × g for 10 min at 4ºC. After protein precipitation and 
simple liquid extraction procedure, plasma concentrations of CPT-11 and its 
major metabolites were determined by a validated HPLC method. Similar blood 
sampling procedure was used for the 5-day multiple-dose thalidomide treatment 
study, whereas thalidomide or the control vehicle (1% DMSO, v/v) at 1 ml/kg/day 
by i.p. was given for five consecutive days before CPT-11 injection. CPT-11 was 
administered by i.v. injection 30 min after thalidomide injection on the 5th day.  
Similar schedule was also adopted for the study of the effect of CPT-11 on the 
plasma pharmacokinetics of thalidomide except that CPT-11 was given 30 min 
before thalidomide injection. To account for the effect of the delivery vehicle (i.e. 
vehicle used for dissolving CPT-11), another group of rats treated with 
thalidomide (100 mg/kg, i.p.) was also pre-treated with the delivery vehicle 
[sterile-filtered D-sorbitol (45 mg/ml) and D-lactic acid (0.9 mg/ml) in Milli-Q 
water, pH 3.5] by i.v. injection.  
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3.2.4 Rat plasma and liver microsome preparation 
Livers and blood were collected from healthy male Sprague Dawley rats and 
livers were stored at -80oC until used. Plasma was freshly separated by 
centrifugation at 1000 × g for 15 min. Hepatic microsomes were prepared by 
differential centrifugation as described. Briefly, liver samples were thawed and 
weighed, and then 3 volumes of ice-cold homogenisation medium (0.1 M sodium 
phosphate buffer with 1.5% KCl at pH 7.4) were added. This and all the 
subsequent operations were carried out on ice. The tissue samples were chopped 
using scissors, and homogenised with a Heidolph homogenizer (Heidolph 
Instruments GmbH & Co. KG, Germany) at 500 rpm for 2 min on ice. The 
resultant homogenates were transferred to centrifuge tubes, and centrifuged at 
9,000 × g for 20 min at 4oC. The supernatant (S9) was collected and centrifuged at 
105,000 × g for 1 hr at 4oC using an ultracentrifuge (Type 70 Ti Rotor, Beckman 
Coulter, Inc. Fullerton, CA, USA). The supernatant fraction served as a cytosol 
source. The microsome pellet was resuspended with homogenization medium. 
Hepatic microsomal suspensions were aliquoted (0.5 ml) into a 1.5-ml test tube 
and stored at -80oC until used. Microsomal protein concentration was determined 
by the Bradford method (Sigma, St. Louis, MO. USA) with bovine serum albumin 
as the standard.  
3.2.5 In vitro plasma protein binding assay 
The effects of thalidomide (25 and 250 μM) and its hydrolytic products (total 
concentration of 10 μM) on the protein binding of CPT-11 and SN-38 were 
investigated in drug-free fresh plasma from healthy male Sprague Dawley rats 
using an ultrafiltration method followed by drug determination using HPLC. CPT-
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11 or SN-38 was added to rat plasma, followed by addition of thalidomide or its 
hydrolytic products. The samples (500 µl) were incubated at 37oC for 30 min in a 
water bath with gentle shaking. Control incubations with 1% DMSO (v/v) were 
also undertaken, which showed no significant effects on CPT-11 or SN-38 plasma 
protein binding. After incubation, an aliquot (400 μl) of the plasma sample was 
transferred to the Centrisart ultrafiltration device (20,000 molecular weight cut-
off, Sartorius Corporation, Germany), and centrifuged at 2,000 × g for 30 min at 
37oC. Samples were capped to minimize changes in pH during filtration. After 
centrifugation, an aliquot (100 μl) was taken from the ultrafiltrate to determine the 
CPT-11 or SN-38 concentration using a validated HPLC method. Before 
ultrafiltration, an aliquot of plasma sample (50 μl) was taken to measure the total 
concentration of CPT-11 or SN-38. The fraction of unbound (fu) CPT-11 or SN-
38 was calculated by the ratio of the drug concentration in the ultrafiltrate to that 
in the rat plasma before ultrafiltration. 
3.2.6 Hepatic microsomal incubation and metabolic inhibition study 
In vitro rat hepatic microsomal incubation conditions for CPT-11 and SN-38 
metabolism were optimized with regard to microsomes concentration, incubation 
time, and substrate concentration. In particular, incubation time (5-90 min) and 
microsomal protein concentration (0.125-10 mg protein/ml) were tested to 
identify optimal conditions that resulted in quantifiable and linear formation of 
SN-38 and SN-38G. The formation of SN-38 from CPT-11 and formation of SN-
38G from SN-38 were determined using a validated HPLC method. For SN-38G, 
it was converted to SN-38 by incubation with β-glu.  
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To investigate the effect of thalidomide (25 and 250 μM) and its hydrolytic 
products (total concentration of 10 μM) on CPT-11 hydrolysis and SN-38 
glucuronidation in rat hepatic microsomes, CPT-11 or SN-38 was incubated with 
hepatic microsomes (2.0 mg protein/ml for CPT-11 and 1.0 mg protein/ml for SN-
38) in 200 µl incubation buffers containing either thalidomide or its hydrolytic 
products for 30 min. The incubation buffer was 0.1 M sodium phosphate buffer 
(pH 7.4) for CPT-11 and 0.1 M sodium phosphate buffer (pH 6.8) containing 4 
mM UDPGA, 10 mM MgCl2, 1 mM D-saccharic acid 1,4-lactone for SN-38.  
Both low and high concentrations of CPT-11 (0.5 or 78 µM, that corresponded to 
the high-affinity Km1 and low-affinity Km2 obtained from the best fit two-binding 
site model) or SN-38 (5.0 µM or 18.2 µM, which is the Km obtained from one-
enzyme equation) were used.  Control incubations with 1% DMSO (v/v) were 
also undertaken, which showed no significant effect on the liver microsomal 
metabolism of CPT-11 and SN-38. SN-38 and SN-38G formation was measured 
as pmol/min/mg protein. In addition, the known CE inhibitor nifedipine (100 µM) 
and BNPP (100 µM) were used as positive control for CPT-11 hydrolysis; while 
nifedipine (100 µM) and bilirubin (100 µM) were used as positive control for SN-
38 glucuronidation. Inhibition was expressed as percentage of the control.  
3.2.7 Cell culture 
H4-II-E cells were obtained from the American Type Culture Collection 
(Rockville, MD) and cultured in complete DMEM supplemented with 10% fetal 
bovine serum, 100 U/ml penicillin G and 100 µg/ml streptomycin. The cells were 
grown in an atmosphere of 5% CO2 /95% air at 37oC and given fresh medium 
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every 3 or 4 days. Experiments were performed on cells within 10 passages. 
Viable cells were counted using the trypan blue exclusion method. 
3.2.8 Cytotoxicity assay in rat hepatoma H4-II-E cells 
The cytotoxic effects of CPT-11, SN-38, thalidomide, and its hydrolytic products 
on H4-II-E cells were determined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazonium bromide (MTT) assay. Drugs were diluted in culture medium 
and added to the cultures 24 hr after cell seeding. Cells were exposed to drugs at 
different concentrations in culture medium for 4 or 48 hr, after which 0.05 mg 
MTT was added to each well, and the plates were further incubated for 4 hr. 
Thereafter, supernatants were removed and the purple precipitates were dissolved 
in 100 μl DMSO each. The absorbance of formazan, a metabolite of MTT, was 
measured at a wavelength of 595 nm using a microplate reader (Tecan Instrument 
Inc., Research Triangle Park, NC, USA). The cytotoxicity was reported as IC50 
value that is the drug concentration causing 50% of growth inhibition compared 
with the control (1% DMSO, v/v). The IC50 values were the means of at least 
three independent experiments, each performed in replicate of eight for each drug 
concentration.  
3.2.9 Metabolic inhibition assay for CPT-11 and SN-38 in rat hepatoma H4-
II-E cells 
For the metabolism study, H4-II-E cells were grown in BD FalconTM cell culture 
dishes (BD Biosciences, San Jose, CA, USA). Different concentrations of CPT-11 
(0.5-50 µM) and SN-38 (0.1-5.0 µM) in DMEM medium were added to confluent 
cell cultures. An aliquot of the culture medium (0.1 ml) was collected from each 
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dish over 120 min, mixed with 300 µl extraction solution (0.01 M HCl : methanol, 
1:1, v/v) containing the internal standard (I.S.), CPT. After vortex-mixing and 
centrifugation at 3,000 × g for 10 min, the concentration of the supernatant was 
analyzed by HPLC. The production of SN-38G was determined by the conversion 
of SN-38G to SN-38 by incubating it with β-glu. Viable cells were monitored 
using the trypan blue exclusion method and the productions of SN-38 and SN-
38G were expressed as pmol/min/106 cells.  
The effects of thalidomide (25 and 250 μM) and its hydrolytic products (total 
concentration of 10 μM) on CPT-11 hydrolysis and SN-38 glucuronidation in rat 
hepatoma H4-II-E cells were investigated in triplicate using optimized incubation 
conditions. Briefly, cells were preincubated with thalidomide or its hydrolytic 
products for 2 hr. After removal of the tested drugs, the cells were washed twice 
with PBS and then exposed to CPT-11 (10 µM) or SN-38 (1 µM) for 5 min. 
Thalidomide or its hydrolytic products were also added to the culture together 
with CPT-11 or SN-38 to test their co-incubation effects on CPT-11 or SN-38 
metabolism. Control incubations containing an equal amount of 1% DMSO (v/v) 
were also conducted. DMSO was also used to dissolve inhibitors. In addition, the 
positive controls for the microsomal metabolic inhibition studies as described 
above were also conducted here. 
Because fetal bovine serum in the culture medium might interfere with the 
metabolism of CPT-11 and SN-38, incubations were also done in HBSS 
containing 10 mM HEPES to rule out the serum effect on the metabolism of these 
drugs by thalidomide and its hydrolytic products. 
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3.2.10 Inhibition assay for intracellular accumulation of CPT-11 and SN-38 
in rat hepatoma H4-II-E cells 
The intracellular accumulation of CPT-11 and SN-38 in H4-II-E cells was 
examined in confluent cell cultures grown in BD FalconTM cell culture dishes (BD 
Biosciences, San Jose, CA, USA) as described [138]. CPT-11 (0.5-50 µM) or SN-
38 (0.1-5.0 µM) in DMEM medium was added to exponentially growing cell 
cultures. The medium was aspirated off at the indicated times over 120 min, and 
the dishes were rapidly washed five times with ice-cold PBS. HPLC analysis of 
final washes ensured that they contained no residual CPT-11 or SN-38. The cells 
were then scraped off and each cell pellet was suspended in 200 µl extraction 
solution (0.01M HCl: methanol, 1:1, v/v) containing CPT (used as the I.S.). After 
vortex-mixing, the cellular homogenates were sonicated and centrifuged at 15,000 
× g for 15 min, and the supernatants were analyzed by HPLC. The intracellular 
accumulation of CPT-11 and SN-38 was expressed as pmol/min/106 cells.  
The effects of thalidomide (25 and 250 μM) and its hydrolytic products (total 
concentration of 10 μM) on CPT-11 and SN-38 intracellular accumulation in rat 
hepatoma H4-II-E cells were investigated in triplicate using optimized incubation 
conditions. Briefly, cells were preincubated with thalidomide or its hydrolytic 
products for 2 hr. After removal of these tested drugs, the cells were washed twice 
with PBS and exposed to CPT-11 (10 µM) for 30 min or SN-38 (1 µM) for 5 min. 
Thalidomide or its hydrolytic products were also added to the cell culture together 
with CPT-11 or SN-38 to test their co-incubation effects on CPT-11 or SN-38 
accumulation. In addition, the effects of the Pgp or MRP inhibitors including MK-
571 (100 µM), verapamil (200 µM), probenecid (200 µM), and nifedipine (100 
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µM) on the intracellular accumulation of CPT-11 or SN-38 were also examined. 
Similar incubations of CPT-11 or SN-38 were also performed in HBSS containing 
HEPES to avoid the interference of fetal bovine serum in the cell culture studies. 
3.2.11 Determination of CPT-11, SN-38, and SN-38 glucuronide and 
thalidomide by HPLC methods  
A Shimadzu HPLC system (Shimadzu Corporation, Japan) was used to quantify 
the CPT-11, SN-38, SN-38G, and thalidomide concentrations in different 
biological matrices. The chromatographic system consisted of a Shimadzu SCL-
10AVP system controller, a LC-10ATVP pump, a DGU-14A degasser, a RF-10A 
XL fluorescence detector (for CPT-11 and SN-38) or a SPD-M10AVP diode array 
detector (for thalidomide), and a SIL-10ADVP autoinjector. Data were monitored 
and analysed using the CLASS VP software. A stainless steel (200 mm × 4.6 mm 
i.d.) analytical column packed with 5 µm Hyperclon ODS (C18) material 
(Phenomenex, Torrance, CA, USA) preceded by a Phenomenex C18 guard 
cartridge was used for separation of test compounds.  
The mobile phase for the determination of CPT-11 and its metabolites was 
composed of acetonitrile-50 mM disodium hydrogen phosphate buffer containing 
10 mM sodium 1-heptane-sulfonate, with the pH adjusted to 3.0 with 85% (w/v) 
orthophosphoric acid (27/73, v/v). The mobile phase was delivered at a flow-rate 
of 1.0 ml/min, and the column effluent was monitored at 540 nm with an 
excitation wavelength of 380 nm.  
Plasma concentrations of CPT-11, SN-38, and SN-38G in rats were determined. 
Briefly, the rat plasma was divided into 2 aliquots (50 μl each): one for CPT-11 
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and SN-38 analysis and the other for SN-38G determination using β-glu. For 
CPT-11 or SN-38 concentration determination, each sample was allowed to thaw 
at room temperature, and 50 µl of a solution of CPT (I.S.) (4 µg/ml) and 100 µl of 
a mixture of acetonitrile-1mM orthophosphoric acid (90:10, v/v) were added to 50 
µl plasma. The tube was vortex-mixed for 10 sec, and centrifuged at 6,000 × g for 
10 min. An aliquot of 150 µl of the resultant supernatant was added to 175 µl 50 
mM disodium hydrogen phosphate (pH 3.0) buffer. After vortex-mixing, 100 µl 
of this mixture was injected into the HPLC system. For SN-38G analysis, the β-
glu was dissolved in the 0.1 M sodium phosphate buffer (pH 6.4) to obtain a 
concentration of 20,000 units/ml. An aliquot of rat plasma sample (50 µl) was 
incubated in water bath with 50 µl of the solution of β-glu (1,000 units) for 2 hr at 
37ºC. Then the samples were processed by the same procedures as for CPT-11 
and SN-38, except that the volumes of all the added solutions were doubled.  
The CPT-11 and SN-38 concentrations in the ultrafiltrate were determined by 
mixing an aliquot of ultrafiltrate (100 µl) with 200 µl H3PO4-acetonitrile (10:90, 
v/v) and 100 µl CPT (I.S.). After vortex-mixing, an aliquot (100 µl) of the mixture 
was injected into the HPLC system. The CPT-11 and SN-38 concentrations in the 
cell homogenate, culture medium or microsome were determined after simple 
liquid extraction by the addition of 0.01M HCl: methanol mixture (1:1, v/v) or 
H3PO4: acetonitrile (10:90, v/v), both containing CPT as I.S. 
The plasma concentrations of thalidomide in rats were determined. Briefly, the 
plasma protein was precipitated by the addition of 200 µl of ice-cold acetonitrile: 
methanol (1:1, v/v) containing 2% (v/v) acetic acid and 10 µl of 2.79 mM 
phenacetin solution (used as I.S.) to 100 µl of plasma samples, then centrifuged at 
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3,000 × g for 10 min. An aliquot (20 µl) of the supernatant was injected into the 
HPLC system with the eluted peaks monitored using a UV detector at 220 nm. 
The mobile phase consisting of acetonitrile-10 mM ammonium acetate buffer (pH 
5.5) (28/72, v/v) was delivered at a flow rate of 0.8 ml/min. Acidifying and quick 
chilling of the plasma samples by ice-cold organic solvents with 2% acetic acid 
(to pH 4.0) were used to prevent the spontaneous degradation of thalidomide. 
All HPLC methods used in this study were well validated. Calibration curves 
were linear over the concentration ranges (CPT-11 and SN-38: 0.01-10 μM; 
thalidomide: 0.02-50 µM) with mean correlation coefficients being greater than 
0.995 (n ≥ 3). All methods had acceptable accuracy (85-115% of true values) and 
precision (intra- and inter-assay coefficient variations < 15%) over the 
concentration ranges (CPT-11 and SN-38: 0.01-10 μM; thalidomide: 0.02-50 
µM). For higher concentrations exceeding the linear concentration range, 
validation for the dilution was also conducted and resulted in acceptable accuracy 
and precision. The limits of quantitation for CPT-11, SN-38, and SN-38G in rat 
plasma or in rat plasma ultrafiltrate were 0.005 μM, and 0.003 μM for CPT-11 
and 0.002 μM for SN-38 in cellular homogenate and culture medium. This value 
was 0.02 μM for thalidomide in rat plasma. Assay specificities for CPT-11, SN-
38, and SN-38G determination were indicated by the absence of interfering 
chromatographic peaks in rat plasma or plasma ultrafiltrate in the presence of 
potentially combined drugs such as thalidomide, or its hydrolytic products, 
nifedipine, probenecid, MK-571, or verapamil. Similarly, a lack of interfering 
peaks in rat plasma in the presence of drugs such as CPT-11, SN-38, and CPT 
indicated good assay specificity for thalidomide determination. 
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3.2.12 Liquid chromatography-mass spectrometry (LC-MS) 
The liquid chromatography-mass spectrometry (LC-MS) analysis was conducted 
to confirm the structures of metabolites of CPT-11 formed in rat liver microsomes 
and rat hepatoma H4-II-E cells. A Finnigan MS system (Thermo Finnigan, 
Egelsbach, Germany) equipped with an electrospray ionization source was used 
for mass analysis. Mass spectrometric analysis was performed in the positive ion 
mode and set up in the selected ion monitoring mode. Nitrogen was used as the 
sheath gas and the auxiliary gas. The capillary temperature was at 350oC. The 
spray voltage was set at 3,500 V. The protonated molecule [M+H]+ was identified 
as quantifying ion.                              
3.2.13 Pharmacokinetic calculation 
The plasma concentration-time curves were obtained by plotting the mean plasma 
concentrations of each analyte versus time on a semi-logarithmic scale. 
Pharmacokinetic parameters were calculated by standard model-independent 
pharmacokinetic formulae using WinNonlin program (Scientific Consulting Inc., 
North Carolina, USA). The t½β value was calculated as 0.693/β, where β is the 
elimination rate constant calculated from the terminal linear portion of the log 
plasma concentration-time curve. The total areas under plasma concentration-time 
curve from time zero to the last quantifiable time point (AUC0-t) and from time 
zero to infinity (AUC0-∞) were calculated using the log trapezoidal rule. The CL 
was estimated by dividing the total administered dose by the AUC0-∞. The Cmax 
for thalidomide and the metabolites of CPT-11 (SN-38 and SN-38G) was obtained 
by visual inspection of the plasma concentration-time curve, whereas the initial 
drug concentration (C0, the extrapolated concentration at zero time) of CPT-11 
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was calculated by back extrapolation of the plasma concentration-time curve to Y-
axis. Alternatively, C0 can be calculated by Dose/Vd. The volume of distribution 
(Vd) was calculated by dividing CL by β. The apparent CL and Vd values of 
thalidomide (i.e. CL/F and Vd/F) were determined as for CPT-11 herein, assuming 
its bioavailability was complete after i.p. injection (100%). 
3.2.14 Statistical analysis 
Refer to 2.2.11. 
3.3 RESULTS 
3.3.1 Thalidomide altered the plasma pharmacokinetics of CPT-11 
For the single-dose thalidomide treatment study, co-administered thalidomide 
significantly (P < 0.05) increased the AUC0-10hr and AUC0-∞ of CPT-11 by 
32.50% and 39.02%, respectively. By contrast, these values for SN-38 were 
significantly (P < 0.01) decreased by 24.58% and 42.62%, respectively (Figure 
3-1 and Table 3-1). The value of t1/2β for SN-38 in rats treated with CPT-11 in 
combination with thalidomide was significantly lower compared to rats treated 
with CPT-11 and control vehicle (1% DMSO, v/v) (4.37 vs. 7.18 hr, P < 0.01). 
However, the combination of thalidomide did not significantly alter the 
pharmacokinetic parameters of SN-38G.  
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Figure 3-1. Plasma concentration-time profiles for CPT-11, SN-38, and SN-38 glucuronide (SN-
38G) in rats treated with CPT-11 and 1% DMSO (v/v) (control vehicle) or CPT-11 in combination 
with thalidomide. A, B, & C, single-dose thalidomide treatment kinetic study; D, E, & F, 5-day 
multiple-dose thalidomide treatment kinetic study. ■, CPT-11 + Thalidomide; ∆, CPT-11 + 1% 
DMSO (v/v) (N = 5). 
 
For the 5-day multiple-dose thalidomide treatment study, pretreatment of rats with 
thalidomide at 100 mg/kg by i.p. significantly increased the C0, AUC0-10hr, and 
AUC0-∞ of CPT-11 by 85.56% (P < 0.05), 45.49% (P < 0.01), and 44.82% (P < 
0.01), respectively, but decreased the Vd and CL of  CPT-11 by 38.98% and 
43.03%, respectively (P < 0.01) (Figure 3-1 and Table 3-2). The values of AUC0-
10hr and AUC0-∞ for SN-38 were significantly decreased in rats treated with CPT-
11 in combination with thalidomide by 28.12% (P < 0.05) and 37.53% (P < 0.01), 
respectively, compared with rats receiving CPT-11 and the control vehicle (1% 
DMSO, v/v). However, there was no significant change in the pharmacokinetic 
parameters of SN-38G. 
 85
Table 3-1. Comparison of pharmacokinetic parameters between two groups of rats treated with a 
single dose of CPT-11 and control vehicle (1% DMSO, v/v) or a single dose of CPT-11 with 
thalidomide (N = 5). ns, not significant. 
 
Treatment Groups 
Parameters CPT-11 + 
Thalidomide  
CPT-11 + 







 C0 (µg/ml) 30.11 ± 19.19  25.23 ± 7.59 19.36 ns 
 t1/2β (hr) 2.93 ± 0.64  2.59 ± 0.51 13.16 ns 
 AUC0-10hr (µg·hr/ml) 60.91 ± 11.57  45.97 ± 10.96 32.50 <0.05 
 AUC0-∞ (µg ·hr/ml) 67.29 ± 14.96  48.40 ± 11.79 39.02 <0.05 
 Vd (L/kg) 3.77 ± 0.27  4.87 ± 1.39 -22.51 ns 
 CL (L/hr/kg) 0.94 ± 0.26  1.34 ± 0.49 -29.68 ns 
   
SN-38 
 Cmax (µg/ml) 0.86 ± 0.23  0.92 ± 0.17 -5.91 ns 
 t1/2β (hr) 4.37 ± 0.64  7.18 ± 1.48 -39.05 <0.01 
 AUC0-10hr (µg·hr/ml) 3.31 ± 0.42  4.39 ± 0.70 -24.58 <0.01 
 AUC0-∞ (µg·hr/ml) 4.45 ± 0.66  7.75 ± 1.85 -42.62 <0.01 
   
SN-38G   
 Cmax (µg/ml) 2.57 ± 1.15  2.57 ± 0.58 0.04 ns 
 t1/2β (hr) 4.38 ± 1.72  3.74 ± 1.32 17.02 ns 
 AUC0-10hr (µg·hr/ml) 6.86 ± 0.95  7.74 ± 0.39 -11.39 ns 
 AUC0-∞ (µg·hr/ml) 8.54 ± 0.14  8.97 ± 0.27 -4.81 ns 
*Comparison of the two groups using Student’s unpaired t-test. 
 
Table 3-2. Comparison of pharmacokinetic parameters between two groups of rats treated with 
CPT-11 and control vehicle (1% DMSO, v/v) or CPT-11 in combination with thalidomide for 5 
consecutive days (N = 5). ns, not significant.  
 
Treatment Groups 
Parameters CPT-11 + 
Thalidomide  
CPT-11 + 







 C0 (µg/ml) 14.28 ± 1.25  7.70 ± 0. 27 85.56 <0.05 
 t1/2β (hr) 2.13 ± 0.58  1.91 ± 0.13 11.33 ns 
 AUC0-10hr (µg·hr/ml) 29.60 ± 1.32  20.35 ± 2.23 45.49 <0.01 
 AUC0-∞ (µg·hr/ml) 30.28 ± 0.93  20.91 ± 2.35 44.82 <0.01 
 Vd (L/kg) 4.85 ± 1.10  7.95 ± 0.71 -38.98 <0.01 
 CL (L/hr/kg) 1.65 ± 0.45  2.90 ± 0.36 -43.03 <0.01 
   
SN-38 
 Cmax (µg/ml) 0.52 ± 0.08  0.70 ± 0.14 -26.36 ns 
 t1/2β (hr) 5.06 ± 1.50  6.86 ± 1.82 -26.31 ns 
 AUC0-10hr (µg·hr/ml) 3.43 ± 0.53  4.78 ± 0.66 -28.12 <0.05 
 AUC0-∞ (µg·hr/ml) 4.80 ± 0.93  7.68 ± 0.84 -37.53 <0.01 
   
SN-38G   
 Cmax (µg/ml) 2.40 ± 0.75  1.93 ± 0.75 24.56 ns 
 t1/2β (hr) 2.50 ± 0.18  3.92 ± 2.21 -36.12 ns 
 AUC0-10hr (µg·hr/ml) 7.38 ± 1.67  5.68 ± 2.43 29.92 ns 
 AUC0-∞ (µg·hr/ml) 7.90 ± 1.74  6.99 ± 4.04 13.01 ns 
*Comparison of the two groups using Student’s unpaired t-test. 
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3.3.2 CPT-11 did not alter the plasma pharmacokinetics of thalidomide 
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Figure 3-2. Plasma concentration-time profiles for thalidomide in rats treated with thalidomide and 
control vehicle or thalidomide in combination with CPT-11 (N = 5). 
 
Figure 3-2 shows the representative plasma concentration-time profiles of 
thalidomide in animals treated with thalidomide and the control vehicle, or 
thalidomide in combination with CPT-11. Co-administration of CPT-11 (i.v., 60 
mg/kg) insignificantly (P > 0.05) increased the Cmax and plasma AUC0-10hr of 
thalidomide by 32.29% and 11.66%, respectively, as compared to the control rats 
(Table 3-3). These results indicated that coadministered CPT-11 did not 
significantly alter the plasma pharmacokinetic of thalidomide in rats. 
 
Table 3-3. Pharmacokinetic parameters of thalidomide in rats treated with thalidomide and control 
vehicle or thalidomide in combination with CPT-11 (N = 5). ns, not significant.  
 
Treatment 










Dose/kg (mg) 100 (258 μmol) 100 (258 μmol) - - 
Cmax (μM) 25.72 ± 10.00 19.44 ± 7.00 32.29 ns 
Tmax (hr) 2.00 ± 0.00 2.00 ± 0.00 0 ns 
AUC0-10hr (μM·hr) 149.02 ± 52.58 133.46 ± 39.17 11.66 ns 
Vd/F (L/kg) 11.88 ± 3.44 13.89 ± 7.30 -14.51 ns 
β (1/hr) 0.19 ± 0.03 0.20 ± 0.06 -3.43 ns 
t1/2β (hr) 3.71 ± 0.69 3.75 ± 1.00 -0.89 ns 
AUC0-∞ (μM·hr) 186.74 ± 56.56 165.10 ± 37.55 13.10 ns 
CL/F (L/hr/kg) 2.24 ± 0.71 2.49 ± 0.79 -10.04 ns 
       *Comparison of the two groups using Student’s unpaired t-test. 
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3.3.3 Effects of thalidomide and its hydrolytic products on the plasma 
protein binding of CPT-11 and SN-38 
CPT-11 and SN-38 are 80% and 99% bound in blood, respectively [65]. Since 
pharmacokinetic parameters of highly plasma protein bound drugs can be 
significantly altered by plasma protein binding displacement by combined drugs, 
we examined whether thalidomide and its hydrolytic products altered the plasma 
protein binding of CPT-11 and SN-38.  
As expected, our data showed that CPT-11 and SN-38 were bound extensively to 
the rat plasma proteins (Table 3-4). Thalidomide (25 and 250 μM) and its 
hydrolytic products (total concentration at 10 μM) did not significantly alter the 
plasma protein binding of CPT-11 and SN-38.  
 
Table 3-4. Effects of thalidomide and its hydrolytic products on the plasma protein binding of 







(Mean ± SD) N 
CPT-11    
       1 0 (Control) 0.047 ± 0.007 3 
 25 (TH) 0.041 ± 0.002 3 
 250 (TH) 0.044 ± 0.000 3 
       20 0 (control) 0.109 ± 0.004 6 
 10 (TH hydrolytic products) 0.113 ± 0.003 6 
      50 0 (Control) 0.164 ± 0.003 3 
 25 (TH) 0.163 ± 0.004 3 
 250 (TH) 0.176 ± 0.007 3 
SN-38    
     0.5 0 (Control) 0.237 ± 0.007 3 
 25 (TH) 0.232 ± 0.003 3 
 250 (TH) 0.233 ± 0.006 3 
    1.0 0 (Control) 0.201 ± 0.003 6 
 10 (TH hydrolytic products) 0.200 ± 0.000 6 
    2.5 0 (Control) 0.217 ± 0.006 3 
 25 (TH) 0.220 ± 0.004 3 
 250 (TH) 0.216 ± 0.015 3 
 TH = Thalidomide. 
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3.3.4 Effects of thalidomide and its hydrolytic products on the hepatic 
microsomal metabolism of CPT-11 and SN-38 
For the hydrolysis of CPT-11, linear SN-38 formation was observed with 
incubation time from 5 to 90 min and with rat liver microsomes from 0.125 to 4.0 
mg microsomal protein/ml. An optimal protein concentration of 2.0 mg/ml and 
incubation time of 30 min were chosen for further inhibition studies. For the 
glucuronidation of SN-38, linear SN-38 formation was observed with incubation 
times of 15 to 60 min and with rat liver microsomes of 0.25 to 2.0 mg microsomal 
protein/ml. Thus, a protein concentration of 1.0 mg microsomal protein/ml and an 
incubation time of 30 min were chosen for further inhibition studies. By 
comparing the models, hydrolysis of CPT-11 to form SN-38 in rat liver 
microsomes was best fitted by a two binding-site model with an estimated Km1 
and Km2 of 0.5 and 78 µM, respectively, and Vmax1 and Vmax2 of 0.58 and 2.34 
pmol/min/mg protein, respectively (Figure 3-3 and Table 3-5). In addition, 
glucuronidation of SN-38 in rat liver microsomes was best fitted by a one-enzyme 
equation with an estimated Km of 18.2 µM and a Vmax of 185.6 pmol/min/mg 
protein.  
The effects of thalidomide and its hydrolytic products on CPT-11 hydrolysis and 
SN-38 glucuronidation are shown in Figure 3-5 and Figure 3-4, respectively. 
Thalidomide (25 µM or 250 µM) had no inhibitory effects on CPT-11 (0.5 and 78 
µM) hydrolysis; while the hydrolytic products of thalidomide (10 µM) 
significantly (P < 0.01) decreased the CPT-11 (0.5 µM) hydrolysis by 15.6%. The 
hydrolytic products of thalidomide significantly inhibited CPT-11 (0.5 µM) 
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hydrolysis in a concentration-dependent manner. However, both thalidomide and 
its hydrolytic products had no significant effects on SN-38 glucuronidation. 
 




























































Figure 3-3. Effects of substrate concentration on the formation of SN-38 from CPT-11 (A) and 
SN-38 glucuronide from SN-38 (B) in rat liver microsomes. The curves represent the best fit of 
two- and one-binding site models, respectively.  
 
Table 3-5. Estimated Km and Vmax values for the metabolism or intracellular accumulation of CPT-
11 and SN-38 in vitro (N = 3). 
 
Km (μM) Vmaxa  Substrate/Reaction or transport Best fit model 
Km1 Km2 Vmax1 Vmax2 
Rat liver microsomes 
CPT-11/hydrolysis Two binding-site 0.50 78 0.58 2.34 
SN-38/glucuronidation One binding-site 18.20 185.60 
    
H4-II-E cells 
CPT-11/hydrolysis (DMEM) One binding-site 43.80 9.68 
CPT-11/SN-38G formation (DMEM) One binding-site 21.22 1.59 
CPT-11/hydrolysis (HBSS) One binding-site 44.47 6.53 
CPT-11/SN-38G formation (HBSS) One binding-site 30.81 1.01 
SN-38/glucuronidation (DMEM) One binding-site 2.50 278.8 
SN-38/glucuronidation (HBSS) One binding-site 3.62 221.9 
CPT-11/accumulation (DMEM) One binding-site 32.71 24.53 
CPT-11/accumulation (HBSS) One binding-site 19.77 40.55 
SN-38/accumulation (DMEM) One binding-site 3.71 1.02 
SN-38/accumulation (HBSS) One binding-site 1.55 0.89 
DMEM = Dulbecco’s modified Eagle’s medium; HBSS = Hank’s balanced salt solution. 
aThe unit was pmol/min/mg protein for rat liver microsomes, and pmol/min/106 cells for 
metabolism and accumulation of CPT-11 and SN-38 in H4-II-E cells. 
 
As expected, nifedipine (100 µM) significantly reduced CPT-11 hydrolysis (0.5 
µM) by 23.4% (P < 0.001), while it had no significant effect for CPT-11 
hydrolysis at a higher concentration (78 µM). By contrast, BNPP at 100 µM 
showed significant (P < 0.001) inhibitory effect on CPT-11 hydrolysis at 0.5 µM 
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(53.7% decrease) or at 78 µM substrate concentration (41.1% decrease). In 
addition, nifedipine (100 µM) had significant (P < 0.001) inhibitory effect on the 
glucuronidation of SN-38 at 5.0 µM (60.0% decrease). However, bilirubin at 100 
µM had no significant effect on SN-38 glucuronidation (5.0 µM and 18.2 µM). 
These results indicated the effectiveness of our microsomal system in the 











































Figure 3-4. Effects of thalidomide, total thalidomide hydrolytic products, nifedipine, and bilirubin 
on SN-38 glucuronidation at 5.0 µM (A) and 18.2 µM (B) in rat liver microsomes. Data are 
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Figure 3-5. Effects of thalidomide, its total hydrolytic products, phthaloyl glutamic acid (PGA), 
nifedipine, and bis (p-nitrophenyl) phosphate sodium salt (BNPP) on the hydrolysis of CPT-11 at 
0.5 (A & C) or 78.0 μM (B) in rat liver microsomes. (C) represents the concentration effects of 
thalidomide hydrolytic products on CPT-11 (0.5 µM) hydrolysis in rat liver microsomes. Data are 
expressed as the percentage of the control group. *P < 0.05; **P < 0.01; ***P < 0.001 compared 
to the control group (N = 3). 
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3.3.5 Cytotoxicity of CPT-11, its metabolites and thalidomide in rat 
hepatoma H4-II-E cells 












































































Figure 3-6. Cytotoxic effects of CPT-11 (A and B) and SN-38 (C and D) in rat hepatoma H4-II-E 
cells when incubated for 4- (A and C) or 48-hr (B and D) (N = 3). 
 
 
When incubated for 48 hr, CPT-11 and SN-38 caused significant cell growth 
inhibition with estimated IC50 of 7.50 ± 1.36 µM and 13.37 ± 5.91 nM, 
respectively (Figure 3-6). SN-38 was 560-fold more cytotoxic to the cells than 
CPT-11. The IC50 for CPT-11 and SN-38 increased to 692.29 µM and 47.20 µM, 
respectively when the drug-exposure time was shortened to 4 hr. By contrast, 
incubation of thalidomide at concentrations up to 1,000 µM or its hydrolytic 
products at the total concentration of up to 100 µM for 48 hr exhibited little or no 
cytotoxic effects in H4-II-E cells. 
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3.3.6 Effects of thalidomide and its hydrolytic products on the metabolism 
of CPT-11 and SN-38 in rat hepatoma H4-II-E cells 
The metabolism of CPT-11 and SN-38 in H4-II-E cells incubated with DMEM or 
HBSS with regard to incubation time and substrate concentration is shown in 
Figure 3-7.  
Both SN-38 and SN-38G were detectable and achieved peak levels after 
incubating CPT-11 with H4-II-E cells for 5 min; thereafter, the formation of both 
metabolites rapidly declined over 180 min in both DMEM and HBSS. The 
formation of both SN-38 and SN-38G in H4-II-E cells increased with increasing 
CPT-11 concentration and followed Michaelis-Menten kinetics with the one-
binding site model being the best fit. The estimated Km and Vmax for SN-38 
formation in DMEM were 43.8 μM and 9.68 pmol/min/106 cells, respectively. For 
SN-38G formation, the Km and Vmax were 21.22 μM and 1.59 pmol/min/106 cells, 
respectively (Table 3-5). These constants were similar for the formation of SN-38 
(Km = 44.47 μM; Vmax = 6.53 pmol/min/106 cells) and SN-38G (Km = 30.81 μM; 
Vmax = 1.01 pmol/min/106 cells) in HBSS.  
In addition, when SN-38 was incubated with H4-II-E cells, SN-38G appeared 
rapidly in the medium or HBSS and then declined over 120 min. The formation of 
SN-38 increased in a substrate concentration-dependent manner and followed 
Michaelis-Menten kinetics. One-binding site model was the best fit for the 
formation of SN-38G in both DMEM and HBSS, with comparable Km and Vmax 
values (Km, DMEM vs. HBSS: 2.50 vs. 3.62 μM; Vmax, DMEM vs. HBSS: 278.8 
vs. 221.9 pmol/min/106 cells).    
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Metabolism in DMEM






























































































































































































































































Figure 3-7. Effects of incubation time and substrate concentration on hydrolysis of CPT-11 (A, B, 
E, & F) and SN-38 glucuronidation (C, D, G, & H) in H4-II-E cells in DMEM (A, B, C, & D) or 
HBSS (E, F, G, & H). The curves in plots B, D, F, & H represent the best fit of one-binding site 




The effects of thalidomide and its hydrolytic products on CPT-11 and SN-38 
metabolism in H4-II-E cells in DMEM are shown in Figure 3-8. Co-incubation of 
thalidomide at 25 μM, PGA at 10 μM or its total hydrolytic products at 10 μM 
significantly inhibit the hydrolysis of CPT-11 by 10.3% (P < 0.01), 20.3% (P < 
0.001), and 9.6% (P < 0.05), respectively. However, co-incubation or 2-hr pre-
incubation of thalidomide at 25 μM and 250 μM and its hydrolytic products at 10 
μM did not show any significant effects on SN-38 glucuronidation. 
Of the control inhibitors, BNPP and nifedipine at 100 µM significantly inhibited 
the hydrolysis of CPT-11 by 9.8% (P < 0.01) and 6.8 % (P < 0.05) and nifedipine 
at 100 µM significantly inhibited the glucuronidation of SN-38 by 14.3% (P < 
0.05). By contrast, bilirubin had no inhibitory effect on SN-38 glucuronidation. 
3.3.7 Effects of thalidomide and its hydrolytic products on the intracellular 
accumulation of CPT-11 and SN-38 in rat hepatoma H4-II-E cells 
The intracellular accumulation of CPT-11 and SN-38 in H4-II-E cells in DMEM 
or HBSS was investigated. As shown in Figure 3-9, the accumulation of CPT-11 
or SN-38 in DMEM or HBSS was not significantly dependent on the incubation 
time, but their accumulation increased depending on the substrate concentration 
and followed Michaelis-Menten kinetics with one-binding site model being the 
best fit. The Km for CPT-11 was 32.71 and 19.77 μM in DMEM and HBSS, 
respectively; and the Vmax for CPT-11 was 24.53 and 40.55 pmol/min/106 cells, 
respectively. For SN-38, the Km was 3.71 and 1.55 μM in DMEM and HBSS, 
































































































































Figure 3-8. Effects of thalidomide, phthaloyl glutamic acid (PGA), total thalidomide hydrolytic products, nifedipine, bilirubin and and bis (p-nitrophenyl) phosphate sodium 
salt (BNPP) on CPT-11 hydrolysis (A & B) and SN-38 glucuronidation (C & D) in H4-II-E cells cultured in DMEM. A & C, co-incubation with the inhibitor; B & D, 2-hr 
pre-incubation with the inhibitor. *P < 0.05; **P < 0.01 compared to the control group (N = 3). 
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The effects of co-incubation and 2-hr pre-incubation of thalidomide and its 
hydrolytic products on the intracellular accumulation of CPT-11 and SN-38 are 
shown in Figure 3-10. Co-incubation or pre-incubation of PGA at 10 µM both 
increased CPT-11 uptake by 21.9% and 10.5% (P < 0.05). Pre-incubation of 
thalidomide at 25 µM decreased CPT-11 uptake by 11.3 % (P < 0.05). Pre-
incubation of thalidomide at 250 µM, PGA at 10 µM, or total thalidomide 
hydrolytic products (10 µM) increased the intracellular accumulation of SN-38 by 
174.0%, 113.3%, and 191.5%, respectively (P < 0.001). However, co-incubation 
of thalidomide and its hydrolytic products did not show any significant effects on 
the intracellular accumulation of SN-38. Not surprisingly, MK-571 at 100 µM 
increased the accumulation of CPT-11 by 35.6% (P < 0.001). Verapamil (200 
µM), MK-571 (100 µM) and probenecid (200 µM) also increased the intracellular 
accumulation of SN-38 by 85.0% (P < 0.05), 670.5% (P < 0.01), and 36.3% (P < 
0.01), respectively. 
3.4 CONCLUSION & DISCUSSION 
The pharmacokinetic study revealed that a single dose of co-administered 
thalidomide significantly increased the AUC0-∞ of CPT-11 but decreased the 
AUC0-∞ of SN-38. Similar results were found in the 5-day multiple-dose 
thalidomide treatment study. Furthermore, in the 5-day multiple-dose thalidomide 
treatment study, administration of thalidomide increased the C0 but decreased Vd 
and CL of CPT-11. Prolonged administration of thalidomide caused greater 
modulating effect on the plasma pharmacokinetics of CPT-11 and SN-38 
compared with short-term (one-day) treatment.  
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 Accumulation in DMEM































































































































































































































































Figure 3-9. Effects of incubation time and substrate concentration on the intracellular 
accumulation of CPT-11 (A, B, E, & F) and SN-38 (C, D, G, & H) in H4-II-E cells cultured in 
DMEM (A, B, C, & D) or in HBSS (E, F, G, & H). The curves in plots B, D, F, & H represent the 




































































































































Figure 3-10. Effects of thalidomide, total thalidomide hydrolytic products, phthaloyl glutamic acid (PGA), nifedipine, probenecid, MK-571, and verapamil on the 
intracellular accumulation of CPT-11 (A & B) and SN-38 (C & D) in H4-II-E cells cultured in DMEM. A & C, co-incubation of the cells with the inhibitor; B & D, 2-hr pre-
incubation of the cells with the inhibitor. *P < 0.05; **P < 0.01; ***P < 0.001 compared to the control group (N = 3). 
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Exposure of intestines to SN-38 is believed to be the main reason for the 
occurrence of CPT-11 induced late-onset diarrhea. There is a clear correlation 
between the toxicity of CPT-11 and its pharmacokinetic parameters for AUC and 
Cmax of SN-38 in cancer patients [295]. Thus, our pharmacokinetic findings may 
suggest that the protective effect of thalidomide against the gastrointestinal 
toxicity of CPT-11 might be partially attributed to the reduced plasma levels of 
SN-38.  
In vitro models including rat liver microsomes and the rat hepatoma cell line, H4-
II-E cells, were used to investigate the in vitro kinetic interactions. In rat liver 
microsomes, a 15.6% decrease (P < 0.05) in the hydrolysis of CPT-11 at 0.5 µM 
by the hydrolytic products of thalidomide (10 µM), instead of thalidomide, was 
observed. In addition, co-incubation of thalidomide at 25 µM, PGA at 10 µM or 
thalidomide hydrolytic products at total concentration of 10 µM caused a decrease 
in CPT-11 hydrolysis in H4-II-E cells. The inhibition of CPT-11 hydrolysis 
caused by the combination of thalidomide observed in the rat liver microsome and 
rat hepatoma cells may explain the increased plasma level of CPT-11 but 
decreased that of SN-38, as indicated in the plasma pharmacokinetic studies. It 
seemed that thalidomide could affect the main metabolic pathway of CPT-11 that 
yields SN-38 though, up to date, little is known concerning drugs that could 
interact with CE, except for ciprofloxacin and loperamide [296]. 
We further examined the effects of thalidomide and its hydrolytic products on 
CPT-11 and SN-38 cellular accumulation in H4-II-E cell line. Incubation of PGA 
at 10 µM increased CPT-11 accumulation, while thalidomide at 25 µM decreased 
CPT-11 accumulation in H4-II-E cells. In addition, thalidomide at 250 µM, PGA 
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at 10 µM, or total hydrolytic products of thalidomide at 10 µM all increased the 
cellular accumulation of SN-38 in H4-II-E cells. The increased accumulation of 
SN-38 in rat hepatoma cells might increase its metabolism via glucuronidation 
due to increased substrate availability for UGT1As, resulting in decreased SN-38 
plasma levels. The mechanism for the increased accumulation of SN-38 by 
thalidomide and its hydrolytic metabolites is unknown, but their inhibitory effects 
on SN-38 transporters such as Pgp and MRP2 are implicated. Tumor cells 
generally exhibit high levels of expression of Pgp or MRPs, thus co-
administration of thalidomide might enhance the anticancer effects of CPT-11 by 
inhibiting these transporters. 
Since thalidomide is a poor substrate for CYPs and that it does not inhibit the 
metabolism of CYP-specific substrates, thalidomide is not involved in clinically 
important drug-drug interactions caused by an inhibition of CYP-mediated drug 
metabolism. However, given that thalidomide can be hydrolysed to more than a 
dozen metabolites in vivo [297], it can be expected that these hydrolytic 
metabolites may have a modulating effect on the metabolism and transport of 
CPT-11 and SN-38 and thus cause altered pharmacokinetics in vivo, as shown in 
our study. However, the specific thalidomide hydrolytic products responsible for 
these effects are not identified. Further studies are needed to identify these 
hydrolytic products and this may allow development of new CE and drug 
transporter modulators.  
Taken together, the protective effects of thalidomide on CPT-11 induced 
gastrointestinal and blood toxicities might be attributed to the inhibition of pro-
inflammatory cytokine expression and intestinal epithelial cellular apoptosis as 
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well as modulation of CPT-11 pharmacokinetic profiles. The abolition or 
alleviation of chemotherapy-induced complication may reduce mortality caused 
by severe diarrhea and inflammation and avoid overall reduction in effectiveness 
of therapy caused by interruptions or dose reductions during treatment. Therefore, 
administration of higher dose chemotherapy regimens with improved tumor 
regression might be achieved.   
The major concern of this combination is that the plasma levels of SN-38 were 
reduced, accompanied with a decrease in TNF-α levels, which may compromise 
the anti-tumor activity of CPT-11. However, drug concentration and TNF-α level 
in tumor tissues play more important roles in the anti-tumor activity of cancer 
chemotherapeutic agent. In addition, combination of chemotherapeutic agent 
CPT-11 with thalidomide, an anti-angiogenic agent, may strengthen the anti-
tumor activity of CPT-11 by targeting endothelial cells, which might be a new 
approach to resolve both toxicity and resistance phenomena for conventional 
cancer treatment. So further studies will be valuable to evaluate the anti-tumor 
activity for the combination of CPT-11 with thalidomide before this combination 
could be successfully used clinically. In addition, the protective effects of 
thalidomide on CPT-11 induced complications may provide a new treatment 
approach for chemotherapy-associated histological damages using anti-TNF-α 
agents through the inhibition of pro-inflammatory cytokine expression and 
intestinal epithelial cellular apoptosis. 
CHAPTER 4 ST. JOHN’S WORT MODULATED DOSE-LIMITING 
TOXICITIES OF CPT-11 IN THE RAT 
4.1 INTRODUCTION 
A pilot clinical study in 5 cancer patients found that oral treatment of SJW at 900 
mg/day for 18 days significantly alleviated irinotecan-induced neutropenia, 
accompanied with a decrease in SN-38 plasma level that may have a deleterious 
impact on treatment outcome of CPT-11 [177, 298]. However, the underlying 
pharmacodynamic mechanisms are not explored although this protective effect of 
SJW on CPT-11 induced toxicity may be partially attributed to the 
pharmacokinetic interactions as indicated by a decrease in the plasma level of SN-
38. SJW has been reported to show anti-inflammatory effects which may help to 
reduce the toxicity of cytotoxic anti-cancer agents. In addition, SJW has shown 
anti-cancer effect and thus it may enhance the anti-tumor activity when combined 
with anti-cancer agents [299-301].  
In the present study, we sought to use a rat model to demonstrate if combination 
of SJW would modulate the histological and hematological toxicities induced by 
CPT-11, and this model was further used to explore the potential 
pharmacodynamic mechanisms for this interaction by examining the intestinal 
epithelial apoptosis and cytokine expression. Although it was advised that patients 
receiving chemotherapeutic treatments such as CPT-11 should refrain from taking 
SJW, the mechanistic study for the protective effects of SJW on CPT-11 induced 
complications may provide some insights into the development of new treatment 
approaches for chemotherapy associated histological damages.  
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4.2 MATERIALS AND METHODS  
4.2.1 Chemicals 
CPT-11 was supplied by Sinochem Ningbo Import and Export Co. (Ningbo, 
China). An injectable formulation of CPT-11 was prepared as described in section 
2.2.1. The SJW sugar-coated tablets [LI-160, 300 mg St. John’s wort dry extract, 
DER 3-6:1, solvent methanol 80% (v/v)], purchased from local pharmacy of 
Singapore, were manufactured by Lichtwer Pharma GmbH  (Berlin, Germany), 
and the SJW-free control vehicle (also formulated as sugar-coated tablet) was 
kindly supplied by Lichtwer Pharma GmbH (Berlin, Germany). The contents of 
hypericin and hyperforin in the SJW tablets have been standardized to 0.3% and 
5%, respectively, by the manufacturer. Analysis using HPLC methods at our 
laboratory found similar contents of both compounds in the preparations. Prior to 
use, the sugar coat was peeled off before the tablets were ground to powder by 
mortar and pestle, then stored in the dryer protected from light. The administration 
form of SJW or vehicle was prepared by suspending SJW or vehicle powder in 
physiological saline for oral gavage administration. All other chemicals were of 
analytical grade or HPLC grade obtained from the same commercial sources as in 
section 2.2.1. 
4.2.2 Animals 
Refer to Section 2.2.2.  
4.2.3 Drug administration schedules 
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The CPT-11 induced diarrhea model in male Sprague Dawley rats was developed 
as previously described. One group of rats (n = 4-7 per group) was treated with 
CPT-11 at a dose of 60 mg/kg/day by i.v. injection via tail vein for four 
consecutive days (days 1-4), and in combination with SJW (400 mg/kg/day by 
oral gavage for eight consecutive days, 6 ml/kg/day) starting one day before the 
first CPT-11 injection. The rats in control group received CPT-11 and SJW-free 
vehicle (400 mg/kg/day by oral gavage for 8 consecutive days, 6 ml/kg/day). 
These groups of rats were used to monitor diarrhea scores, body weight changes 
and counts of leucocytes. Doses used here for SJW in rats are higher than those 
used in humans (900 - 1,050 mg/day) [302, 303]. We adopted this dosage from 
other rat studies [247, 304, 305], where significant drug metabolizing enzyme and 
transporter inducing effects have been observed. This dose was reported to show 
no sign of toxicity in rats. Eight additional groups of rats (n = 4-6 per group) 
received CPT-11 for four consecutive days with or without SJW (400 mg/kg/day 
by p.o. for 5-8 consecutive days starting one day before CPT-11 injection, 6 
ml/kg/day) combination and sacrificed on days 5, 7, 9, and 11 to monitor 
macroscopic and microscopic gastrointestinal damages. Physiological saline was 
given (3 ml/kg/day) by i.v. injection for four consecutive days for the blank 
groups. Tissues and serum samples were collected from these groups of rats for 
further cytokine quantification and examination of intestinal epithelial cellular 
apoptosis. 
4.2.4 Toxicity evaluation and pharmacodynamic study  
Refer to Section 2.2.4 for monitoring of CPT-11 induced diarrhea; Section 2.2.5 
for counting of leucocytes; Section 2.2.6 for evaluation of intestinal damages; 
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Section 2.2.7 for TUNEL assay of intestinal epithelial cellular apoptosis; Section 
2.2.8 for ELISA assay for cytokine protein levels; Section 2.2.9 for protein 
determination by Bradford method; Section 2.2.10 for RT-PCR assay for mRNA 
levels of TNF-α; and Section 2.2.11 for statistical analysis.  
4.3 RESULTS 
4.3.1 Effects of SJW on CPT-11 induced toxicities 
Rats treated with CPT-11 alone experienced rapid decrease in body weight, 
reached a nadir by day 6 with a decrease of 10% compared to the baseline (day 1), 
and recovered to 108% of the baseline by day 11 (Figure 4-1). Co-administration 
of SJW with CPT-11 resulted in lower body weight loss compared to rats 
receiving CPT-11 alone, with a decrease of 3% by day 6 and recovery to 118% of 
the baseline by day 11. Rats that received physiological saline showed only a 
gradual increase of body weight over 11 days.  























Figure 4-1. Body weight changes (% compared to day 1) in two groups receiving CPT-11 and 
control vehicle or CPT-11 in combination with St. John’s wort. Data were expressed as mean ± SD. 
○, Blank (without any drug treatment); ▲, CPT-11+ St. John’s wort; □, CPT-11 + Control vehicle 
(N = 4-6). 
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Figure 4-2. Changes of lymphocyte and neutrophil counts in rats treated with CPT-11 and control 
vehicle or in combination with St. John’s wort. Asterisks (*P < 0.05; **P < 0.01) denote 
significant differences between rats pretreated with St. John’s wort and control vehicle (N = 4-6). 
 
Administration of CPT-11 alone at 60 mg/kg by i.v. for four consecutive days 
induced severe early- (days 1-4) and late-onset (days 5-8) diarrhea, with mean 
severity scores of 0.14, 0.14, 0.43, 1.43, 1.71, 2.07, 1.25, and 0.75 by days 1-8, 
respectively (Table 4-1). The severity scores for late-onset diarrhea were brought 
down in rats treated with CPT-11 and SJW (400 mg/kg, oral), with significant 
effect on day 5 (P < 0.05, Wilcoxon rank sum test).  
 
The counts of neutrophils and lymphocytes were significantly decreased and 
reached a minimum by day 7 and day 5, respectively, in rats treated with CPT-11 
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s were also 
increased by the combination of SJW on days 5, 7, and 9 (P < 0.05).  
-
11 with SJW Figure 4-7).  
t. John’s wort (SJW) or control 
vehicle. Asterisks (*P < 0.05, **P < 0.01, ***P < 0.001) denote significant differences between 
rats pretreated with St. John’s wort and control vehicle (N = 4-6). 
alone. The combination of CPT-11 with SJW increased the numbers of 
lymphocytes on day 5 (P < 0.01) and day 7 (P < 0.05) compared to the control 
group receiving CPT-11 alone (Figure 4-2). The neutrophil number
Marked macroscopic pathological differences were observed in the 
gastrointestinal tissues between the rats receiving CPT-11 injection with or 
without SJW pretreatment. In the control rats receiving CPT-11 alone, wide 
macroscopic changes including wall thickening, hyperemia, hemorrhage, 
ulceration, and adhesion were observed in the intestinal tissues at days 5 and 7, 
although these symptoms were alleviated after day 9. Surprisingly, most of these 
rats experienced severe stomach swell at the same time. By contrast, 
gastrointestinal tissues from rats pretreated with SJW were significantly (P < 
0.05) less impaired (Figure 4-3). Marked microscopic pathological damages were 
also observed in the intestinal tissues treated with CPT-11 and control vehicle. 
However, these damages were significantly alleviated in the rats receiving CPT
 pre-treatment (Figure 4-4, Figure 4-5, Figure 4-6, and 























Day after 1st CPT-11 injection
 
Figure 4-3. Scores of macroscopic intestinal (including ileum, caecum, and colon) damages by 




Table 4-1. Incidence of early- and late-onset diarrhea in rats treated with CPT-11 and control vehicle or in combination with St. John’s wort (SJW). The values are the 
number of animals with each score. 
Early-onset diarrhea 
Diarrhea Scorea 
Day 1  Day 2  Day 3  Day 4 Treatment Group n 
0 1 2 3 Mean  0 1 2 3 Mean  0 1 2 3 Mean  0 1 2 3 Mean 
Blank 5 10    0  10    0  10    0  10    0 
CPT-11+ SJW 5 9 1   0.10  10    0  10    0  8 1 1  0.30 




Day 5  Day 6  Day 7  Day 8 Treatment Group n 
0 1 2 3 Mean  0 1 2 3 Mean  0 1 2 3 Mean  0 1 2 3 Mean 
Blank 5 10    0  10    0  10    0  10    0 
CPT-11+ SJW 5 3 4 3 0 1.00*  3 1 3 3 1.60  5 2 3 0 0.80  9 1 0 0 0.10 
CPT-11+ Vehicle 7b 2 3 6 3 1.71  2 3 1 8 2.07  1 4 3 0 1.25  2 6 0 0 0.75 
          *P < 0.05, CPT-11 + SJW vs. CPT-11 + Vehicle; 
a Two readings at am and pm everyday; 
b Three rats died of severe diarrhea on Day 7. 
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Figure 4-4. Scores of microscopic intestinal (including ileum, caecum, and colon) damages on 
days 5, 7, 9, and 11 induced by CPT-11 in rats pretreated with St. John’s wort (SJW) or control 
vehicle. *P < 0.05; **P < 0.01; ***P < 0.001 (N = 4-6). 
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Figure 4-5. Micrographs (magnification × 100) of ileum showing histological damages on days 0, 
5, 7, 9, and 11 in rats. The rats were treated with CPT-11 and control vehicle, or CPT-11 in 
combination with St. John’s wort (SJW). 
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Figure 4-6. Micrographs (magnification × 100) of caecum showing histological damages on days 0, 
5, 7, 9, and 11 in rats. The rats were treated with CPT-11 and control vehicle, or CPT-11 in 
combination with St. John’s wort (SJW). 
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Figure 4-7. Micrographs (magnification × 100) of colon showing histological damages on days 0, 
5, 7, 9, and 11 in rats. The rats were treated with CPT-11 and control vehicle, or CPT-11 in 
combination with St. John’s wort (SJW). 
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4.3.2 TUNEL assay 
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Figure 4-8. Detection of apoptotic cells in rat ileum (4-μm slices) using TUNEL assay. The 
fragmented DNA of TUNEL-positive apoptotic cells (green spots) were incorporated with 
fluorescein-dUTP at free 3’-hydroxyl ends and visualized by fluorescence microscopy 
(magnification × 100). 
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Figure 4-9. Detection of apoptotic cells in rat caecum (4-μm slices) using TUNEL assay. The 
fragmented DNA of TUNEL-positive apoptotic cells (green spots) were incorporated with 
fluorescein-dUTP at free 3’-hydroxyl ends and visualized by fluorescence microscopy 
(magnification × 100). 
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Figure 4-10. Detection of apoptotic cells in rat colon (4-μm slices) using TUNEL assay. The 
fragmented DNA of TUNEL-positive apoptotic cells (green spots) were incorporated with 
fluorescein-dUTP at free 3’-hydroxyl ends and visualized by fluorescence microscopy 
(magnification × 100). 
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Figure 4-11. Counts of intestinal epithelial apoptotic cells per crypt in rats treated with CPT-11 
and control vehicle or in combination with St. John’s wort (SJW). *P < 0.05; **P < 0.01 (N = 4-6).  
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In normal rats without any drug treatment, the number of epithelial apoptotic cells 
per crypt in ileum, caecum, and colon were 2.0 ± 0.7, 5.0 ± 1.6, and 3.2 ± 1.3, 
respectively. Administration of CPT-11 with control vehicle caused a maximal 
epithelial apoptosis (75.2 ± 13.7 per crypt) on day 5 in the ileum, and then 
decreased thereafter. Combination of SJW significantly reduced ileal epithelial 
apoptosis on day 5 by 48.7% (P < 0.01), on day 7 by 40.2% (P < 0.01), and on 
day 11 by 52.8% (P < 0.05), respectively, compared to rats treated with CPT-11 
alone (Figure 4-8 and Figure 4-11).  
Similarly, maximal epithelial apoptosis was detected in the caecum and colon on 
day 7 and day 5, respectively. SJW pretreatment led to decreased CPT-11 induced 
epithelial apoptosis on day 5 by 44.8%, on day 7 by 59.0%, on day 9 by 41.3%, 
and on day 11 by 31.0% (P < 0.01) (Figure 4-9 and Figure 4-11) in the caecum, 
respectively. In addition, coadministered SJW reduced CPT-11 induced apoptosis 
on day 5 by 47.0% (P < 0.01), on day 7 by 34.3%, and on day 9 by 27.9% (P < 
0.05) in the colon, respectively (Figure 4-10 and Figure 4-11). 
4.3.3 Quantitation of cytokines by ELISA 
The levels of TNF-α, IFN-γ, IL-1β, IL-2, and IL-6 in intestinal tissues and liver, 
spleen as well as serum were shown in Figure 4-12, Figure 4-13, Figure 4-14, 
Figure 4-15, and Figure 4-16, respectively. Treatment of CPT-11 generally 
increased the levels of TNF-α, IFN-γ, IL-1β, and IL-6  compared to day 0, which 
achieved peak levels by day 5 or day 9 and declined thereafter; while the level of 
IL-2 decreased compared to day 0, reaching minimum levels by day 5 or day 7 in 
above tissues.  
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Figure 4-12. Protein levels of TNF-α in rat ileum (A), colon (B), caecum (C), liver (D), spleen (E), 
and serum (F) on days 0, 5, 7, 9, and 11 after CPT-11 administration in control group treated with 
CPT-11 and control vehicle and combination group treated with CPT-11 and St. John’s wort 
(SJW). *P < 0.05 (N = 4-6). 
.
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Figure 4-13. Protein levels of IFN-γ in rat ileum (A), colon (B), caecum (C), liver (D), spleen (E), 
and serum (F) on days 0, 5, 7, 9, and 11 after CPT-11 administration in control group treated with 
CPT-11 and control vehicle and combination group treated with CPT-11 and St. John’s wort 
(SJW). *P < 0.05 (N = 4-6). 
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Figure 4-14. Protein levels of IL-1β in rat ileum (A), colon (B), caecum (C), liver (D), spleen (E), 
and serum (F) on days 0, 5, 7, 9, and 11 after CPT-11 administration in control group treated with 
CPT-11 and control vehicle and combination group treated with CPT-11 and St. John’s wort (SJW) 
(N = 4-6). 
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Figure 4-15. Protein levels of IL-2 in rat ileum (A), colon (B), caecum (C), liver (D), spleen (E), 
and serum (F) on days 0, 5, 7, 9, and 11 after CPT-11 administration in control group treated with 
CPT-11 and control vehicle and combination group treated with CPT-11 and St. John’s wort (SJW) 








































































































Figure 4-16. Protein levels of IL-6 in rat ileum (A), colon (B), caecum (C), liver (D), spleen (E), 
and serum (F) on days 0, 5, 7, 9, and 11 after CPT-11 administration in control group treated with 
CPT-11 and control vehicle and combination group treated with CPT-11 and St. John’s wort 
(SJW). *P < 0.05 (N = 4-6). 
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Results showed that combination of SJW caused differential effects on protein 
levels of cytokine expressions in the tissues examined compared to the control 
group administered with CPT-11 alone.  
Decreases in TNF-α expression were seen in the rats coadministered with SJW in 
caecum on day 5 by 64.5% and on day 7 by 46.3% (P < 0.05). Increased TNF-α 
was also suppressed in serum by coadministration of SJW on day 11 by 46.0% (P 
< 0.05).  
Co-administered SJW caused differential effects on the levels of IFN-γ in 
different tissues. Co-administration of SJW significantly suppressed the increased 
protein level of IFN-γ in colon on day 7 by 52.6% (P < 0.05). Similar inhibitory 
effects on increased IFN-γ expression were observed in spleen on day 9 by 58.0% 
and serum on day 5 by 58.4% (P < 0.05). However, the combination of SJW 
resulted in an increase in protein levels of IFN-γ in colon on day 9 by 64.9% (P < 
0.05) compared to rats treated with CPT-11 alone.  
Combination of SJW reduced the expression of IL-6 in ileum on day 7 by 37.7% 
(P < 0.05) and in serum on day 5 by 62.7% (P < 0.05). However, protein levels of 
IL-6 were increased in the combination group compared to the control group in 
colon on day 5 by 63.6%, in caecum on day 5 by 60.1%, and in spleen on day 7 
by 111.5% (P < 0.05), respectively. 
Coadministered SJW had no significant effects on IL-1β and IL-2 expressions 
compared to the control group received CPT-11 alone. 
4.3.4 TNF-α mRNA expression  
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Figure 4-17. Representative illustrations of the expression pattern of TNF-α in ileum (A&B), 
caecum (C&D), and colon (E&F) after CPT-11 injection on days 0, 5, 7, 9, and 11 from rats in the 
absence or presence of SJW pretreatment. B, D, and F, RT-PCR analysis of TNF-α; A, C, and E, 
fold-increase in intensity of the bands compared to day 0 obtained from three independent 
experiments. Significant differences compared with values obtained in rats treated with CPT-11 
alone: *P < 0.05; **P < 0.01; ***P < 0.001 (N = 4-6).  
 126
The expression pattern and kinetics of the transcripts for TNF-α were examined 
over 11 days after administration of CPT-11 in intestinal tissues including ileum, 
caecum and colon (Figure 4-17). The transcripts for TNF-α were detectable in the 
ileum from healthy rats without any drug therapy. The intensity increased after 
CPT-11 injection and reached a peak level on day 7 (4.8-fold compared to that of 
day 0) in rats treated with CPT-11 alone and then dropped to day 11. However, 
combination of SJW brought down the expression levels of TNF-α mRNA, as 
indicated by reduced fold-increase of band intensity on days 7, 9 and 11 with a 
decrease of 35.8% (P < 0.05), 65.4% (P < 0.001) and 60.0% (P < 0.05),  
respectively.  
Although the transcripts for TNF-α in the caecum were almost undetectable from 
healthy rats, they were readily detectable on days 5 to 11, with gradual decrease in 
the expression level after CPT-11 administration. Decreased TNF-α transcript was 
observed in the group treated with combined SJW over 11 days. The fold increase 
in band intensity was brought down by the combination of SJW on days 5 and 7 
by 31.1% and 33.3% (P < 0.05), respectively.  
The transcripts for TNF-α were detectable in the colon from healthy rats. They 
were increased after CPT-11 injection and achieved the maximum level on day 5 
(6.7-fold compared to that of day 0) in the control group treated with CPT-11 and 
the control vehicle and then decreased. Similar expression pattern could be seen in 
the combination group but with dcreased levels of TNF-α over 11 days. 
Significant decrease in the fold increase in band intensity was observed on day 5 
by 70.6% (P < 0.01).  
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4.4 CONCLUSION & DISCUSSION 
The results showed that co-administered SJW ameliorated the dose-limiting 
toxicities of CPT-11 in rats by SJW attenuating the severity of late-onset diarrhea 
on day 5; increased the counts of neutrophil and lymphocyte on days 5, 7, and 9; 
alleviated the histological damages in intestinal tissues and subsequently reduced 
the stomach swell compared to the control rats without SJW pre-treatment. 
Serious leukopenia induced by CPT-11 administration would adversely allow the 
bacteria to infect the intestinal epithelium, thus exacerbating the intestinal 
toxicity. Therefore reduced hematological toxicity by the combination of SJW 
may help to alleviate CPT-11 induced histological damages by inhibiting 
These beneficial protective effects of SJW against CPT-11-induced toxicities are 
thought to be comparable to those caused by thalidomide. However, co-
administration of thalidomide significantly alleviated body weight loss caused by 
CPT-11 and ameliorated late-onset diarrhea on both day 6 and day 7, while 
combination of SJW had no effect on body weight changes and only reduced late-
Our study showed that combination of SJW suppressed the protein expression of 
NF-α and IFN-γ. Increased mRNA levels of TNF-α in intestinal tissues were 
opportunistic bacterial infections of the intestinal tissues.  
onset diarrhea score on day 5 with significant effect. In the mean time, SJW 
increased leukocyte counts (including lymphocyte and neutrophil) with significant 
effects on days 5, 7, and 9 while thalidomide only increased leukocyte counts on 
day 7. Thus, by comparing, it seems that thalidomide might be more effective on 
CPT-11-induced gastrointestinal toxicity while SJW may be more efficient for 
CPT-11-induced hematological toxicity.  
T
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also brought down by the combination of SJW. The effects of SJW on the 
inhibition of TNF-α protein expression might be attributed to its effect on mRNA 
level of TNF-α. As shown in our data, the combination of SJW reduced the 
transcription product levels of TNF-α mRNA compared to the group treated with 
CPT-11 alone. However, inhibitory effects on the translation and post-
translational modification of TNF-α by SJW can not be excluded.  
he inhibition of IFN-γ 
production by SJW was also indicated in human peripheral blood mononuclear 
cells [306].  
 be ascribed to the modulation effect of 
SJW on apoptosis in leukocytes. Additionally, studies showed venous congestion 
induced mucosal apoptosis via TNF-α-mediated cell death in the rat small 
Down-regulation of intestinal IFN-γ by SJW in the present study may be 
attributed to the inhibition of TNF-α production and/or direct inhibitory effects on 
the local immunocompetent cells. It has been advised that the immune responses 
of many other proinflammatory cytokines including IL-12 and IFN-γ could be 
potentiated by the increased TNF-α level. In addition, t
Our study showed that coadministered SJW alleviated apoptosis in intestinal 
epithelial cells. SJW and quercetin have been reported to inhibit apoptosis induced 
by various mechanisms in several cell lines [307] and exerted a protective effect 
against H2O2-induced apoptosis in human neuroblastoma cells, cardiomyoblast 
cells and macrophages. Hypericin prevented the apoptosis induced in murine L-
cells with recombinant TNF-α [308]. In addition, SJW extract modulated 
apoptosis in mice splenic lymphocytes in vivo [309]. This was consistent with our 
study that combination with SJW showed marked protective effect on CPT-11 




epithelial cells to physiological and therapeutic inducers of apoptosis [311]. So the 
down-regulation of IFN-γ by SJW may also lead to the decreased apoptosis in 
intestinal epithelial cells.  
tion of relevant cytokines and intestinal epithelial cellular apoptosis.  
 
intestine with a variety of intermediates and protein-protein interactions involved 
[310]. This finding is consistent with our result that congestion is observed in 
intestinal tissues accompanied with increased TNF-α level and apoptosis after 
CPT-11 treatment. The reduced TNF-α level after SJW combination also inhibited 
the intestinal damages caused by apoptosis, arising from venous congestion. In 
addition, as a pro-inflammatory cytokine, IFN-γ could sens
In summary, these results provided additional support for the apoptosis- and TNF-
α-associated mechanisms for CPT-11 induced toxicity and partially explained the 




CHAPTER 5 EFFECTS OF ST. JOHN’S WORT ON THE 
PHARMACOKINETICS OF CPT-11 AND THE UNDERLYING 
MECHANISMS  
5.1 INTRODUCTION  
Clinical study and our study in rats showed that the combination of SJW 
ameliorated the toxicities induced by CPT-11. The modulation of cytokine levels 
and intestinal epithelial apoptosis may partially explain this effect; however, 
pharmacokinetic interactions could also be involved. In an unblinded, randomized 
SJW because of the dramatically reduced SN-38 plasma levels caused by 
combination with SJW which may have a deleterious impact on treatment 
utcome. However, the in vitro kinetic interactions for CPT-11 with SJW were 
not fully studied, although induction of CYP3A4 expression by SJW was 
indicated as a component for this interaction.    
In the present study, we aimed to using the rat model and in vitro models to 
explore the potential kinetic interactions between CPT-11 with SJW. The effects 
of SJW extracts, hypericin, hyperforin, and quercetin on CPT-11 and SN-38 
metabolism were conducted using rat liver microsomes and a rat hepatoma cell 
line, H4-II-E cells. H4-II-E cells were also used to investigate the effects of these 
compounds on the transport of CPT-11 and SN-38. The effect of the combination 
crossover study in 5 cancer patients, it was found that treatment of SJW (900 
mg/day, oral) for 18 days decreased the plasma levels of the active metabolite SN-
38 by 42%, which was accompanied by decreased myelosuppression [177]. The 
authors advised that patients on irinotecan treatment should refrain from taking 
o
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of SJW with CPT-11 will be further evaluated. The greater understanding of the 
modulation effects of SJW on drug metabolizing enzymes and transporters for 
CPT-11 using in vitro models may also provide insights into the combination of 
chemotherapeutic agents with herbal medicines and their potential 
s.   
5.2.1 Chemicals 
eidolph Instruments GmbH & Co. 
KG, Germany). After that, the remaining was transferred into a tube and subjected 
dry. So there will be more hydrophilic components in the aqueous extract and 
components for each extract would need to be identified. Hypericin and 
pharmacokinetic interaction
5.2 MATERIALS AND METHODS 
Refer to Sections 3.2.1 and 4.2.1. Hypericin, hyperforin, and quercetin were 
purchased from Sigma Chemical Co. (St. Louis, Mo, USA). The SJW aqueous 
extract (AE) were freshly prepared by suspending the SJW powder in 0.9% 
physiological saline at the concentration of 10 µg/ml, and ultrasonicating at room 
temperature for 10 min. After centrifugation at 6,000 × g for 15 min, the 
supernatant was collected for experimental use. For the preparation of ethanolic 
extract (EE) of SJW, the SJW powder was suspended in 80% ethanol (v/v) at a 
concentration of 1:9 (w/v). After vortex-mixing, the suspension was 
ultrasonicated at room temperature for 1 hr before evaporating the ethanol in a 
Heidolph LR4002 Control rotary evaporator (H
to a freeze drier (FD3, Dynavac engineering, Sydney, Australia) until completely 
more lipophilic components in the ethanolic extract. However, the exact 
hyperforin were dissolved in DMSO and methanol, respectively, and stored in 
dark at -20°C.  
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5.2.2 Animals 
5.2.3 Drug administration and sampling  
Refer to Section 3.2.2. 
The pharmacokinetic interaction studies included experiments with short-term (3 
n of SJW to rats. Rats were randomized 
to four groups (at least 5 rats per group) receiving SJW at 400 mg/kg/day (6 
ml/mg) or SJW-free control vehicle for 3 or 14 consecutive days by oral gavage 
5.2.4 Rat liver microsomal preparation 
5.2.5 Hepatic microsomal metabolic inhibition study 
luding hypericin (20 nM and 200 nM), and hyperforin (1 µM) on 
days) or long-term (14 days) administratio
before CPT-11 injection. On day 4 or 15, CPT-11 (60 mg/kg, i.v.) was 
administered via tail vein. Blood samples (~200 µl) were collected into 
heparinized tubes from tail vein 0.25, 0.5, 1, 2, 4, 6, 8, and 10 hr after CPT-11 
injection. Plasma was obtained by immediate centrifugation at 1,500 × g for 10 
min at 4ºC, and stored at -80ºC until analysis. After deproteinization, plasma drug 
concentrations were analysed by HPLC.   
Refer to Section 3.2.4 for rat liver microsome preparation. In addition to normal 
rat liver microsomes, SJW-induced microsomes were also prepared using the 
same procedure in which rats were administered with SJW or SJW-free vehicle 
(as control group) by oral gavage (400 mg/kg/day) for 14 days continuously 
before the livers were collected.   
To investigate the effects of SJW AE (10 µg/ml), EE (5 µg/ml) and its major 
components inc
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CPT-11 hydrolysis and SN-38 glucuronidation in rat hepatic microsomes, CPT-11 
or SN-38 was incubated with hepatic microsomes (2.0 mg/ml for CPT-11 and 1.0 
mg/ml for SN-38) in 200 µl incubation buffers containing either SJW extracts or 
n conditions refer to Section 3.2.6. 
Control incubations with 1% (v/v) DMSO were also undertaken, which showed 
no significant effect on the liver microsomal metabolism of CPT-11 and SN-38. 
SN-38 and SN-38G formation was measured as pmol/min/mg protein. Inhibition 
was expressed as percentage of the control. In addition, the known CE inhibitor 
nifedipine (100 µM) and BNPP (100 µM) [312, 313] were used as positive control 
for CPT-11 hydrolysis, while nifedipine (100 µM) and bilirubin (100 µM) were 
used as positive control for SN-38 glucuronidation [314-316]. The induction 
effects of SJW on rat hepatic microsomal enzyme activity were also evaluated by 
comparing the Km and Vmax values for CPT-11 hydrolysis and SN-38 
glucuronidation in SJW-induced microsomes and SJW-free control vehicle 
pretreated microsomes. 
5.2.6 Cell culture & cytotoxicity assay in rat hepatoma H4-II-E cells 
The cytotoxic effects of SJW AE, SJW EE, hypericin, hyperforin, and quercetin 
on H4-II-E cells were determined using MTT assay. Refer to Section 3.2.7 for cell 
culture and 3.2.8 for cytotoxicity assay. 
ar accumulation inhibition assay for CPT-11 
and SN-38 in rat hepatoma H4-II-E cells 
The effects of SJW AE, SJW EE, hypericin, hyperforin, and quercetin on CPT-11 
hydrolysis and SN-38 glucuronidation as well as CPT-11 and SN-38 intracellular 
its major components. For detailed incubatio
5.2.7 Metabolic and intracellul
 134
accumulation in rat hepatoma H4-II-E cells were investigated in triplicate by pre-
incubation of cell cultures with these compounds for 2 hr (short term) or 4 days 
(long-term, to observe whether there is induction effect).  
Refer to Sections 3.2.11 and 3.2.12. 
Refer to Sections 3.2.13 and 3.2.14.  
5.3 RESULTS 
5.3.1 SJW altered the plasma pharmacokinetics of CPT-11 
Figure 5-1 shows the representative plasma concentration-time profiles for all 
analytes studied in rats r
5.2.8 Determination of CPT-11, SN-38, and SN-38 glucuronide by HPLC 
methods and LC-MS 
5.2.9 Pharmacokinetic calculation & statistical analysis 
eceiving CPT-11 alone and in combination with SJW. For 
/kg for 
consecutive 3 days) did not significantly alter the pharmacokinetic parameters for 
ys) significantly decreased the Cmax of 
SJW for 14 days did not 
significantly alter the pharmacokinetic parameters of CPT-11 and SN-38G 
the short-term (3 days) study, pretreatment of rats with SJW (p.o. 400 mg
CPT-11 and its metabolites (Table 5-1) compared to rats receiving CPT-11 and 
control vehicle alone. For the long-term (14 days) study, pretreatment of rats with 
SJW (p.o. 400 mg/kg for consecutive 14 da
SN-38 by 38.9 % (P < 0.01) (Table 5-2). However, the AUC0-∞ of SN-38 was not 
significantly altered. Pretreatment of rats with 
compared to the control group. 
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Table 5-1. Comparison of pharmacokinetic parameters between two groups of rats receiving CPT-
 
Treatment Groups 
11 and control vehicle or pretreated with St. John’s wort (SJW) for 3 days (N = 5). 
Parameters 
ehicle (%) value* CPT-11 + SJW  CPT-11 + V
Change P 
CPT-11 
 C0# (ng/ml) 8966.8 ± 1967.2  12140.0 ± 6695.3 -26.1  ns 
 AUC (ng·hr/ml) 18903.4 ± 3497.0  21472.7 ± 3532.1 -12.0 ns 
 ± 1382.0  7533.6 ± 1264.6 3.5 ns 
 CL (ml/hr/kg) 3263.0 ± 579.2  2856.8 ± 510.9 14.2 ns 
   
S
 max 7.3  846.9 ± 136.1 -21.4 ns 
 AUC0-10hr (ng·hr/ml) 4158.7 ± 1544.5  4824.6 ± 1079.6 -13.8 ns 
72 1.9 ns 
.9 -11.9 ns 
   
SN-38G   
 3.3  3124.5 ± 1236.3 -28.9 ns 
 AUC0-10hr (ng·hr/ml) 7332.9 ± 1056.5  9943.7 ± 2936.8 -26.3 ns 
 t1/2β (hr) 2.88 ± 0.93  3.88 ± 0.71 -25.8 ns 
 8074.6 ± 1063.7  11733.8 ± 3754.7 -31.2 ns 
 t1/2β (hr) 1.68 ± 0.34  1.85 ± 0.32 -9.2 ns 
 AUC0-10hr (ng·hr/ml) 18523.3 ± 3265.2  20959.8 ± 3429.0 -11.6 ns 
0-∞ 
 Vd (ml/kg) 7799.7
N-38 
C  (ng/ml) 665.9 ± 27
 t1/2β (hr) 3.70 ± 0.73  3.63 ± 0.
 AUC0-∞ (ng·hr/ml) 5073.9 ± 1600.5  5759.6 ± 1360
Cmax (ng/ml) 2220.4 ± 46
 AUC0-∞ (ng·hr/ml)
* Compared with the controls using Students’ unpaired t-test. ns, not significant. 
# Obtained by back-extrapolation to the zero time using WinNonlin program. 
Table 5-2. Comparison of pharmacokinetic parameters between two groups of rats receiving CPT-





Parameters Change P 
CPT-11 + SJW  CPT-11 + vehicle (%) value* 
CPT-11 
 C0# (ng/ml) 9358.4 ± 1971.4  15469.9 ± 6206.0 -39.5  ns 
 t1/2β (hr) 2.01 ± 0.31  1.73 ± 0.15 16.2  ns 
 AUC0-10hr (ng·hr/ml) 23227.6 ± 4847.1  28678.5 ± 9284.8 -19.0  ns 
 AUC0-∞ (ng·hr/ml) 23967.5 ± 5389.2  29104.7 ± 9368.2 -17.7  ns 
d
 CL (ml/hr/kg) 2597.1 ± 509.3  2242.4 ± 723.5 15.8  ns 
SN-38 
 C  (ng/ml) 639.4 ± 200.3  1046.9 ± 232.2 -38.9  <0.01 
 AUC0-10hr (ng·hr/ml) 4342.7 ± 1250.0  5895.3 ± 1372.7 -26.3  s 
 t1/2β (hr) 4.25 ± 1.63  4.82 ± 3.81 -11.8  ns 
0-∞ 
   
 Cmax (ng/ml) 2681.8 ± 963.1  2320.8 ± 544.8 15.6  ns 
 AUC (ng·hr/ml) 7038.2 ± 1837.7  6523.4 ± 1577.1 7.9  ns 
 t1/2β (hr) 2.61 ± 0.50  2.79 ± 0.56 -6.5  ns 
 AUC0-∞ (ng·hr/ml) 7649.9 ± 2293.1  7073.1 ± 1688.3 8.2  ns 
 V  (ml/kg) 7393.9 ± 1077.5  5541.5 ± 1636.8 33.4  ns 
   
max
n
 AUC (ng·hr/ml) 5688.7 ± 1409.9  8644.4 ± 5543.2 -34.2  ns 
SN-38G   
0-10hr 
* Compared with the controls using Stud
# Obtained by back-extrapolation to th
ents’ unpaired t-test. ns, not significant.  
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CPT-11 (0.5 and 78 µM) hydrolysis and SN-38 glucuronidation (5.0 µM and 18.2 
µM) except that the ethanolic extract of SJW significantly decreased SN-38 (18.2 
µM) glucuronidation by 45.1% (P < 0.01).  
As expected, nifedipine (100 µM) significantly reduced CPT-11 hydrolysis (0.5 
µM) by 23.4% (P < 0.001), while it had no significant effect on CPT-11 
hydrolysis at a higher concentration (78 µM). By contrast, BNPP at 100 µM 
showed a significant (P < 0.001) inhibitory effect on CPT-11 hydrolysis at 0.5 µM 
(53.7% decrease) or at 78 µM substrate concentration (41.1% decrease). In 
addition, nifedipine (100 µM) also had significant inhibitory effect on the 
glucuronidation of SN-38 at 5.0 µM (60.0% decrease, P < 0.001) or at 18.2 µM 
(53.0% decrease, P < 0.01). However, bilirubin at 100 µM had no significant 
effect on SN-38 glucuronidation (5.0 µM) but inhibited SN-38 glucuronidation at 
18.2 µM by 25.6% (P < 0.05). These results indicated the effectiveness of our 
microsomal system in the metabolic inhibition studies. 
In our study, an optimal protein concentration of 2.0 mg/ml and incubation time 
of 30 min and a protein concentration of 1.0 mg microsomal protein/ml and an 
incubation time of 30 min were chosen for the CPT-11 hydrolysis and SN-38 
5-2). By comparing the fitted models, the hydrolysis of CPT-11 to form SN-38 in 
the control and SJW-induced rat liver microsomes is best represented by a one 
binding-site model with estimated Km of 68.57 and 70.82 µM and Vmax of 9.6 and 
glucuronidation study in control microsome and SJW-induced microsome (Figure 
11.03 pmol/min/mg protein, respectively. In addition, the glucuronidation of SN-
38 in rat liver microsomes is best represented by a one-enzyme equation in the 
control and SJW-induced rat liver microsomes with estimated Km of 24.86 and 
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SN-38 glucuronide from SN-38 (B) in control- and SJW-induced rat liver microsomes (N = 3).  
Table 5-3. Estimated K  and V  values for the metabolism of CPT-11 and SN-38 in the control 
microsome and St. John’s wort (SJW)-induced microsome (N = 3). 
 
Substrate Parameters Control SJW-induced 




Km (µM) 68.57 70.82 CPT-11 Vmax (pmol/min/mg protein) 9.60 11.03 
    
Km (µM) 24.86 29.86 SN-38 
maxV  (pmol/min/mg protein) 287.00 357.00 
 
5.3.3 Cytotoxicity of SJW extract and its major components in rat 
hepatoma H4-II-E cells 
When incubated for 4 hr, hyperforin, hypericin, quercetin, and SJW EE caused 
significant cell growth inhibition with an estimated IC50 of 19.1, 44.1, 106.5µM, 
and 165.6 µg/ml, respectively (Figure 5-4). The IC50 for hyperforin, hypericin, 
quercetin, and SJW EE decreased to 9.1, 15.6, 19.0 µM, and 48.2 µg/ml, 
respectively when the drug-exposure time was increased to 48 hr (Figure 5-5). By 
contrast, incubation of SJW AE at concentrations up to 1,000 µg/ml for 48 hr 
exhibited little cytotoxic effects to H4-II-E cells. 
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re 5-4. Cytotoxic effects of SJW ethanolic extracts (EE) (A), hyperforin (B), hype )








Figure 5-5. Cytotoxic effects of SJW ethanolic extracts (EE) (A), hyperforin (B), hype ), 
and quercetin (D) in rat hepatoma H4-II-E cells when incubated for 48 hr (N = 3). 






















































































































































5.3.4 Effects of SJW extract and its major components on the metabolism 
of CPT-11 and SN-38 in rat hepatoma H4-II-E cells 
The effects of SJW extract and its major components on CPT-11 and SN-38 
metabolism in H4-II-E cells in DMEM are shown in Figure 5-6. Pre-incubation of 
SJW extract and its major components for 2 hr or 4 days had no inhibitory effects 
on CPT-11 hydrolysis. A 2-hr pre-incubation of SJW AE at 10 µg/ml and SJW EE 
at 5 µg/ml increased the glucuronidation of SN-38 by 15.1 and 13.9% (P < 0.05). 
A 4-day pre-incubation of SJW AE at 10 µg/ml, quercetin at 10 µM, and 
hyperforin at 1 µM all increased the conversion of SN-38 to SN-38G by 26.8% (P 
< 0.01), 35.2% (P < 0.001), and 57.7% (P < 0.001), respectively. In addition, 
NPP and nifedipine at 100 µM significantly inhibited the hydrolysis of CPT-11 
hibited the glucuronidation of SN-38 by 14.3% (P < 0.05). By contrast, bilirubin 
showed no inhibitory effect on SN-38 glucuronidation. 
5.3.5 Effects of SJW extract and its major components on the intracellular 
accumulation of CPT-11 and SN-38 in rat hepatoma H4-II-E cells 
The effects of SJW extract and its major components on CPT-11 and SN-38 
cellular accumulation in H4-II-E cells in DMEM are shown in Figure 5-7. Pre-
incubation of SJW EE and AE for 2 hr or 4 days had no inhibitory effects on 
CPT-11 cellular accumulation. A 2-hr pre-incubation of MK 571 at 100 µM 
increased the cellular accumulation of CPT-11 by 35.2% (P < 0.001). 
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Figure 5-7. Effects of SJW ethanolic extracts (EE), SJW aqueous extracts (AE), hypericin, hyperforin, quercetin, nifedipine, verapamil, MK-571, and probenecid on cellular 
accumulation of CPT-11 (A & B) and SN-38 (C & D) in H4-II-E cells cultured in DMEM. A & C, 2-hr pre-incubation with the inhibitor;  B & D, 4-day pre-incubation with 
the inhibitor. *P < 0.05; **P < 0.01; ***P < 0.001 (N = 3). 
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However, a 2-hr pre-incubation of hypericin at both 20 nM and 200 nM inhibited 
the cellular accumulation of CPT-11 by 14.0% (P < 0.05) and 22.3% ( 001). 
Inhibitory effects could also be seen for a 4-day pre-incubation with hyperforin at 
1 µM (by 24.0%, P < 0.05) and hypericin at 200 nM (by 23.6%, P < 0.0
A 2-hr pre-incubation of hypericin at 20 nM, hypericin at 200 nM, hyperforin at 1 
µM, quercetin at 10 µM and 100 µM, SJW AE (10 μg/ml), MK-571 at 100 µM, 
verapamil at 100 µM and probenecid at 200 µM all increased the cellular 
accumulation of SN-38 with significant effects by 176.2% (P < 0.05), 134.3% (P 
< 0.01), 91.9% (P < 0.001), 93.6% (P < 0.01), 944.1% (P < 0.001), 62.5% (P < 
0.001), 670.5% (P < 0.01), 85.0% (P < 0.05), and 36.3% (P < 0.01), respectively. 
In addition, a 4-day pre-incubation with SJW EE at 5 µg/ml and hypericin at 200 
nM increased the cellular accumulation of SN-38 by 51.6% (P < 0.05) and 40.1% 
(P < 0.05), respectively; while a 4-day pre-incubation with SJW AE at 10 µg/ml 
and quercetin at 10 µM inhibited the cellular accumulation of SN-38 by 73.2% (P 
< 0.001) and 61.0% (P < 0.001), respectively. 
5.4 CONCLUSION & DISCUSSION 
Results showed that co-administered SJW for 14 consecutive days significantly 
decreased the maximum plasma concentration (Cmax) of SN-38. A clear 
correlation between the toxicity of CPT-11 and its pharmacokinetic par for 
Cmax of SN-38 was observed in cancer patients [65]. Thus, the reduction in the 
Cmax of SN-38 after SJW pre-treatment in our study may partially explain the 





The reason for the reduced plasma SN-38 levels by SJW may be due to reduced 
formation of SN-38 and/or increased glucuronidation of SN-38. Reduced CE 
activity or induced CYP3A expression by SJW may result in reduced SN-38 
formation. SJW is a potential inducer of CYP3A4 in human [315, 317]. In a rat 
study, the administration of SJW to rats for 14 days was reported to result in a 2.5-
Hyperforin, hypericin and other flavonoids in SJW may be able to up-regulate 
UGT1A by stabilizing mRNA and increasing protein expression. Pre-incubation 
of SJW aqueous extract (AE) at 10 µg/ml, SJW EE, hyperforin at 1 µM, and 
quercetin at 10 µM, all significantly increased the glucuronidation of SN-38 in 
H4-II-E cells. However, surprisingly, in the rat hepatic microsomes, combination 
of SJW ethanolic extracts significantly reduced SN-38 glucuronidation by 45% (P 
< 0.05). In addition, the induction effects of SJW on CE and UGT1A activities 
were not clearly demonstrated in our study, as there was no significant difference 
or CPT-11 hydrolysis and SN-38 
glucuronidation in SJW-induced microsomes and control microsomes. 
Additionally, in the long-term incubation study, the SN-38G levels were not 
significantly influenced by SJW, suggesting the lack of marked inducing effect of 
SJW on UGT1As or the induction of multiple drug metabolizing enzymes was 
masked by other effects.  
the altered pharmacokinetics of SN-38, given that CPT-11, SN-38 and SN-38G 
fold increase in hepatic CYP3A2 expression. This could subsequently lead to the 
increased metabolism from CPT-11 to APC and NPC, though the latter could be 
partially converted into SN-38 by carboxylesterases.  
between the Km and Vmax values f
In addition, the induction of Pgp (MDR1) and MRP1-2 by SJW may contribute to 
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are known substrates for Pgp, MRP1, and MRP2 [103, 318, 319]. Pre-incubation 
of hypericin (20 nM and 200 nM) and hyperforin (1 µM) inhibited the cellular 
accumulation of CPT-11 while pre-incubation of hypericin, hyperforin, SJW EE, 
and quercetin increased the cellular accumulation of SN-38. The increased 
accumulation of SN-38 into rat hepatoma cells might increase their metabolism 
via glucuronidation due to increased substrate availability for UGT1As. The 
increased accumulation cannot be attributable to damage of the cellular plasma 
membrane, which in turn could increase drug influx. The increased accumulation 
of the active metabolite of CPT-11, SN-38 by SJW and its major components has 
important clinical implication. Tumor cells generally exhibit high levels of 
expression of Pgp or MRPs, thus co-administration of SJW and its major 
components might enhance the anti-cancer effects of CPT-11 by inhibiting these 
transporters.  
In addition, SJW and its major components have shown anti-cancer effects and 
thus may enhance the anti-tumor activity when combined with anti-cancer agents. 
Taken together, the protective effects of SJW on CPT-11 induced gastrointestinal 
and blood toxicities could be attributed to the inhibition of pro-inflammatory 
cytokine expression and intestinal epithelial cellular apoptosis, as well as, 
modulation of CPT-11 pharmacokinetic profiles. The achievement in abolition or 
alleviation of chemotherapy-induced complication may reduce mortality caused 
by severe diarrhea and inflammation and avoid overall reduction in effectiveness 
of therapy caused by interruptions or dose reductions during treatment. 
Hypericin and hyperforin induced apoptosis in a variety of tumor cell lines and 
inhibited cancer invasion and metastasis. Some studies showed that quercetin 
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induced apoptosis and inhibited the growth of tumor cells in vitro and in vivo. 
More interestingly, studies indicated that the major component of SJW, 
hyperforin, phloroglucinol derivatives found in SJW related mainly to its anti-
depressant effects, inhibits key steps of angiogenesis in vitro in bovine aortic 
endothelial cells, as well as in vivo in the chorioallantoic membrane assay, which 
may open the way for the possibility of a new pharmacological use of SJW for the 
treatment of angiogenesis-related malignancies [320]. The same was observed for 
hypericin [321], which may increase the anti-tumor activity when SJW was 
combined with other chemotherapeutic agents.  
However, the co-administration of SJW leading to the decreased plasma level of 
SN-38, accompanied with decrease in TNF-α level, may compromise the anti-
tumor activity of CPT-11. Although the major components of SJW, hypericin and 
hyperforin, have shown certain anti-tumor and anti-angiogenic properties, their 
 CPT-11.  
Therefore, based on the study of the interactions between CPT-11’s 
pharmacokinetics and SJW, caution should be exercised with co-administration of 
chemotherapeutic agents and modulators of drug metabolizing enzymes and 
transporters such as CPT-11 with SJW, considering that the pharmacokinetic 
contents in SJW, a complicated herbal medicine, are too low to exert their effects 
(0.3% and 5% for the contents of hypericin and hyperforin in the SJW tablets). 
Therefore it is strongly recommended that patients receiving chemotherapeutic 
treatments should refrain from taking SJW. Specific dosing guidelines should be 
followed for patients on such combinations. Further anti-tumor activity evaluation 
is necessary before the clinical application of the combination of SJW with CPT-
11 although this combination could alleviate the toxicity induced by
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profiles of the anti-cancer agents might be changed, and might lead to a 
deleterious impact on treatment outcome.  
CHAPTER 6 GENERAL DISCUSSION & CONCLUSION 
Chemotherapy is a major approach to treat cancer. However, intestinal mucositis 
accompanied with severe diarrhea is a common dose-limiting toxicity of many 
forms of cancer chemotherapy, especially in treatment of colorectal cancer by use 
of irinotecan (CPT-11), 5-fluorouracil, oxaliplatin, capecitabine, or raltitrexed 
[322, 323]. Mucositis has a significant impact on health, quality of life and 
economic outcomes that are associated with chemotherapy. It also indirectly 
affects the success of anti-neoplastic therapy by limiting the ability of patients to 
tolerate optimal dosing-intensified regimens. About 50-80% of patients 
administered with these chemotherapeutic agents alone or in combination in 
randomized phase III trials experienced severe diarrhea. For CPT-11, the 
incidence of grade 3 or 4 diarrhea increased to 40% [324]. Severe diarrhea causes 
dehydration, renal failure, and thromboembolic events, limiting the completion of 
optimal dosing regimens in many patients. Furthermore, diarrhea combined with 
severe neutropenia commonly leads to Gram-negative sepsis and such 
complications have contributed to the high incidence of mortality for patients who 
received CPT-11-based regimens. Invariably, high-dose loperamide is 
recommended to manage CPT-11-induced diarrhea, consisting of an initial dose 
of 4 mg followed by 2 mg every 2 hr until a 12-hr interval without loose motions 
[325]. However, a number of patients do not respond to this agent. Therefore 
efforts to reduce the incidence of severe diarrhea should be of considerable value. 
This thesis has demonstrated that combination of thalidomide or SJW reduced the 
gastrointestinal and hematological toxicities induced by CPT-11 in the rat, as 
indicated by alleviation of late-onset diarrhea, body weight loss, macroscopic and 
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microscopic intestinal damages as well as hematological toxicity. The protective 
effects of thalidomide or SJW on CPT-11 induced toxicities might be partially 
explained by the pharmacokinetic interactions between CPT-11 and thalidomide 
or SJW. These interactions could be explained by the altered metabolism and 
transport of CPT-11 in rat liver microsomes and the rat hepatoma cell line, H4-II-
E cells, by thalidomide, its hydrolytic products, SJW and its major components. 
The pharmacodynamic mechanisms, including the modulatory effects on cytokine 
expression and intestinal epithelial apoptosis by the co-administration of 
thalidomide or SJW, also played a role in the protective effects of these two drugs. 
These mechanistic findings for CPT-11 induced histological damages and the 
protective effects of thalidomide and SJW may provide some insights for new 
effective strategies to circumvent CPT-11 induced toxicities.  
6.1 PROTECTION AGAINST CPT-11 INDUCED TOXICITY BY 
COMBINATION WITH THALIDOMIDE OR ST. JOHN’S WORT 
The present study demonstrated that co-administered thalidomide or SJW both 
ameliorated the gastrointestinal and hematological toxicities of CPT-11, as 
indicated by alleviation of late-onset diarrhea, alleviation of macroscopic and 
microscopic intestinal damages as well as up-regulation of decreased leukocyte 
counts, in a rat model with dose-limiting toxicity profiles that are similar to those 
observed in patients treated with CPT-11. Our results also showed that both 
thalidomide and SJW had no protective effects on CPT-11 induced early-onset 
diarrhea, on day 1 to day 4 in our study. In addition, similar effects were observed 
for macroscopic and microscopic evaluations of histological damages for the 
combination with thalidomide and SJW.  
 151
However, coadministration of thalidomide significantly alleviated body weight 
loss caused by CPT-11 and ameliorated late-onset diarrhea on both day 6 and day 
7, while the combination with SJW showed no body weight changes and only 
reduced late-onset diarrhea score on day 5 with significant effect. In the mean 
time, SJW up-regulated decreased leukocyte counts (including lymphocyte and 
neutrophil) with significant effects on days 5, 7, and 9 while thalidomide only 
increased leukocyte counts on day 7. Thus, our findings suggest that thalidomide 
might be more effective on CPT-11-induced gastrointestinal toxicity while SJW 
might be more efficient for CPT-11-induced haematological toxicity.  
6.2 PHARMACODYNAMIC MECHANISMS OF THE PROTECTIVE 
EFFECTS OF THALIDOMIDE AND ST. JOHN’S WORT  
There is increasing understanding of the molecular events that lead to 
chemotherapy-induced intestinal mucosal injury. The mucosal damages appear to 
be associated with intestinal exposure to these drugs which induce epithelial 
h CPT-11 chemotherapy appeared to be 
apoptosis, decreased crypt cell renewal, complicated inflammatory responses, and 
destruction of the mucosal architecture [326]. In addition, several possible 
mechanisms of CPT-11-induced diarrhea, especially late-onset diarrhea have been 
previously proposed, ranging from changes in architecture and large intestinal 
absorption rates to increases in intestinal β-glucuronidase levels due to changes in 
intestinal bacteria [326]. However, many of these studies were unable to assess 
the effect of CPT-11 throughout the gastrointestinal tract. Our study differed from 
these studies by investigating histological changes and cytokine expression as 
well as apoptosis in the ileum, caecum, and colon. The beneficial effects of 
thalidomide and SJW observed in rats wit
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systemic, as indicated by the protective effects on multiple organs and tissues. 
Their actions on multiple sites of the host, in particular the intestinal tissues and 
immune system, may work together to antagonize the toxic effects of CPT-11.  
- +
Treatment of CPT-11 caused marked apoptosis in intestinal crypts. An increased 
number of apoptotic crypt cells and loss of complete epithelial architecture due to 
inflammation may increase secretion of Cl  and Na  and lead to severe diarrhea. In 
addition, apoptosis of blood cells may induce hematological toxicity as indicated 
by marked decrease in leucocytes. It was hypothesized that chemotherapy 
nonspecifically targeted the rapidly proliferating cells of the basal epithelium, 
iated with 
mucositis. Chemotherapy-induced mucositis has mainly been attributed to basal-
cell damage that results when drugs permeate to these cells from the submucosal 
blood supply [326]. Studies have further shown that chemotherapy–induced 
intestinal mucositis appears to be associated with intestinal exposure to these 
drugs which induce epithelial apoptosis characterized by the generation of DNA 
fragments through the action of endogenous endonucleases, decreased crypt cell 
renewal, and destruction of the mucosal architecture [327]. Treatment with CPT-
11 at 100 mg/kg daily for 4 days caused characteristic mucosal changes in murine 
intestinal tissues including ileum and caecum and severe diarrhea by inducing 
apoptosis and cell differentiation. Increasing evidence has shown that apoptosis 
represents an important event during gut inflammatory responses. The findings in 
our study that thalidomide and SJW exhibited marked in vivo anti-apoptotic 
effects in intestinal epithelial cells associated with alleviated histological toxicity 
causing the loss of the ability of the tissue to renew itself, which led to atrophy, 
thinning and ulceration of the mucosal epithelium that is assoc
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also provide further support for this apoptosis-associated mechanism for CPT-11 
induced toxicity and the protective effects of thalidomide and SJW.  
Apart from the modulatory effects on intestinal epithelial cellular apoptosis, 
Over-expressions of TNF-α and other pro-inflammatory cytokines such as IL-1 
and IL-6 in intestinal mucosa have been reported to be associated with intestinal 
toxicities induced by cancer chemotherapy agents [330]. TNF-α, a potent pro-
inflammatory cytokine, is mainly produced by activated macrophages and is a key 
cytokine in the initiation of mucosal immuno-inflammatory responses and 
damages. TNF-α is a critical cytokine that could orchestrate inflammatory 
regulation of cytokine expression is also involved in the protective effects of 
thalidomide and SJW against CPT-11 induced gastrointestinal and hematological 
toxicity. Cytokines are relatively small molecular weight polypeptides released by 
all nucleated cells in the body that have specific effects on the interactions and 
communications between cells. Cytokines mainly include the ILs, lymphocytes 
and cell signal molecules, such as TNF-α and the IFNs. The majority of cytokines 
is pleiotropic in their functional activities and they are extracellular signalling 
molecules essential to host development, maturation, immune, and inflammatory 
responses, and tissue repair processes [328]. Cytokines are highly inducible and 
fast turn-over molecules during immunological reactions and inflammatory 
conditions. Many known cytokines have been shown to mediate predominant 
proinflammatory effects. TNF-α, IL-1β, IL-6, IL-12, and IFN-γ are cytokines that 
exert predominant proinflammatory effects in vitro and in vivo, among which IL-6 
can also exert anti-inflammatory effect, depending on the specific physiologic or 
pathophysiologic state [329].   
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responses by activating a wide range of cells including neutrophils, macrophages, 
and NK cells. Activation of these cells in turn induces the production of 
inflammatory cytokines such as IL-1β, IL-6, and IL-8 and up-regulation of 
adhesion molecules on cell surface. TNF-α also plays a critical role in initiation of 
chemotherapy-induced primary mucosal damage responses including early 
damage to connective tissue and endothelium, reduction of epithelial oxygenation, 
and ultimately, epithelial basal-cell death and injury [331]. The histological 
damage including increased intestinal permeability and leukocyte infiltration 
accompanied with anti-cancer agent such as CPT-11 leads to an inflammatory 
response through the overproduction of pro-inflammatory cytokines like TNF-α 
by epithelial cells and infiltrating leukocytes within the intestinal mucosa. 
Moreover, the overall pathology initiated by CPT-11 cytotoxicity is exacerbated 
with increased TNF-α expression by TNF-α-mediated apoptosis, tissue matrix 
degradation and vascular leakage [332]. A study conducted on BALB/c mice 
treated with combination of RDP58 with CPT-11 also showed over-expression of 
TNF-α after CPT-11 administration and its role involved in CPT-11 induced 
histological pathology. Consistent with our data in the rat model, administration 
of CPT-11 for four consecutive days in rats showed significant increase in TNF-α 
production in rat intestinal tissues both at protein and mRNA levels, associated 
with severe diarrhea and histological damages. This finding may support the 
hypothesis that the intestinal damage induced by CPT-11 results from increased 
production of pro-inflammatory cytokines like TNF-α. Our studies also showed 
that co-administration of thalidomide or SJW effectively reduced the diarrhea and 
intestinal damages induced by CPT-11. Moreover, thalidomide or SJW reduced 
the TNF-α production at both protein and mRNA levels compared to the control 
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group treated with CPT-11 alone. This finding indicated that the protective effect 
of thalidomide or SJW on CPT-11 induced toxicity might be ascribed to its down-
regulatory effect on TNF-α over-expression.  
A close interaction between intestinal epithelial cellular apoptosis and intestinal 
pro-inflammatory cytokines expression was observed. TNF-α has been shown to 
play an essential role in regulating intestinal epithelial cell apoptosis and/or 
survival during chronic inflammation [333]. Members of the TNF-superfamily, 
such as Fas/CD95/APO-1 and TRAIL, are involved in the extrinsic pathway for 
production of apoptosis and play a role in apoptosis induced by chemotherapy and 
cellular immunity. TNF-α has been shown to share common intracellular 
The inhibitory effects of thalidomide and SJW on TNF-α protein expression might 
be ascribed to their effects on mRNA level of TNF-α. As shown in our data, the 
co-administration of thalidomide or SJW reduced the transcription product levels 
of TNF-α mRNA compared to the group treated with CPT-11 alone, which might 
be attributed to the increased degradation of TNF-α mRNA by thalidomide [329]. 
Besides, inhibitory effects on the translational and post-translational expression of 
TNF-α by thalidomide or SJW could not be excluded. The expression patterns of 
the protein and mRNA of TNF-α in both control and combination groups are 
consistent. However, there is some inconsistency between the protein expression 
and mRNA transcription levels of TNF-α in the same group of rats. Most of 
protein expression of TNF-α reached peak levels on day 5 and then slowly 
decreased; while of the expression of mRNA transcripts reached a maximum level 
on day 7 or day 9. This might be attributed to the differences in the translational 
and post-translational modification in the intestines.  
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pathways of apoptosis with Fas and has the ability to modulate Fas expression 
itself [334]. The inhibition of intestinal apoptosis by thalidomide or SJW might be 
partially ascribed to the inhibition of TNF-α expression. Studies also showed 
venous congestion induced mucosal apoptosis via TNF-α-mediated cell death in 
the rat small intestine with a variety of intermediates and protein-protein 
interactions involved [335]. This finding is consistent with our result that 
congestion is observed in intestinal tissues accompanied with increased TNF-α 
level and apoptosis after CPT-11 treatment. The reduced TNF-α level after 
thalidomide or SJW combination also inhibited the intestinal damages caused by 
apoptosis, arising from venous congestion. SJW and quercetin have also been 
reported to inhibit apoptosis induced by various mechanisms in several cell lines 
and exerted protective effects against H2O2-induced apoptosis in human 
neuroblastoma cells, cardiomyoblast cells and macrophages. Hypericin prevented 
the apoptosis induced in murine L-cells with recombinant TNF-α [309], while 
quercetin protected glomerular mesangial cells from oxidant-triggered apoptosis 
[331]. In addition, SJW extract modulated apoptosis in mice splenic lymphocytes 
in vivo. The splenic lymphocytes from mice treated with SJW extract at 100 
mg/kg per day for 14 days were significantly more resistant to apoptosis than 
those from mice treated only with the vehicle [336]. This action could be 
mediated in part by a decrease in Fas-Ag expression and in part by an increase in 
Bcl-2 expression. This was consistent with our study that combination of SJW 
with CPT-11 offered marked protective effect on CPT-11 induced leukocyte 
decrease, which might be ascribed to the modulation effect of SJW on apoptosis 
in leukocytes.  
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TNF-α, the main lethal mediator of sepsis and inhibitor for the toxic effects of 
bacterial endotoxins, has been identified as a key inflammatory mediator. The 
development of anti-TNF-α molecules (soluble receptors and antibodies) for 
important diseases including rheumatoid arthritis and Crohn’s disease is now 
under research [334]. Infliximab, the human-mouse anti-TNF antibody cA2, has 
shown efficacy in patients with Crohn’s disease or rheumatoid arthritis [332]. 
Etanercept (human p75 TNF receptor-IgG fusion protein) and adalimumab 
(human anti-TNF monoclonal antibody) are being evaluated in patients for the 
treatment of Crohn’s disease [334]. These monoclonal antibodies against TNF-α 
may act by neutralizing TNF-α and reducing the expression of adhesion 
molecules and other cytokines [332]. However, the use of TNF-α antibodies has 
been associated with increased risk of tuberculosis [337]. Besides TNF-α 
antibodies, a variety of small molecular weight molecules also showed TNF-α 
inhibitory effects with therapeutic benefits in experimental colitis [337]. For 
example, selective inhibitors of the phosphodiesterase (PDE) are potent inhibitors 
of TNF-α synthesis. Recently, some thalidomide analogs such as lenalidomide 
and Revlimid have been found to have potent inhibitory effects on TNF-α [338]. 
Thalidomide has been widely used in the treatment of various inflammatory and 
autoimmune disorders including Crohn’s disease, Bechcet’s disease, and 
rheumatoid arthritis [334]. The TNF-α antagonist property of thalidomide may 
partly explain its beneficial effects in these TNF-α-associated complications 
[335]. The pivotal role of TNF-α in mucosal inflammation and injury might infer 
that, inhibition of TNF-α production may become a potential approach for 
managing chemotherapy-induced intestinal mucositis. In the present study, we 
investigated the efficacy and potential mechanism of action of anti-TNF-α 
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treatment in chemotherapy-induced intestinal damages. We report herein that 
administration of thalidomide, as a TNF-α inhibitor, efficiently reduced CPT-11 
induced diarrhea and mucosal inflammation in rats. Furthermore, our results 
showed that anti-TNF-α treatment suppressed the overproduction of pro-
inflammatory cytokines in intestinal tissues and reduced intestinal epithelium 
cellular apoptosis. Taken together, these data indicated that the increased 
intestinal TNF-α expression and epithelial apoptosis by chemotherapy could be 
suppressed by anti-TNF-α agent such as thalidomide. In addition, the protective 
effect of SJW against CPT-11 induced toxicity could also be attributed to the 
suppression of TNF-α expression. So, the protective effects of thalidomide and 
SJW on CPT-11 induced complications could provide alternatives for 
chemotherapy-associated histological damages by anti-TNF-α agent by inhibiting 
inflammatory cytokines expression and intestinal epithelial cellular apoptosis.  
TNF-α can potentiate the immune response of many other pro-inflammatory 
cytokines including IL-1β, IL-2, IL-6, and IFN-γ. Modulation of these cytokines 
may also play a role in the anti-inflammatory effects of thalidomide and SJW. IL-
1β plays a central role in mediating immune and inflammatory responses. 
Although normal production of IL-1β is obviously critical for initiation of normal 
host responses to injury and infection, inappropriate or prolonged production of 
IL-1β has been implicated in the production of a variety of pathological conditions 
including intestinal inflammatory damages. The naturally occurring IL-1 receptor 
antagonist (IL-1ra, anakinra or Kineret) has been approved for the treatment of 
rheumatoid arthritis with large amounts (100 mg) daily [339]. Thus, as shown in 
our results, the inhibition of IL-1β may contribute to the protective effect on CPT-
11 associated intestinal inflammation by combination with thalidomide. In 
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addition, the modulatory effect of thalidomide on IL-1β may be attributed to its 
inhibitory effect on TNF-α.  However, no inhibitory effect for IL-1β was observed 
for the SJW combination.  
Thalidomide also suppressed the production of IL-6 and SJW inhibited the 
production of IFN-γ. IL-6 is a multifunctional protein that plays important roles in 
host defense, acute phase reactions, immune responses, and hematopoiesis [340]. 
IL-6 is expressed by a variety of normal and transformed cells including T cells, B 
cells, and macrophages [330]. Its expression is increased in Crohn’s disease and 
leads to suppression in growth. Application of IL-6 antibody restore linear growth 
but did not suppress intestinal inflammation. A mouse monoclonal antibody that 
blocks IL-6 action has shown hints of efficacy in B-lymphoproliferative disorders 
and Castleman’s disease in small trials [330]. In addition, increased IL-6 
expression was seen in the peripheral blood and/or mucosa of patients and animals 
with chemotherapy-induced mucositis. IFN-γ is produced by CD8+, NK, and Th1 
(T helper) cells, that documented antiviral, anti-protozoal and immunomodulatory 
effects on cell proliferation and apoptosis, as well as the stimulation and 
repression of a variety of genes. As a pro-inflammatory cytokine, IFN-γ was 
shown to mediate pleiotropic effects in the innate and adaptive response to 
infection  and sensitize intestinal epithelial cells to physiological and therapeutic 
inducers of apoptosis via up-regulation of caspases-1 [341]. In the present study, 
down-regulated intestinal IL-6 by thalidomide and IFN-γ by SJW is probably due 
to the inhibition of TNF-α production and direct inhibitory effect on local 
immunocompetent cells. Studies have shown that TNF-α activates invading T 
cells and NK cells to produce IFN-γ, which directly leads to increased mucosal 
damage [342]. Reduced TNF-α expression may consecutively lead to a reduced 
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synthesis of IFN-γ and a reduced infiltration of activated lymphocytes. In 
addition, studies have shown that blockade of TNF abrogated the production of 
IL-6 [342].   
IL-2 is a pleiotropic cytokine produced primarily by mitogen- or antigen-activated 
T lymphocytes. It plays a key role in promoting the clonal expansion of antigen-
specific T cells by binding sequentially to the α, β, and common γ chain receptor 
subunits [343]. IL-2 mediates multiple immune responses on a variety of cell 
types including stimulation of the proliferation and differentiation of activated B 
cells and induction of cytokine production such as TNF-α and IFN-γ and cytolytic 
activity by NK cells [343]. IL-2 administration results in expansion of lymphoid 
cells, but also associated with a variety of autoimmune disorders, including 
immune thyroiditis, rheumatoid arthritis, and other arthropathies. The 
combination of CPT-11 with thalidomide decreased the expression of IL-2 
compared to treatment with only CPT-11, as IL-2 may have attenuated the effect 
of thalidomide on CPT-11 induced histological damage. 
Besides, a recent mouse study indicated that thalidomide treatment at 200 mg/kg 
orally significantly lowered the severity of colon injury induced by dinitrobenzene 
sulfonic acid [344]. This was accompanied with a substantial reduction of the 
increase in intestinal myeloperoxidase activity, TNF-α, IL-1β, vascular 
endothelial growth factor, and intercellular adhesion molecule-1. In experimental 
models, it has been found that increased expression of TNF-α is believed to be the 
major reason that leads to sepsis, while increased IL-12, IFN-γ, GM-CSF, and IL-
8 expression may each play a part. In addition, modulation of other cytokines, 
such as IL-10, COX-2, and NF-κB transcription factor, is involved. Other 
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mechanisms related to epithelial or endothelial function or growth could also be 
involved. Thalidomide may inhibit TNF-α-driven calcium and potassium 
secretion directly or through inhibition of cyclooxygenase [345]. Thalidomide 
also increases T-helper-2 cell (humoral) immune function and decreases T-helper-
1 cell (cellular) immune function by upregulating IL-4 and IL-5, and 
downregulating the IL-12. In addition, a number of studies have shown that COX-
2 is overexpressed in many forms of human cancers [346]. A direct link between 
COX-2 overexpression and tumorigenesis has been observed. Inhibition of
apoptosis, increased angiogenesis, increased invasiveness, modulation of 
inflammation/immunosuppression, and conversion of procarcinogens to 
carcinogens by COX-2 are involved in this contribution [347]. CPT-11-induced 
diarrhea is reported to be, at least in part, mediated by a COX-2-dependent 
mechanism. Thalidomide could have inhibited the lipopolysaccharide-mediated 
induction of COX-2 in murine macrophages, which could explain how 
thalidomide reduce the severity of CPT-11-induced diarrhea in human patients 
[213, 348]. In addition, to elucidate the mechanism underlying the reduction of 
Moreover, the hematological toxicity as the dose-limiting toxicity of CPT-11 
administration could also be involved in the induction of late-onset diarrhea. 
Serious leukopenia induced by CPT-11 administration could assist the bacteria in 
adversely infecting the intestinal epithelium. Clinically, granulocyte colony-
stimulating factor can be co-administered to inhibit the exacerbation of the 
hematologic toxicity induced by dose-escalating CPT-11 [349], and may alleviate 





the side effect, the thalidomide/St. John’s Wort-regulated NF-κB activity should 
also be investigated in the future studies. 
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intestinal tissue. Results in our study are consistent with reduction in numbers of 
leucocytes and reduced gastrointestinal toxicity.  
6.3 PHARMACOKINETIC MECHANISMS OF THE PROTECTIVE 
EFFECTS OF THALIDOMIDE AND ST. JOHN’S WORT  
Taken together, the protective effects of thalidomide and SJW on CPT-11 induced 
complications may be ascribed to the modulation of intestinal epithelial cellular 
apoptosis and cytokine expression. The greater understanding on the involvement 
of TNF-α in CPT-11 induced toxicity and the similar modulation effects of both 
SJW and thalidomide on TNF-α expression may provide a new treatment for 
chemotherapy-associated histological damages by an anti-TNF-α agent through 
the inhibition of inflammatory cytokines expression and intestinal epithelial 
cellular apoptosis.  
Although the modulation of cytokine levels and intestinal epithelial cellular 
apoptosis could partially explain the protective effects of thalidomide and SJW on 
CPT-11 induced toxicity, pharmacokinetic interactions between CPT-11 with 
thalidomide/SJW might be also involved. We have examined the effects of 
thalidomide and SJW on the plasma pharmacokinetics of CPT-11 and its major 
Different effects were observed for the pharmacokinetic interactions between 
 
dosage regimens of thalidomide exhibited similar modulations on 
metabolites, SN-38 and SN-38 glucuronide, and explored the kinetic interactions 
using the in vivo rat and in vitro models.  
CPT-11/thalidomide and CPT-11/SJW combinations. Both single and multiple
pharmacokinetic parameters of CPT-11, whereas, only long term treatment with 
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SJW affected pharmacokinetics of CPT-11. Thalidomide showed more 
modulatory effects on the plasma pharmacokinetic profiles of CPT-11 compared 
with SJW, which might be ascribed to the complexity, purity and efficacy of SJW, 
as a herbal medicine. However, thalidomide, as a pure compound, may exert its 
effects faster than SJW. In addition, the pharmacokinetic properties of both 
combinations in the rat model were comparable to those observed in clinical 
studies though some discrepancies existed. In a clinical pilot study in cancer 
patients [255], combination of thalidomide only increased AUC and decreased t1/2 
of CPT-11 with significant effects but had no effect on SN-38 pharmacokinetic 
profiles while another clinical study revealed that combination of thalidomide 
decreased CL and Cmax of CPT-11, decreased AUC of SN-38 but increased AUC 
 the species 
differences in drug metabolism and transport between humans and rats. It has 
been reported that the duration of exposure to CPT-11 and SN-38 may affect the 
severity of intestinal cytotoxicity, because DNA topo I inhibitors appear to be 
cell-cycle specific and SN-38 is much more cytotoxic than CPT-11. Therefore, 
SN-38 exposure is assumed to be the principal cause of late-onset diarrhea. A 
clear correlation between the toxicity of CPT-11 and C of SN-38 was also 
observed in cancer patients. In our study, both the incidence of late-onset diarrhea 
and the degree of impairment of the intestinal epithelium depended on the 
of SN-38G. Combination of SJW not only reduced Cmax of SN-38 but also 
decreased AUC of SN-38 in a clinical study. This might be ascribed to
max 
duration (AUC) and plasma concentration of SN-38. Thus, the reduction in the 
AUC or Cmax of SN-38 after thalidomide or SJW pre-treatment might partially 
explain the finding that co-administered thalidomide and SJW reduced the 
gastrointestinal toxicity of CPT-11.  
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The significant decreased Vd of CPT-11 in rats receiving CPT-11 with combined 
thalidomide compared with those rats receiving CPT-11 and control vehicle (1% 
DMSO, v/v) in the 5-day multiple-dosing study may reflect an effect of 
thalidomide and its metabolites on the plasma protein binding of CPT-11.  
However, this was not supported by our in vitro plasma protein binding results in 
which thalidomide at a high dose of 250 μM did not cause significant effect in the 
fu of CPT-11. However, modulation of the tissue binding of CPT-11 and its 
binding to target protein (Topo I) by thalidomide and its metabolites is possible. 
The reason for the reduced plasma SN-38 levels by SJW may be due to the 
induced CYP3A expression. SJW is a potential inducer of CYP3A4 in human 
[350]. In a study, the administration of SJW to rats for 14 days resulted in a 2.5-
fold increase in hepatic CYP3A2 expression. This may subsequently lead to the 
increased metabolism from CPT-11 to APC and NPC, though the latter one can be 
partially converted into SN-38 by carboxylesterases. In addition, the induction of 
Pgp (MDR1) and MRP1-2 by SJW may contribute to the altered SN-38’s 
pharmacokinetics, given that CPT-11, SN-38 and SN-38G are known substrates 
for Pgp, MRP1, and MRP2.  
m1 m2 
max1 max2 
Rat liver microsomes were used as an in vitro model to study the metabolism of 
CPT-11 and SN-38. The hydrolysis of CPT-11 to form SN-38 and SN-38 
glucuronidation followed Michaelis-Menten kinetics, with a two and one binding-
site model being the best fit for CPT-11 hydrolysis and SN-38 glucuronidation, 
respectively. The estimated K and K for CPT-11 hydrolysis were 0.50 and 78 
µM, respectively; and V  and V were 0.58 and 2.34 pmol/min/mg protein, 
respectively. This indicates that there are at least two CEs with differential affinity 
and catalysing capacity involved in the hydrolysis of CPT-11 in rat liver 
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microsomes. The estimated Km for SN-38 glucuronidation was 18.2 µM and a 
Vmax of 185.6 pmol/min/mg protein. This suggests a predominant UGT1A enzyme 
or multiple UGT1A enzymes with similar affinity catalyze SN-38 glucuronidation 
in rat liver microsomes. These observed constants for CPT-11 and SN-38 
metabolism are comparable with those reported previously in rat or human liver 
microsomes. Some dissimilarity existed for the hydrolysis of CPT-11 between rat 
liver microsomes and H4-II-E cells. This may be due to the presence of 
competition between metabolism, efflux and binding to target protein for SN-38 
in H4-II-E cells, but not in rat liver microsomes. When SN-38 was incubated with 
H4-II-E cells, the formation of SN-38G was comparable with that in rat liver 
microsomes. Replacement of DMEM with HBSS just slightly affected the 
metabolism of CPT-11 and SN-38 with comparable Km and Vmax values, 
indicating that fetal bovine serum had little effect on the metabolism of CPT-11 
and SN-38 in H4-II-E cells. In addition, there are similarities and differences with 
regard to concentrations of enzymes metabolizing CPT-11 and SN-38 in the two 
in vitro systems that were used in this study. 
In rat liver microsomes, a 16% decrease (P < 0.05) in the hydrolysis of CPT-11 at 
0.5 µM by the hydrolytic products of thalidomide (10 µM), instead of 
thalidomide, was observed. Such inhibitory effect was dependent on the total 
concentration of the hydrolytic products of thalidomide. This inhibitory effect 
could also be seen for the hydrolysis of CPT-11 at a higher concentration (78 µM) 
without significant effect. This may explain the increased AUC and C0 of CPT-11 
by combination of thalidomide. In the rat hepatic microsomes, combination of 
SJW ethanolic extracts significantly reduced SN-38 glucuronidation. 
Additionally, the induction effects of SJW on CE and UGT1A activities were not 
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clearly demonstrated in our study, as there was no significant difference between 
the Km and Vmax values for CPT-11 hydrolysis and SN-38 glucuronidation in 
SJW-induced microsomes and control microsomes. Also in the long-term 
incubation study, the SN-38G levels were not significantly influenced by SJW, 
suggesting the lack of inducing effect of SJW on UGT1As or induction of 
multiple drug metabolizing enzymes and transporters with negating effect.  
H4-II-E cells were also used to investigate the accumulation of CPT-11 and SN-
38 and the effects of thalidomide, its hydrolytic products, SJW and its major 
components on their accumulation. The mechanism for the accumulation of CPT-
11 and SN-38 by H4-II-E cells is unknown, but both active and passive transport 
are likely to be involved. CPT-11 and SN-38 can be readily taken up by human 
intestinal Caco-2 cells through passive diffusion [103, 351]. However, the best fit 
of one binding-site model for the accumulation of both CPT-11 and SN-38 in H4-
II-E cells indicates the involvement of one predominant transporter or multiple 
transporters with similar affinity to the substrates, whereas passive diffusion 
played a minor or negligible role. The accumulation of both CPT-11 and SN-38 in 
H4-II-E cells appeared to saturate within several minutes after incubation of the 
cells with the drug. Pgp, MRP1-2 and MRP4 are all possibly involved in the 
transport (mainly efflux) of SN-38 in H4-II-E cells, as verapamil (a Pgp inhibitor) 
and MK-571 [an inhibitor for MRP1-4 [294]] could significantly increased the 
intracellular accumulation of SN-38. The uptake of CPT-11 in H4-II-E cells 
appears to be mediated by MRP1-4 as MK-571, but verapamil or nifedipine did 
not significantly increased its uptake. Both CPT-11 and SN-38 appeared to enter 
tumor cells at a rapid rate, and are then distributed within cells and bound by 
subcellular organelles, drug metabolizing enzymes located on endoplasmic 
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reticulum and the target protein in nucleus (Topo I). The organelles may represent 
a store of active drug. Both drugs are finally cleared from the cells by metabolism 
and transporter-mediated efflux. Notably, the accumulation profile of CPT-11 in 
H4-II-E cells is different from that of SN-38 with differential Michaelis-Menten 
constants. This may be due mainly to the different physico-chemical properties of 
the two compounds. For example, SN-38 has higher lipophilicity than CPT-11, 
probably resulting in different affinity to the transporters, uptake, subcellular 
compartmentation, and efflux of the two drugs. Different uptake rate and extent of 
CPT-11 and SN-38 have also been observed in intestinal and lung cancer cells 
[97, 352]. Metabolism is considered an important determinant for the intracellular 
accumulation of CPT-11 and SN-38. CPT-11 is hydrolysed by cellular 
carboxylesterase, whereas SN-38 is readily conjugated by UGT1A1/1A9 which is 
associated with increased efflux of the drug from HT29 and HCT116 cells. 
Interestingly, the metabolism study in H4-II-E cells for the combination of 
thalidomide with CPT-11 showed similar effects with those observed in 
microsomes, as indicated that incubation of total hydrolytic products of 
thalidomide at 10 μM, PGA at 10 μM, and thalidomide at 25 μM all decreased 
CPT-11 hydrolysis, which might have contributed to the decreased AUC of SN-38 
but increased AUC of CPT-11. It seemed that thalidomide could affect the main 
metabolic pathway of CPT-11 that yields SN-38 though, up to date, little is known 
concerning drugs that could interact with carboxylesterases, except for 
ciprofloxacin and loperamide. The metabolism study in H4-II-E cells for the 
combination of CPT-11 and SJW showed that SJW increased the glucuronidation 
of SN-38 which was different from those observed in microsomes. This could be 
attributed to similarities and differences with regard to the concentrations of 
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enzymes. In addition, competition between metabolism, efflux, and binding to 
target protein could occur for SN-38 in H4-II-E cells, but not in rat liver 
microsomes. The increased glucuronidation of SN-38 could explain the decreased 
Cmax of SN-38 when combined with SJW.  
In the accumulation study, our results showed that thalidomide at 250 µM, PGA at 
10 µM, or thalidomide hydrolytic products at 10 µM increased the cellular 
accumulation of SN-38 in H4-II-E cells. Same trends could be observed for the 
preincubation of SJW extract and its major components. The increased 
accumulation of SN-38 into rat hepatoma cells might increase its metabolism via 
glucuronidation due to increased substrate availability for UGT1As, thus resulting 
in decreased SN-38 plasma levels. The mechanism for the increased accumulation 
of SN-38 by thalidomide, its hydrolytic metabolites, SJW, and its major 
components is unknown, but their inhibitory effects on SN-38 transporters such as 
Pgp and MRP2 are implicated. The increased accumulation cannot be attributable 
to damage of the cellular plasma membrane, which in turn could increase drug 
influx. The tumor cells remained viable during drug accumulation studies over 
180 min as measured using trypan blue exclusion. Co-administered thalidomide 
has been found to inhibit the MRP2-mediated biliary excretion of the 
glucuronides of the anti-vascular agent DMXAA and decreased the clearance of 
cyclophosphamide [267], a potential substrate for MRP4, in mice. However, 
thalidomide did not induce Pgp expression in LS180 cells and affect the uptake of 
rhodamine 123 in leukaemia cell line over-expressing Pgp. Interestingly, long-
term thalidomide therapy resulted in lack of MDR1 gene expression in a patient 
with primary resistant multiple myeloma. These results indicate that thalidomide 
does not interact with Pgp, neither as a substrate nor as an inhibitor, but it may be 
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a suppressor of MDR1 gene. Thalidomide and/or its metabolites, however, may be 
substrates or modulators for other drug transporters and they may modulate the 
transport and excretion of the substrates of these transporters. The increased 
accumulation of the active metabolite of CPT-11, SN-38, by thalidomide and SJW 
has important clinical implication. Tumor cells generally exhibit high levels of 
expression of Pgp or MRPs, thus co-administration of thalidomide and SJW, 
might enhance the anti-cancer effects of CPT-11 by inhibiting these transporters. 
In addition, the possible reduced biliary excretion of SN-38 caused by decreased 
transport of SN-38 may lead to the decrease in t1/2 of SN-38 observed in the 
plasma pharmacokinetic study for the combination of thalidomide. Additionally, 
our study also showed that PGA increased accumulation of CPT-11 while 
hypericin and hyperforin reduced it in H4-II-E cells, leading to decreased 
substrate for hCE, followed by decreased SN-38 plasma levels.  
CYP2C-mediated metabolism only plays a minor role in thalidomide elimination 
[290]. Since thalidomide is a poor substrate for CYPs and it does not inhibit the 
metabolism of CYP-specific substrates, thalidomide is not involved in clinically 
important drug-drug interactions caused by inhibition of CYP-mediated drug 
metabolism. However, given that thalidomide can be hydrolysed to more than a 
dozen of metabolites in vivo [353], it can be expected that these hydrolytic 
metabolites may have a modulating effect on the metabolism and transport of 
CPT-11 and SN-38, thus causing altered pharmacokinetics in vivo. This study 
demonstrated that the total hydrolytic products of thalidomide modulated the in 
vitro metabolism of CPT-11, but intact thalidomide at high concentration, 
hydrolytic products of thalidomide, and PGA affected SN-38 transport. 
Modulation of the metabolism and transport of CPT-11 and its metabolites was 
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also observed for the extract of SJW and its major components. These findings 
indicate that intact thalidomide and its hydrolytic products as well as SJW and its 
major components have differential effects on drug metabolism and transport, 
probably due to their different affinities to drug metabolizing enzymes (e.g. CEs) 
and drug transporters. However, the specific thalidomide hydrolytic products and 
SJW components responsible for these effects have not been identified in our 
study. Further studies are needed to identify these compounds and this may lead to 
the development of new CE and drug transporter modulators. Additionally, to 
fully understand the mechanism for the reduced metabolism, the expression of 
phase I and phase II enzymes and transporters should be studied.  
The present study demonstrated that concomitant CPT-11 did not significantly 
alter the plasma pharmacokinetics of thalidomide in rats. This is not surprising, as 
spontaneous hydrolysis is the major elimination pathway of thalidomide, while 
In summary, the results from the pharmacokinetic studies in the rat provided 
partial explanation for the observation that co-administered thalidomide or SJW 
reduced the gastrointestinal and blood toxicities of CPT-11. The rat is a suitable 
model for the pharmacokinetic and toxicological study of CPT-11 in combination 
with thalidomide. Mechanistic studies on in vitro models including rat liver 
microsomes, rat hepatoma cell line H4-II-E cells indicated that the hydrolytic 
CYP2C-mediated metabolism plays only a minor role in its elimination. The Vd of 
thalidomide was insignificantly altered in rats receiving combination therapy 
compared to those receiving thalidomide and control vehicle, indicating that CPT-
11 and SN-38 did not influence the binding of thalidomide to serum and tissue 
proteins. 
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products of thalidomide exhibited inhibitory effects on the hydrolysis of CPT-11, 
and increased the intracellular accumulation of SN-38, probably resulting from 
inhibition of Pgp and MRPs that transport SN-38; whereas the combination of 
CPT-11 and SJW increased the glucuronidation and cellular accumulation of SN-
38, which may explain the pharmacokinetic interactions for the combination of 
thalidomide or SJW with CPT-11.  
In summary, our study showed that the combination of thalidomide or SJW with 
CPT-11 both ameliorated the gastrointestinal and hematological to
6.4 CONCLUSION 
xicities of CPT-
11 in rats, as indicated by alleviation of histological damages and up-regulation of 
decreased leukocyte counts. These protective effects might be attributed to the 
modulation of cytokine expression and inhibition of intestinal epithelial cellular 
apoptosis as well as modulation of CPT-11 pharmacokinetic profiles. The 
achievement in abolition or alleviation of chemotherapy-induced complication 
may reduce mortality caused by severe diarrhea and inflammation and avoid 
overall reduction in effectiveness of therapy caused by interruptions or dose 
reductions during treatment.  
The major concern for the combination of CPT-11 with thalidomide is the 
reduction of plasma levels of SN-38, thereby compromising the anti-tumor 
activity of CPT-11. In addition, our study showed that thalidomide brought down 
the increased intestinal TNF-α expression and diminished intestinal epithelial 
cellular apoptosis, thus TNF-α expression and apoptosis in tumor tissues might be 
alleviated too, and again diminishing the anti-tumor activity of CPT-11. However, 
thalidomide has been demonstrated to possess anti-neoplastic activity in several 
 172
tumor models when used alone and in combination with cytotoxic drugs, with 
variable degrees of success. So the combination with thalidomide may increase 
anti-tumor activity of CPT-11. Furthermore, it has been demonstrated that 
thalidomide targets both the cancer cell and its microenvironment [210, 354]. So 
combination of chemotherapeutic agent CPT-11 with thalidomide, an anti-
angiogenic agent, may further strengthen the anti-tumor activity of CPT-11 by 
targeting endothelial cells, which could become a new approach to resolve both 
toxicity and resistance phenomena for conventional cancer treatment. Moreover, 
The same concern was observed for the combination of CPT-11 with SJW, as 
indicated by decreased plasma levels of SN-38, accompanied with decrease in 
clinical trials have shown that a good response rate was demonstrated in patients 
with metastatic cancer treated with the CPT-11/thalidomide combination [255]. 
therefore the combination could be promising for alleviation of CPT-11 induced 
toxicity and possibly enhancement of its anti-tumor activity. Further studies are 
warranted to establish whether the anti-tumor activity is improved in this strategy. 
If a positive response obtained, then the clinical relevance of the results obtained 
in the rat model system needs to be validated and confirmed using large-scale, 
comparative clinical trials.  
TNF-α levels, which may also compromise the anti-tumor activity of CPT-11. 
However, it is reported that hypericin and hyperforin induced apoptosis in a 
variety of tumor cell lines and inhibited cancer invasion and metastasis [244, 355] 
and some studies showed that quercetin induced apoptosis and inhibited the 
growth of tumor cells in vitro and in vivo. Furthermore, several studies established 
that hypericin and hyperforin expressed powerful in vivo and in vitro anti-
neoplastic and apoptosis-inducing activities upon photoactivation with either 
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visible or UV light. These findings indicate that both hyperforin and hypericin are 
potent inducers of tumor cell apoptosis by targeting multiple signalling molecules. 
This may provide a rationale for the combination use of SJW with other 
chemotherapeutic agents for increasing efficacy. However, as a herbal medicine, 
SJW contains over two dozens of constituents and the contents of hyperforin and 
hypericin in SJW are very low (the contents of hypericin and hyperforin in the 
SJW tablets have been standardized to 0.3% and 5%, respectively, by the 
manufacturer) so that they may not potentiate the anti-tumor activity of the 
chemotherapy when combined with CPT-11. The decrease in the plasma level of 
the active metabolite SN-38 could suggest that patients receiving CPT-11 
treatment should refrain from SJW, although the TNF-α level and cellular 
apoptosis may be not suppressed in tumor tissues. The SJW combination may 
compromise overall anti-tumor activity of CPT-11 although CPT-11 toxicity is 
altered. Specific dosing guidelines should be be given when patients are given 
such combinations.  
Furthermore, the underlying pharmacokinetic study for the combination of SJW 
with CPT-11 indicated that the altered pharmacokinetic profiles of CPT-11 by 
SJW may be ascribed to the modulation of SJW and its component on CPT-
11/SN-38 metabolism and transport, thus resulting in decreased SN-38 plasma 
levels. Therefore, caution should be taken when chemotherapeutic agents, that are 
substrates for cytochrome P450 and MDR1 P-glycoprotein, are taken with herbal 
medicines that are modulators of such enzymes and transporters, as the 
pharmacokinetic profiles of the anti-cancer agent could be changed, leading to a 
deleterious impact on treatment outcome.  
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Our preliminary toxicity studies further support the hypothesis that the intestinal 
damages induced by CPT-11 results from increased production of pro-
inflammatory cytokines like TNF-α and epithelial apoptosis. The underlying 
mechanisms for the protective effects of thalidomide and SJW against CPT-11 
induced complications may provide a new treatment approach for chemotherapy-
associated histological damages using anti-TNF-α agents through the inhibition of 
pro-inflammatory cytokine expression and intestinal epithelial cellular apoptosis. 
However, the anti-tumor activity of this combination therapy should also be 
evaluated. 
For the future direction of this project, anti-tumor activity study should be firstly 
performed for the identification of the feasibility of these two combinations. In the 
mean time, in order to further understand the mechanism for the reduced 
metabolism of CPT-11 by thalidomide and SJW, the expression of phase I and 
phase II enzymes and transporters should be involved. Similarly, to understand 
the mechanism of reduced side effect, the thalidomide/SJW-regulated NF-κB 
In conclusion, based on our experimental observations, the combination with 
thalidomide would be a promising strategy for reducing CPT-11’s toxicity with 
possible enhanced anti-cancer activity, whereas CPT-11 should not be 
activity should be examined. In addition, the protective effects of 
thalidomide/SJW on CPT-11 induced toxicity should be evaluated using animal 
model with colon cancer, such results will be more persuasive compared with 
normal animal model. In order to mimic the clinical conditions, the colon cancer 
animal model should be pre-treated firstly with 5-FU/CPT-11 before the 
administration of thalidomide or SJW.  
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coadministered with SJW to patients receiving CPT-11 therapy to avoid a 
deleterious treatment outcome. Furthermore, caution should be taken when 
chemotherapeutic agents are coadministered with herbal medicines that are 
modulators of drug enzymes and transporters. In addition, anti-TNF-α agents 
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